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ABSTRACT 
This dissertation focuses on two aspects, targeted cancer therapy based on epigenetics and 
cancer diagnostics using DNA encoded glycan libraries. The first part addresses cancer therapy, 
wherein we discuss the discovery of a new class of G9a inhibitors and development of dual 
inhibitors targeting epigenetic enzymes G9a and Histone Deacetylases (HDAC). Aberrant 
enzymatic activities or expression profiles of epigenetic regulations are therapeutic targets for 
cancers. Among these, histone 3 lysine 9 methylation (H3K9Me2) marked by methyltransferase 
enzyme G9a and global de-acetylation on histone proteins by deacetylation enzyme HDAC 
typically associated with multiple cancer phenotypes including leukemia, prostatic carcinoma, 
hepatocellular carcinoma and pulmonary carcinoma. Our structure-based virtual screening 
identified a series of compounds as potential inhibitors of G9a. Among these new class of G9a 
inhibitors, DCG066 was confirmed by in vitro biochemical, and cell-based enzyme assays. In 
another effort, several compounds featuring both G9a and HDAC pharmacophore was synthesized 
and screened for their dual activity and presented their detailed structure-activity relationship 
studies. 
Secondly, this dissertation elaborates a new method for the detection of cancer. Tumor-
associated antigens like Globo H, are found in many cancers including breast cancer and ovarian 
cancer. Applying principles of DNA encoding and screening, we developed a DNA encoded 
glycan library (DEGL) of these tumor specific glycans. Then, DEGL is used to detect cancer by 
screening the serum samples for anti-Globo H antibodies.  
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inhibitors, MALDI-TOF assay, DNA encoded glycan library, Glyco-PCR, Carbohydrate 
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1 INTRODUCTION 
1.1 Cancer therapy 
Cancer is one of the leading causes of death across globe and is the second leading cause 
of death in the United States.[1] More than 14 million new cases and 8.2 million deaths reported 
were related to cancer in 2012. Cancer cases are projected to rise over 22 million by next two 
decades.[2] Even though with these continued increase in reported cancer cases, death rate related 
to the cancer is recently in decline largely contributed by the advancement in cancer therapy. 
Traditionally cancer is being treated by chemotherapies, irradiation and surgery and more recently 
by targeted therapies and cancer immunotherapies. Traditional chemotherapy act on rapidly 
dividing cancer cells, but it also affects rapidly dividing normal tissues like hair, gastrointestinal 
epithelium and bone marrows. Unlike this, targeted therapies aim a specific pathway in cancer 
proliferation that is either exclusively used by the cancer tissues or overexpressed compared to the 
normal cells.[3, 4]  
Targeted therapies, which refers to monoclonal antibodies and small molecule inhibitors 
are the major class of cancer therapy today. It span to all different sort of malignancies and a major 
drug component in many of the cancer treatments including breast, lung, pancreatic, and colorectal 
cancers, as well as lymphoma, leukemia, and multiple myeloma.[3] In this dissertation, we focus 
on small molecules based therapies for cancer. Small molecules have several advantages over the 
monoclonal antibodies, they are administered orally, and their chemical synthesis is much cheaper 
than the bioengineered antibodies. Small molecule therapies rose to prominence after the discovery 
of the Imatinib, a tyrosin kinase inhibitor with its tremendous success in treating chronic 
myelogenous leukemia (CML). The success of Imatinib is attributed to the single causal mutation 
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of the CML and a similar success was not seen in other cancers because they are often associated 
with multi factorial origin.[5]  
 
Figure 1.1. Modulation of covalent modifications on chromatin. 
 A 147 bp sequence of DNA is wrapped around a core of eight histone proteins to compact the 
genome into nucleosomes and then into chromatin and chromosomes. A subset of covalent 
modifications (yellow circles) on both the histone and DNA components, which control 
accessibility of DNA to transcription factors and other regulators, are shown. Covalent marks are 
established by ‘writers’, such as histone lysine methyltransferases (KMTs), histone 
acetyltransferases (HATs) and DNA methyltransferases (DNMTs). These modifications are 
interpreted by ‘readers’, including methyl-CpG binding domain (MBD) proteins on the DNA and 
multiple proteins for the histone marks as shown. Progress over the past decade has shown that 
almost all of the marks can be removed by ‘erasers’, such as histone demethylases (KDMs), histone 
deacetylases (HDACs) and by the ten-eleven translocation (TET) family of 5-methylcytosine 
oxidases. The interplay between these enzymes helps to establish and maintain cellular identity in 
addition to the central role of transcription factors by regulating access to the DNA sequence. PHD, 
plant homeodomain.[6] 
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More recently epigenetics has taken center stage in cancer therapy. Epigenetics refers study 
of heritable changes that regulate gene expression but do not involve changes to the underlying 
DNA sequence. Epigenetic changes governed by the covalent modifications occurred to the 
chromatin components, which includes DNA, RNA and histone proteins (Figure 1.1). The most 
common epigenetic modifications also called as post translational modifications includes DNA 
methylation, histone methylation, acetylation, phosphorylation, glycosylation and 
ubiquitylation.[7] Conversely to genetic alterations, epigenetic modifications are reversible and 
controlled by three sets of enzymes called ‘Erasers’ who mark the modification, ‘Reader’ who read 
the modifications and respond with either gene activation or deactivation, and ‘Erasers’ who 
reverse the modifications (Figure 1.1).[6] The entire process is significantly affected by the 
external factors like environmental exposure to carcinogens, life style, smoking and widely altered 
in cancer. Tumor cells use epigenetic process to escape from the immune surveillance and 
chemotherapy. Hence, these modifications and their corresponding enzymes are fiercely pursued 
as drug discovery targets. Most recent status of epigenetic drug development is listed in Table 1, 
drugs targeting DNA methylation writers and histone acetylation erasers are already approved for 
therapy and several more drugs are currently under clinical trial.[8] 
In this study, we targeted two epigenetic enzymes G9a and HDAC. Histone 3 lysine 9 
methylation (H3K9Me2) and global de-acetylation at histone proteins are associated with multiple 
cancer phenotypes including leukemia, prostate carcinoma, hepatocellular carcinoma and lung 
cancer.[9-11] Cancer is a disease with difficult treatment options due to the multifactorial basis of 
initiation, and progression; a treatment targeting multiple components instead of a single 
component would therefore be of interest in cancer therapeutics.[12-14] G9a and HDAC are 
proven targets for cancer and several groups published many inhibitors for each class with 
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crystallography data suggesting the specific binding and related pharmacological action.[11, 15, 
16] Our Structure based design, synthesis, and activity studies discovered the first small molecule 
as a hybrid targeting HDAC and G9a. In another work, we discuss the structure based virtual 
screening of a library of 200,000 small molecules for the discovery of G9a specific inhibitors. This 
two works are elaborated in the first half of the dissertation. 
Table 1.1. Epigenetics drugs in clinical trials 
Compound Target Status 
Decitabine DNMT1 FDA approved 
Azacitidine DNMT1 FDA approved 
Guadecitabine DNMT1 Phase III 
4-Thio-2-deoxycytidine       DNMT1 Phase I 
ASTX727 DNMT1 Phase II 
AG-120 IDH1 Phase III 
AG-221 IDH2 Phase III 
AG-881 IDH1 and IDH2 Phase I 
IDH305 IDH1 Phase II 
FT-2102 IDH1 Phase I 
BAY1436032 IDH1 Phase I 
IDH1 peptide vaccine IDH1 Phase I 
Belinostat HDACs FDA approved 
Vorinostat HDACs FDA approved 
Romidepsin HDACs FDA approved 
Panobinostat HDACs FDA approved 
Valproic acid HDACs FDA approved 
KA2507 HDAC6 Phase I 
ACY-241 HDACs Phase I 
Tucidinostat HDACs Phase III 
CKD-581 HDACs Phase I 
CUDC-907 HDACs Phase I 
CXD101 HDACs Phase I 
EDO-S101 HDACs Phase I 
Givinostat HDACs Phase II 
MPT0E028 HDACs Phase I 
OBP-801 HDACs Phase I 
Resminostat HDACs Phase II 
Tefinostat HDACs Phase II 
AR-42 HDACs Phase I 
Entinostat HDACs Phase III 
Mocetinostat HDACs Phase II 
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Ricolinostat HDACs Phase II 
ABBV-075 BETs Phase I 
BMS-986158 BETs Phase II 
GSK2820151 BETs Phase I 
INCB054329 BETs Phase II 
INCB057643 BETs Phase II 
TEN-010 BETs Phase I 
ZEN003694 BETs Phase I 
OTX015 BETs Phase I 
CPI-0610 BETs Phase II 
FT-1101 BETs Phase I 
GSK525762 BETs Phase II 
MAK683 EED Phase II 
Tazemetostat EZH2 Phase II 
CPI-1205 EZH2 Phase I 
DS-3201 EZH2, EZH1 Phase I 
GSK2816126 EZH2 Phase I 
Pinometostat DOT1L Phase I 
Tranylcypromine KDM1A FDA approved 
GSK2879552 KDM1A Phase II 
INCB059872 KDM1A Phase II 
 
1.2.  Cancer diagnosis 
Early detection of cancer is one of the most significant part in the success of cancer 
therapies. Cancer diagnosis has advanced tremendously in recent years, yet they rely 
predominantly on invasive (i.e. random biopsies and surgery) methods, and the noninvasive 
methods available are limited to certain cancer types. More often noninvasive methods are not 
sensitive enough to distinguish aggressive tumors from indolent ones like in the case of Prostate 
Specific Antigen (PSA) test in prostate cancer diagnosis.[17] Hence, new methods for the early 
detection of cancer with high sensitivity, specificity and throughput are equally essential with 
the advancement in cancer therapeutics. 
In past two decades, cancer biology specifically cancer glycobiology has moved 
substantially. Understanding the role of glycans in cancer related mechanism like cell-cell 
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recognition, cell adhesion, metastasis formation and immune modulation etc. greatly facilitated 
therapeutic intervention of various types of cancers.[18] This, understanding how the glycan 
structure are modified in the tumor cells and how they behave to the tumor microenvironment is 
of critical importance. The alterations of glycosylation or glycan presentation on tumor cells are 
cell specific, protein specific and site specific, hence considered as tumor biomarkers.[18-22]  
Several alloantibodies are generated against the tumor associated glygans (TAG) and 
detection of this antibodies can correlate with the cancer. Patient sera has the TAG specific 
antibodies way before the aggressive cancer is diagnosed, hence the early detection is possible by 
the screening of patient sera for the cancer specific antibodies. Aberrant glycosylation of MUC-1 
is observed in colorectal cancer and detection of autoantibodies specific to this glycan epitope has 
predicted the CRC with more than 95% specificity.[23] Another cancer associated carbohydrate 
antigen globo-H, which is an hexasaccharide present in cell surface as a glycolipid is a proven 
biomarker, and screening of antibodies against this glycan is found to be effective in diagnosing 
breast cancers, ovarian cancer, and thyroid cancer.[24-26] In the second part of the dissertation, 
we describe a novel method for the ultra-sensitive detection of glycan specific antibodies using 
DNA encoded glycan libraries (DEGL).  
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2 SMALL MOLECULE INHIBITORS OF G9A AND HDAC FOR TARGETED 
CANCER THERAPY  
2.1 Discovery of novel small molecule inhibitors of lysine methyltransferase G9a and 
their mechanism in leukemia cell lines 
The work presented in this chapter is reproduced with some modification as to fit the format with 
permission from the journal European journal of medicinal chemistry. My contributions as first 
author were the design, chemical synthesis and figure/manuscript preparation. 
Kondengaden, Shukkoor M., Liu-fei Luo, Kenneth Huang, Mengyuan Zhu, Lanlan Zang, Eudoxie 
Bataba, Runling Wang et al. "Discovery of novel small molecule inhibitors of lysine 
methyltransferase G9a and their mechanism in leukemia cell lines." European journal of medicinal 
chemistry 122 (2016): 382-393. 
ABSTRACT: Lysine methyltransferase G9a regulates the transcription of multiple genes by 
primarily catalyzing mono- and di-methylation of histone H3 lysine 9, as well as several non-
histone lysine sites. An attractive therapeutic target in treating leukemia, knockout studies of G9a 
in mice have found dramatically slowed proliferation and self-renewal of acute myeloid leukemia 
(AML) cells due to the attenuation of HoxA9-dependent transcription. In this study, a series of 
compounds were identified as potential inhibitors through structure-based virtual screening. 
Among these compounds, a new G9a inhibitor, DCG066, was confirmed by in vitro biochemical, 
and cell based enzyme assays. DCG066 has a novel molecular scaffold unlike other G9a inhibitors 
presently available. Like G9a’s histone substrate, DCG066 can bind directly to G9a and inhibit 
methyltransferase activity in vitro. In addition to suppressing G9a methyltransferase activity and 
reducing histone H3 methylation levels, DCG066 displays low cytotoxicity in leukemia cell lines 
with elevated levels of G9a expression, including K562. This work presents DCG066 as an 
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inhibitor of G9a with a novel structure, providing both a lead in G9a inhibitor design and a means 
for probing the functionality of G9a. 
2.1.1 Introduction 
Epigenetic regulation plays a vital role in gene transcription and expression, occurring not 
through alterations in the genetic code, but rather by modifications to histones or other vital 
proteins. Among the regulatory processes utilized in posttranslational modifications, histone 
modification is crucial.[27] Comprised of at least eight variations, including acetylation, 
methylation, phosphorylation, sumoylation and so forth, the causal relation between histone 
methylation in gene expression and histone lysine residues is unusual.[28] Frequently, the 
methylation of H4 lysine 20 (H4K20), H3 lysine 9 (H3K9), and H3 lysine 27 (H3K27) are 
associated with transcription suppression, whereas methylation of H3 lysine 4 (H3K4), H3 lysine 
36 (H3K36) and H3 lysine 79 (H3K79) tends lead to transcription activation.[28-34] Of interest, 
H3K9-methylation correlates with transcription suppression, gene silencing and genomic stability. 
H3K9-methylation is regulated by histone lysine N-methyltransferase EHMT2 (G9a) and 
analogous protein GLP (G9a like protein). G9a is responsible for catalyzing the mono- and di-
methylation of H3K9 in euchromatic regions. G9a is also capable of methylating H3K27, lysine 
373 of p53 and other gene expression regulators. However in several cancers, particularly chronic 
myeloid leukemia, G9a and homologous protein GLP are found to be overexpressed with the 
proliferation of cancer cells suppressed through knocking out G9a.[35, 36] Because G9a and GLP 
also play a significant role in gametogenesis and embryonic development,[37-40] G9a/GLP 
inhibitors have been used with success in cell reprograming studies and in producing inducible 
pluripotent stem cells (iPSCs) by various groups.[41-44] As displayed in Table 1, current G9a 
inhibitors can be classified into three overall categories: type I with BIX-01294 and its 
9 
derivatives,[45, 46] type II with BIX-0138 and its derivatives,[47] and type III with fungal 
metabolite chaetocin.[48, 49] Reported in 2007, BIX-01294 was the first G9a selective inhibitor 
that did not target the binding pocket of cofactor S-adenosyl-methionine (SAM).[50] Since the 
discovery of BIX-01294, many G9a inhibitors including UNC0224, UNC0638, UNC0642, E72 
and A-366 have emerged based on the pharmacophore of BIX-01294 (Figure 2.1).[45, 47, 51-54] 
All of the current G9a inhibitors except chaetocin possess the same quinazoline core and display 
similar biological activity, performing well in enzyme and cellular assays.  
 
Figure 2.1. Structures of known G9a inhibitors. 
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Of particular interest is the inhibitors belonging to the type I and III categories, as clinical trials 
have indicated their high efficacy in inhibiting the proliferation of leukemia cells. By attenuating 
HoxA9-dependent transcription, G9a inhibitors are able to reduce the self-renewal and 
proliferation of acute myeloid leukemia (AML) cells.[46] Previous studies have indicated that 
mutations involved in DNA methylation could be responsible for mediating abnormal self-renewal 
and differentiation in leukemia stem cells (LSCs) and, discovery of targeted drugs for epigenetic 
enzymes could provide a new route for leukemia treatment.[55, 56] G9a has emerged as an 
attractive drug target for leukemia. However, current inhibitors of G9a are derivatives of parent 
compound BIX-01294 generated through manual or structure-activity relationship (SAR) analysis, 
offering limited design space for new inhibitors. Thus, there is an interest in searching for new 
scaffolds capable of inhibiting its activity. This study aims to search for new scaffolds for G9a 
inhibition through a combination of virtual and enzymatic screening. 
  High-throughput and structure-based virtual screenings (SBVS) are widely utilized methods 
in the discovery of lead structures. Through SBVS, DCG066 was identified as an inhibitor with 
binding affinity comparable to that of the native substrates. In vitro biochemical and cell based 
assays verified that DCG066 had a level of activity comparable to that of BIX-01294, in addition 
to induction of cell apoptosis. In studying inhibitors for G9a, the expression levels of G9a in 
varying cancer cell lines were also examined to determine which cell line would be most 
appropriate for in vitro assays. From these observations, a trend emerged; the expression levels of 
G9a in most hematologic cancer cells were much higher than in normal blood cells.  
Since the overexpression of G9a is related to several cancers,[57] we analyzed the G9a mRNA 
and protein level using quantitative real-time PCR and western blotting, respectively, in order to 
quantify expression levels across different cell lines. K562, a leukemia cell line, was found to have 
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G9a expression levels higher than all solid tumor cells, and thus was used in further in vitro cell 
assays. DCG066 decreases di-methylation levels of histone H3 lysine 9 (H3K9Me2), inhibits cell 
proliferation and induces cell apoptosis. Displaying comparable activity to BIX-01294 and lower 
cytotoxicity in leukemia cells, DCG066 offers possibilities as both a probe for the functions of 
G9a and as a novel lead in G9a inhibitor design.  
2.1.2 Results and Discussion 
2.1.2.1 Virtual screening 
A schematic representation of the overall procedure is presented in Figure 2.2. The crystal 
structure of G9a in complex with UNC0638 (PDB entry: 3RJW) was selected to be the binding 
pocket in docking studies. Chain A of the protein and the corresponding UNC0683 were both 
extracted from 3RJW to serve as the template for the binding pocket model. In generating the 
library of compounds to screen, we searched for a public database containing enormous number 
of small molecule compounds that would be available for subsequent in vitro screening. The 
SPECS database (http://www.specs.net/), containing 200,000 small molecule compounds, was 
found to meet the criteria. The database was then filtered for compounds with log P value smaller 
than 5 by Pipeline Pilot 7.5, leaving about 90,000 compounds that would likely be soluble in 
aqueous solution to a certain degree. In evaluating which of the two available docking methods 
(Glide 5.5, Gold 5.0) were to be used, two criteria were employed: the root mean-square deviation 
(RMSD) value and the enrichment factor. The RMSD value of UNC0683 between the best-ranked 
pose by the docking methods and the initial pose would provide a measure for the accuracy of the 
docking algorithm in comparison with experimentally determined results. The enrichment factor 
would measure the fraction of active compounds found in a certain percentage divided by the 
fraction of the screened library. Between these two criteria, Glide 5.5 was found to be the best and 
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was used in docking studies. The Glide XP mode with default settings was used, following 
standard procedure. The hit compounds were ranked based on G-score and the top 1000 
compounds were selected for scaffold diversity analysis by Pipeline Pilot 7.5 and visual inspection. 
Afterwards, candidate molecules were chosen based on the following criteria: (1) molecular weight 
of the ligand is lower than 600 Da, which would benefit from further structural optimization, (2) 
both geometric and chemical features correspond with the active site of G9a, and (3) the binding 
poses and chemical structures were reasonable. From this, 125 candidate molecules were identified 
for purchase and further G9a inhibition activity assessment. 
 
Figure 2.2. Flow chart for the virtual screening 
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2.1.2.2  In vitro screening for direct binding and enzymatic inhibition 
To verify whether the 125 selected compounds could inhibit G9a activity, two different 
approaches were used to determine the direct binding and the enzymatic inhibition. Surface 
plasmon resonance (SPR) biosensor (Biacore 3000) was used to test for binding affinity; this was 
followed by radioactive methylation assay to test the inhibition of enzymatic activity. As SPR is 
one of the best methods for studying label-free binding affinity,[58, 59] it is frequently used in 
drug discovery. To verify whether the 125 compounds could potentially inhibit G9a activity 
through direct binding to the enzyme, we carried out the experiments by using Biacore 3000. G9a 
was immobilized on the sensor chip; then the ligand and the candidate compounds sequentially 
flowed over the chip surface in the concentration range of 10-100 µM. Any interactions between 
the compounds and G9a would be detected as changes of response units (RU) in the sensorgram. 
Among the 125 candidates, 14 were found to interact with G9a (Fig. 2.3). The sensorgram response 
to the candidate compounds ranged from 10RU to approximately 200RU. Compounds that failed 
to display any interactions with G9a were excluded from subsequent testing.  
 
Figure 2.3. Small molecules binding screen by SPR (Biacore 3000). 
Through small molecule-protein binding assay using SPR, out of the 125 compounds obtained 
from virtual screening 14 were found to have the capacity to interact with the G9a catalytic domain. 
The compounds concentration is 100uM dissolved in the analysis buffer (PBS added P20 and 5% 
DMSO). 
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Table 2.1. Chemical structures of identified small molecules and their inhibition potency. 
 
Hypothesis SPECS ID Compound structure 
Inhibition   
Ratio* % 
Cell  
Inhibition
* % 
DCG001 
 
AH-034/32473019 
  
61 34 
DCG020 AE-848/11486036 
 
74 65 
DCG033 AK-968/40335567 
 
74 91 
DCG066 AK-105/40833871 
 
98       97 
BIX-01294 - 
  
88       98 
 
*Compounds used in both G9a enzyme inhibition assay and cell proliferation inhibition 
assay had a concentration of 10 μM. 
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Having recognized that 14 of the compounds screened showed significant binding with G9a, we 
employed a tritium (H3)-labeled radioactive methylation assay to test the inhibition of enzymatic 
activity.[60] 10 µM solutions of the compounds were used for radioactive assays and four of these 
compounds displayed more than 50% inhibition at this concentration. Of these four compounds, 
DCG066 displayed inhibition comparable to that of BIX-01294 (Table 2.1). Moreover, all four 
compounds possess molecular structures that do not fall into any of the three categories of existing 
G9a inhibitors. Tentatively, the newly discovered DCG066 could be classified as a type IV 
inhibitor. 
2.1.2.3 Synthesis  
 
Scheme 2.1. Synthesis of DCG066 
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For confirmation and further detailed mechanistic studies, we synthesized DCG066 
(Scheme I). Commercially available methyl 1-benzylpiperidine-4-carboxylate (1) was used as the 
starting material to synthesize 3 upon reaction with 1-bromo-4-(trifluoromethyl)benzene (2) after 
lithiation. Subsequent hydrogenolysis afforded a free secondary amine (4), which was converted 
to 6 upon nucleophilic substitution with para-nitrobenzylchloride (5). Reduction of the nitro group 
to amine 7 followed by reaction with dimethylcarbamic chloride yielded the targeted compound 
DCG066. 
2.1.2.4 In-vitro biochemical assays 
To confirm the result of the radioactive methylation assay, we did two more assays. To examine 
the interactions between DCG066 and G9a, a kinetic assay by SPR was used with concentrations 
of DCG066 ranging from 25 µM to 300 µM. The test was performed using Biacore 3000 in Wizard 
mode. G9a protein was immobilized on the CM5 sensor chip as ligand by amine coupling. The 
concentration of DCG066 was from 25 μM to 300μM. Since the sensogram of each concentration 
can reach equilibrium, we choose steady-state analysis to calculate the affinity constant (Kd) of 
DCG066 (Kd=18.05±2.48 µM, Figure 2.4 A and 2.4 B). MALDI-TOF mass spectrum was used to 
quantitatively determine the methylation of the histone H3 peptides catalyzed by G9a enzyme with 
and without DCG066. The assay was performed ass followed, 100 nM of protein G9a, 2 µM of 
substrate peptide and 1 µM S-adenosyl methionine (SAM) were added to 50 mM HEPES pH 8.0, 
5 µg/ml BSA and 0.1% β-mercaptoethanol with DCG066 at a final concentration of 10 µM. After 
30 minutes of reaction, TFA was added to the buffer to terminate the reaction. 1 µL of the reaction 
solution was used to detect the modifications of histone H3 (1-24). The relative intensity of 
H3K9me2 in the sample after the addition of DCG066 was found to be lower than that without 
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DCG066, indicating the ability for DCG066 to inhibit H3K9-dimethylation (Figure 2.4 C & 2.4 
D). 
 
Figure 2.4. In vitro kinetic assay and enzyme activity inhibition of DCG066. 
(A) Binding assay of DCG066 and recombinant G9a catalytic domain by Biacore 3000. The Kd is 
approximately 18 µM calculated by nonlinear least-square (NLLSQ) fitting. (B) DCG066 can 
inhibit G9a methyltransferase activity with an IC50 of 6.5 µM, which is like that of BIX-01294. 
(C, D) In MADI-TOF-MS, dimethyl level of synthetic peptide of histone H3 (1-20) decreased with 
the addition of DCG066, while the monomethyl level increased. 
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2.1.2.5 DCG066 inhibits cancer cell proliferation, decreases histone H3 lysine 9 (H3K9) di-
methyl levels, blocks cell cycle and induces apoptosis 
 
Figure 2.5. G9a expression in human cells and cancer cells. 
(A) Pattern of G9a expression across diverse normal and tumor tissues was obtained from GENT 
(http://medical-genome.kribb.re.kr/GENT/). The average G9a expression in cancer tissue is higher 
than normal tissues, particularly for hematology system. (B) Analysis of G9a expression level in 
different cancer cell lines. The statistical data was obtained from CCLE (http: // www. 
broadinstitute. org/ccle/home). G9a is expressed higher in leukemia cell lines than other cancer 
cells. (C, D) The expression of G9a in different cancer cells (K562, HL-60, HepG2, A549 and 
HUVEC) was detected in both mRNA level (C) and protein level (D). Expression of G9a in 
leukemia cells is higher than other cancer cells (A549 and HepG2) and normal cells (HUVEC). 
 
In order to find a good system to test the G9a inhibitor’s inhibition activity in cell, the distinction 
of G9a gene expression between cancer tissues and normal tissue were analyzed by using 
GENT[61, 62] (Gene Expression across Normal and Tumor tissues) database (http://medical-
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genome.kribb.re.kr/GENT/). Meanwhile, the G9a gene expression levels of all available cancer 
cell lines were analyzed by using the databased of Broad-Novartis Cancer Cell Line Encyclopedia 
(http: // www. broadinstitute. org/ccle/home). Compared to normal cells, G9a expression levels of 
cancer cells are higher, especially in malignant hematologic cancer cell lines (Figure 2.5 A and 2.5 
B). To ensure that the cells lines used in our following experiments have appropriate levels of G9a 
expressed, the G9a mRNA expression levels were tested by using real time-PCR (Figure 2.5 C) 
and G9a protein expression levels were checked by using western blot (Figure 2.5 D). mRNA and 
protein levels of G9a in the tested leukemia cells (HL60 and K562 cell lines) are higher than the 
levels in solid cancer cells (A549 for lung cancer and HepG2 for liver cancer). Although normal 
cells (HUVEC) has detectable G9a protein expressed, it is obviously lower than that in leukemia 
cells.  
Throughout the in vitro enzymatic activity assay, DCG066 is the best compound in inhibiting 
G9a activity among the 125 tested compounds.  To verify the ability of these compounds to inhibit 
cell proliferation, DCG066 was tested at varying concentrations in HL-60, K562, A549 and HepG2 
cell lines, and BIX-01294 was used as a control (Figure 2.6 C). The half maximal inhibitory 
concentrations (IC50) of DCG066 were roughly equivalent to BIX-01294 across the cell lines, with 
K562 displaying the greatest sensitivity to DCG066 (IC50 =1.7±0.3 µM) (Figure 2.6 A).  
DCG066 was also considered for its ability to decrease the level of dimethylated histone 
substrate (H3K9me2). After treating K562 cells with DCG066 at varying concentrations (0.5 µM 
to 2 µM) and incubating for 72 hours, histones were extracted from cell. The quantified total 
histones were measured through immuno-blotting by using anti-histone H3 antibody (Cell 
Signaling Technology) and anti-histone H3 methylation antibodies (Abcam) to detect expression 
levels of the relevant histone methylation levels. DCG066 reduced histone H3 lysine 9- 
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Figure 2.6. The anti-cancer effect of DCG066 in cell 
 (A) IC50 of the DCG066 on inhibition of cells proliferation, similar with BIX-01294, the effect 
acted on leukemia cells maybe much better than it on adherent cells (A549 for lung cancer and 
HepG2 for liver cancer). (B) The test of histone methylation level in K562 with the treatment of 
DCG066. DCG066 can reduce histone H3 lysine 9 dimethylation (H3K9me2) levels in K562 cell 
but can’t influent H3K27me3 level. (C) DCG066 can inhibit the proliferation of several cancer 
cells, but effects in healthy cells are small. The cell viability rates shown as bar, the half maximal 
inhibitory concentrations (IC50s) are shown as table under the bar Fig. 4A. The IC50 of DCG066 
is like BIX-01294 and may act better on leukemia cells compared to adherent cells, such as A549 
and HepG2. (D) The test of histone methylation level in K562 with the treatment of DCG066. 
DCG066 can reduce histone H3 lysine 9 dimethylation (H3K9Me2) levels in a lower concentration 
than BIX-01294. (E, F) DCG066 can induce apoptosis of K562 cell, with the treatment of 2 μM 
DCG066 for 24 hours. Meanwhile, DCG066 can block cell cycle in G2/M stage in a low 
concentration. All these procedures were taken by flow cytometry assay. 
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dimethylation (H3K9Me2) levels in a comparable manner as BIX-01294 (Figure 2.6 D). 1.0 -2.0 
µM DCG066 decreased H3K9-dimethylation in K562 cells but displayed no changes in H3K27 
tri-methylation (Figure 2.6 B). Based on these findings, it can be concluded that DCG066 is a G9a 
selective inhibitor. Upon confirming DCG066’s ability to inhibit K562 cell proliferation, the 
potential impact of DCG066 on the cell cycle and apoptosis was investigated. After treating K562 
cells with DCG066 and incubating for 24 hours, cell cycle and apoptosis were detected using flow 
cytometry. DCG066 was found to block the cell cycle at stage G2/M in the K562 cells, potentially 
leading to cell apoptosis (Figure 2.6 E, 2.6 F). 
2.1.2.6  DCG066 binding pocket similarity to BIX-01294 binding pocket 
 
Figure 2.7. Docking images selected from select molecules. 
Two positive controls (UNC0638 and BIX-01294) and four hit compounds (Molecule 1 to 4) 
were docked into G9a binding pocket. 
 
To better understand the binding mechanism, we conducted molecular docking studies with 
the two positive controls (UNC0638 and BIX-01294) and the selected 14 molecules from virtual 
screening. Because UNC0638 is also the co-crystallized ligand, we calculated RMSD between the 
re-docked ligand and co-crystalized ligand. Our result showed that the RMSD value is 0.995 Ao, 
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suggesting our re-docking procedure is reliable.  All 16 re-docked molecules are ranked by 
“Docking Score” and “Enzymatic Inhibit Activity” (Table 2.2). Considering the overall ranking, 
DCG066 has the highest performance, therefore DCG066 was chosen for the detailed study (Table 
2.2). Selected docking result images were rendered in Figure 2.7. 
Table 2.2. Docking score and enzymatic inhibition activity 
 
Molecules 
Docking 
Score 
Enzymatic 
Inhibit 
Activity (%) 
SPR 
Response 
(RU/MW) 
Cell Growth 
Inhibition 
Activity (%) 
Positive Control UNC0638 8.7093 100% Not Test 100% 
Molecule 1 DCG066 7.6982  98% 0.07 97% 
Positive Control BIX01294 7.593 88% Not Test 98% 
Molecule 2 DCG020 5.6658 74% 0.01 65% 
Molecule 3 DCG033 4.7977 74% 0.17 91% 
Molecule 4 DCG001 6.7903 61% 0.02 34% 
Molecule 5 DCG025 7.0443 less than 50% 0.15 Not Test 
Molecule 6 DCG026 6.7541 less than 50% 0.11 Not Test 
Molecule 7 DCG081 6.4155 less than 50% 0.01 Not Test 
Molecule 8 DCG082 6.0256 less than 50% 0.15 Not Test 
Molecule 9 DCG096 5.8841 less than 50% 0.07 Not Test 
Molecule 10 DCG099 5.6738 less than 50% 0.02 Not Test 
Molecule 11 DCG100 5.4047 less than 50% 0.06 Not Test 
Molecule 12 DCG101 5.1079 less than 50% 0.06 Not Test 
Molecule 13 DCG107 4.9077 less than 50% 0.23 Not Test 
Molecule 14 DCG004 4.3035 less than 50% 0.38 Not Test 
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We also studied the interactions between DCG066 and G9a compared to BIX-01294 and 
UNC0638 (Figure 2.8). Top scored conformations were chosen for analysis. Results indicated that 
UNC0683, BIX-01294 and DCG066 all bind to the peptide substrate pocket (Figure 2.8 A & 2.8 
B). From the model, BIX and DCG066 were shown to form hydrophobic contacts with residues 
Y1085, Y1067, F1087, F1152, Y1154, R1157 and F1158 (Figure 2.8 C-2.8 F).  In addition to 
these, DCG066 also forms extra hydrogen bonds with Y1154 and R1157 (Figure 2.8 F), offering 
a potential explanation of its binding. 
 
Figure 2.8. Complex models of G9a with superimposed inhibitors (UNC0683, BIX-01294, 
DCG066). 
Left panel (A, C, E) shows the structural electrostatic surfaces (blue indicates positive charge and 
red indicates negative charge) and small molecules shows as sticks. Right panel (B, D, F) shows 
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detailed interactions. G9a shows as cartoon in green color and residues, which could form 
interactions with UNC0683, BIX-01294 or DCG66 are shown as green sticks. (A, B) The binding 
pocket of crystal structure of G9a-UNC0683 (PDB: 3RJW). [45] (C, D) The computational model 
of G9a-BIX-01294. (E, F) The computer mimic model of G9a-DCG066. In these models, the 
interaction surfaces of all these compounds are very similar. Both BIX-01294 and DCG066 can 
form hydrophobic interactions with Tyr1085, Tyr1067, Phe1087, Phe1152, Tyr1154, Arg1157 and 
Phe1158. DCG066 can also form hydrogen bond with Tyr1154 and Arg1157 (F). 
 
2.1.3 Conclusion 
 H3K9 methylation is a crucial epigenetic regulator in gene transcription and embryonic cell 
differentiation. Thus, G9a is emerging as a drug target for leukemia treatments. Recent studies 
have shown that G9a may selectively regulate the fast proliferating myeloid progenitors but 
displays no effects on hematopoietic stem cells (HSCs). Primary acute myeloid leukemia (AML) 
cells from patients are found to be sensitive to G9a inhibition, causing reduction in proliferation 
and self-renewal through attenuating HoxA9-dependent transcription.[46]   
   Many of the current G9a selective inhibitors can be sorted into three categories, all of 
which are derivatives of BIX-01294. In this study, several small molecules from the SPECS 
Database were screened using virtual screening to discover potential G9a inhibitors. Virtual 
screening followed by bioassays allowed us to identify a new scaffold embedded in DCG066 for 
further inhibitor development. Initially we investigated various cancer cell lines for their G9a 
expression profile using immune assay and found leukemia cell lines to have the highest 
expression levels of target protein, hence this cell line were used for the cell based assay. Inhibition 
of cancer cell growth was tested by CCK8 and the IC50 of DCG066 found to be comparable to 
BIX-01294 (1.7±0.1 and 3.9±0.3 respectively in K562 cell line). DCG066 also demonstrated the 
ability to induce apoptosis through blocking the cell cycle at stage G2/M in the K562 cells. Further 
experiments with DCG066 showed that compound decreased H3K9 dimethylation levels in K562 
cells.  
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To examine the interactions between DCG066 and the catalytic domain of G9a more 
closely, a binding assay was performed by SPR and the structure-function relationship was 
modeled using GLIDE. DCG066 can bind to G9a with low dissociation constant (Kd =18 µM) as 
measured by SPR. While DCG066 binds in the peptide substrate pocket in G9a with a pose similar 
to BIX-01294, DCG066 forms extra hydrogen bonds with residues Y1154 and R1157, suggesting 
an explanation for the relative activity between the two molecules. In this study, a new lead 
compound for G9a inhibition with a similar activity to BIX-01294 and a novel structure, DCG066, 
was identified from a database of small molecules. This discovery provides both new avenues in 
G9a inhibitor design and a potential probe for G9a. In future studies, we plan to examine the 
structure activity relationship (SAR) of DCG066 analogs to G9a in an effort to improve potency 
and reduce toxicity. 
2.1.4 Experimental Section 
2.1.4.1  Materials and physical measurements  
All reactions were carried out under an atmosphere of dry nitrogen. All reagents and 
anhydrous solvents were obtained commercially and used without further purification. 1H NMR 
spectra were recorded at 400 MHz and 13C NMR spectra were recorded at 100 MHz using Me4Si 
as an internal standard. High-resolution mass spectra (MS) data were acquired using a Thermo-
Fisher Orbitrap Elite mass spectrometer with an electrospray ionization (ESI) source. All the 
samples were run under FT control at 600,000 resolution. All chromatographic purification was 
performed on Biotage Isolera One using normal phase silica gel 60. HPLC chromatogram for 
DCG066 compound was acquired using an Agilent 6110 Series system with UV detector set to 
254 nm. Samples were injected (5 μL) onto an Agilent Eclipse Plus 4.6 × 250 mm, 3.5 μM, C18 
column at room temperature. Sample was eluted using a linear gradient of 5% to 95% B (ACN + 
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0.1% TFA) in 30 min with A being H2O + 0.1% TFA. DCG066 had >95% purity using the HPLC 
method described above. 
2.1.4.2  Chemical synthesis 
(1-Benzylpiperidin-4-yl)bis(4-(trifluoromethyl)phenyl)methanol: Synthesis of the intermediate 
compound 6 was carried out according to the previously reported procedure.[63] n-Butyllitium 
solution (19 mL, 1.6 M in hexane) was added to 6.8 g of 4-bromobenzotrifluride 2 (30 mmol) in 
diethyl ether. To this mixture 2.4 g (10 mmol) of methyl-1-benzylpiperidine-4-carboxylate 1 were 
added dropwise at 5 oC. The reaction mixture was stirred at room temperature for one hour and at 
45 oC for 2 hours.  The crude product was obtained according to the reported procedures, and 
purified by silica gel flash column chromatography using 0-50% ethyl acetate/hexane as eluent to 
yield a brown solid. (4.4 g, 77% yield). 1H NMR (CDCl3): δ 7.64 (m, 8H, 2 x trifluromethylphenyl 
ArH), 7.33-7.30 (m, 5H, Benzyl ArH) 3.56 (s, 2H, Benzylic CH2), 3.00-2.97 (m, 2H, N-CH2-CH2), 
2.54 (t, J=11.6Hz, 1H, N-CH2-CH2-CH), 2.10-2.07 (m, 2H, N-CH2-CH2), 1.60-1.45 (m, 4H, 2 x 
N-CH2). 13C NMR (CDCl3) δ 150.9, 149.6, 139.4, 128.4 (2C), 128.1 (4C), 127.3 (2C), 126.1 (2C), 
125.8 (2C), 125.3 (3C), 125.2 (2C), 81.4, 62.7, 53.8 (2C), 43.8, 26.2 (2C). HRMS (ESI) m/z: calcd 
for C27H25F6NO [M + H]
+ 494.1919; found 494.1883. 
(1-(4-Nitrobenzyl)piperidin-4-yl)bis(4-(trifluoromethyl)phenyl)methanol: The mixture of 
compound 3 (2 g, 4.04 mmol) and 5 wt% Pd/C (500 mg) in ethanol (200 mL) was stirred for 24 
hours at room temperature under hydrogen balloon (1 atm). The reaction mixture was filtered and 
concentrated to a sticky solid. HRMS (ESI) m/z: calcd for C20H19F6NO [M + H]
+ 404.1449 ; found 
404.1426. Compound 4 was used for next step without further purification. The mixture of 
compound 4 (1.2 g, 3 mmol) and DIPEA (1.2 mL) in 10 mL of methylene chloride were added 
into the solution of 4-nitrobenzylchloride 5 (600 mg, 3.5 mmol) in 20 mL of methylene chloride. 
27 
The reaction mixture was stirred for 3 hours at room temperature; then saturated NaHCO3 was 
added. The mixture was extracted with ethyl acetate, washed with water, dried and concentrated 
to give the crude product, which was purified by column chromatography using 0 -40% ethyl 
acetate/hexane as an eluent to yield a pale yellow solid. (1.1 g; 67% yield). 1H NMR (CDCl3): δ 
8.17 (d, J=8.7Hz, 2H, Benzyl, m- ArH), 7.61 (m, 8H, 2 x trifluromethylphenyl ArH), 7.50 (d, 
J=8.7Hz, 2H, Benzyl, o- ArH), 3.60 (s, 2H, Benzylic CH2), 2.92 (m, 2H, N-CH2-CH2), 2.52 (m, 
1H, N-CH2-CH2-CH), 2.12-2.09 (m, 2H, N-CH2-CH2), 1.59-1.45 (m, 4H, 2 x N-CH2). 13C NMR 
(CDCl3) δ 149.0 (2C), 147.1, 146.3, 129.4 (4C), 129.0, 126.0 (6C), 125.4 (2C), 125.3, 123.5 (2C), 
79.3, 62.1, 53.7 (2C), 43.8, 23.2 (2C). HRMS (ESI) m/z: calcd for C27H24F6N2O3 [M + H]
+ 
539.1769; found 539.1737. 
(1-(4-Aminobenzyl)piperidin-4-yl)bis(4-(trifluoromethyl)phenyl)methanol: SnCl2.2H2O (900 
mg, 4.0 mmol) was added into the solution of compound 6 (1.1 g, 2.0 mmol) in EtOH (20 mL) at 
r.t., a mild exotherm was observed. The resulting yellow solution was stirred for 2 days, and then 
the solvent was removed in vacuo. The residue was made basic with a 2N NaOH solution and the 
aqueous layer was extracted with DCM (2x25 mL). The combined organic layers were dried over 
Na2SO4 and then filtered. The solvent was removed in vacuo to yield a pale yellow solid  (0.65 g, 
65% yield), which was used in the next step without further purification.[64]  1H NMR (CDCl3) δ 
7.59 (m, 8H, 2 x trifluromethylphenyl ArH), 7.07 (d, J = 7.5 Hz, 2H, benzyl, m- ArH), 6.63 (d, J 
= 7.5 Hz, 2H, benzyl, o- ArH), 3.62 (s, 1H, OH), 3.45 (s, 2H, benzylic CH2), 3.27 (s, 2H, NH2), 
2.97 (d, J = 11.2 Hz, 2H, N-CH2-CH2 ), 2.49 (t, J = 11.6 Hz, 1H, N-CH2-CH2-CH), 2.03 (t, J = 
11.4 Hz, 2H, N-CH2-CH2), 1.69 – 1.50 (m, 2H, N-CH2), 1.43 (d, J = 12.6 Hz, 2H, N-CH2). 13C 
NMR (CDCl3) δ 149.4 (2C), 145.6, 130.7 (4C), 129.1, 128.8, 126.7, 126.1 (2C), 125.4 (4C), 125.2 
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(2C), 114.9 (2C), 79.28, 62.5, 53.1 (2C), 43.8, 25.7 (2C). HRMS (ESI) m/z: calcd for C27H26F6N2O 
[M + H]+ 509.1983; found 509.2000. 
3-(4-((4-(Hydroxybis(4-(trifluoromethyl)phenyl)methyl)piperidin-1-yl)methyl)phenyl)-1,1-
dimethylurea (DCG066): Compound 7 (254 mg, 0.5 mmol) was dissolved in 20 mL of methylene 
chloride. To this resulting solution was then added DIPEA (0.18 ml, 1 mmol). After stirring for 30 
min at 0 oC, dimethyl carbamoyl chloride (54 µl, 0.6 mmol) was added and the reaction was stirred 
for another 3 hours. Saturated NaHCO3 solution was added and the mixture was extracted with 
DCM (3x20 mL). The combined organic phase was dried over Na2SO4 and concentrated under 
reduced pressure. The residue was purified on silica gel column, eluting with 5% MeOH in DCM 
(containing 0.5% Et3N) to give a yellow solid (180 mg, 62% yield).  
1H NMR (CDCl3): δ 7.57 (m, 
8H, 2 x trifluromethylphenyl ArH), 7.30 (d, J=8.4Hz, 2H, benzyl, m- ArH), 7.16 (d, J=8.4Hz, 2H, 
benzyl, o- ArH), 6.57 (s, 1H, OH), 3.47 (s, 2H, benzylic CH2 ), 2.99 (s, 6H, N(CH3)2), 2.91 (d, 
J=11.4Hz, 2H, N-CH2-CH2), 2.47 (t, J=11.6Hz, 1H, N-CH2-CH2-CH), 2.03 (t, J=11.0Hz, 2H, N-
CH2-CH2), 1.60-1.52 (m, 2H, N-CH2), 1.38 (d, J=12.3Hz, 2H, N-CH2). 
13C NMR (CDCl3) δ 155.9, 
149.5 (2C), 138.2, 129.8 (2C), 128.9, 128.7, 126.2 (5C), 125.4 (2C), 125.2 (2C), 122.7 (2C), 119.9 
(2C), 79.2, 62.3, 53.2 (2C), 43.8, 36.4 (2C), 25.8 (2C). HRMS (ESI) m/z: calcd for C30H31F6N3O2 
[M + H]+ 580.2354; found 580.2373. 
2.1.4.3  Pharmacophore-Based Screening and Computational model. 
Pharmacophore models were automatically constructed using LigandStout for the further 
screening. The SPECS database was filtered with log S > −4 to construct a database of theoretically 
soluble compounds (log P < 5). The compounds were then docked into G9a (PDB entry: 3RJW) 
at the UNC0638 binding pocket using the GLIDE program in standard precision mode.[65] The 
compounds with the highest binding characteristics were then purchased from SPECS Corp (The 
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Netherlands). The computer model of compound DCG066 and BIX-01294 were docked into G9a 
(PDB entry: 3RJW) using GLIDE in the XP mode. The final graphs were drawn by Pymol 
software. Docking validation of 16 molecules was done using Surflex-Dock 2.1[66] by following 
our previous procedures.[67] RMSD value was calculated using Openeye Toolkit.[68] 
2.1.4.4  Biological evaluations 
Cloning, protein expression and purification 
Mouse histone methyltransferase G9a (969-1263) cDNA was amplified from the cDNA of 
BALB/c mouse thymus, and the fragment was sub-cloned into a vector with a 6His-sumo tag. The 
mouse G9a (mG9a) was expressed in Escherichia coli BL21 (DE3) by the addition of 1 mM 
isopropyl-1-thio-D-galactopyranoside (IPTG) and incubated overnight at 16 ℃. 
The 6His-sumo mG9a (969-1263) protein was purified using the following procedure: 
harvested cell pellet was re-suspended in 20 mM Tris (pH 8.0), 500mM NaCl, 0.1% β-
mercaptoethanol, and 1mM PMSF. Cells were lysed by sonicating for 15 seconds with 6-second 
intervals for a total of 15 minutes on an ice bath. The supernatant of cell lysate was loaded onto a 
Ni+ affinity column (Invitrogen) and eluted with buffer (20mM Tris-HCl pH 8.0, 500 mM NaCl, 
20 mM imidazole, 0.1% β-mercaptoethanol, and 1 mM PMSF). The 6His-sumo tag was cleaved 
from the column by adding ubiquitin-like-specific protease 1 (ULP-1) at 4 ℃ for 12 hours. Wash 
buffer was then run through the Ni+ column again and the elution buffer collected. Subsequently, 
advanced protein purification was done by HiTrap Q HP sequential Superdex 200 10/300 GL. 
Elute of every step was analyzed by SDS PAGE, stained by Coomassie brilliant blue (CBB).  
2.1.4.4.1 Tritium-labeled radioactive methylation assay 
The tritium labeled radioactive methylation assay was used to test the inhibitory effects of the 
compounds on enzyme activity.[60] In the methylation assay, 2 μM biotin labeled peptide 
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substrate, 5μM [methyl-3H]-SAM (78Ci/mmol, PerkinElmer), and varied concentrations of 
inhibitor were pre-incubated in the reaction buffer (50 mM HEPES pH 8.0, 10 mM NaCl, 1 mM 
DTT) for 30 minutes at room temperature. The reaction was initiated by adding recombination 
mG9a (969-1263) for a final concentration of 2ug/ml. 2uL of the reaction mixture was transferred 
to a 96 well plate coated with avidin (Corning), incubated for 30 minutes in PBST with 5 mM of 
unlabeled SAM. The plate was washed 3 times with 200 μl PBST per well to remove the remaining 
3H-SAM. Later, 50 mM HCl was used to elute the avidin binding peptide. Finally the elution buffer 
mixed with 200 μL scintillator fluid was analyzed by 1450 Microbeta scintillation counter 
(PerkinElmer). 
2.1.4.4.2 MALDI-TOF-MS 
The in vitro inhibition of G9a by the compounds was measured by MALDI-TOF mass 
spectrum (4800 Plus MALDI TOF/TOF Analyzer, ABI). 100 nM purified mG9a, 2 µM 
synthesized histone H3 (1-24) and 1 µM non-radioactive S-adenosyl methionine (Sigma) were 
added into a reaction buffer (50 mM HEPES pH 8.0, 5  µg/ml BSA and 0.1% β-mercaptoethanol) 
with or without an inhibitor for a final concentration of 10 µM. The reaction was incubated at room 
temperature for an hour, and stopped by TFA addition.  
The result of mass spectrum was analyzed using the Data Explorer (TM) software, providing 
peak area scores while a statistical graph was drawn by Graphpad Prism 5.0. 
2.1.4.4.3 Surface Plasmon Resonance 
The ability of the small molecular compounds to bind to the target enzyme was tested by using 
SPR (Biacore 3000, GE). Approximately 5000RU of the target protein was immobilized on a CM5 
sensor chip. Test compounds were dissolved in running buffer (PBS + P20 + 5% DMSO) at a 
concentration of 100 µM. 
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To screen the compounds, solutions were sequentially injected for 1 minute at the associated 
stage, dissociated in running buffer for 1 minute, and the sensor chip was then regenerated by 
running buffer for 1 minute. In this test, an empty cycle per every 5 cycles was run. From the 
Biacore evaluation software (BIA evaluation version 4.1), the maximum binding values of every 
compound were obtained. 
For the G9a catalytic domain kinetics assay, five concentrations of the compounds were 
prepared and DMSO contents in these samples were equivalent with 5%. The test was performed 
in the Wizard mode; and the injection time and dissociation times were recorded. The results were 
analyzed using the static analysis option in the BIA evaluation software. 
2.1.4.4.4 Cell culture 
All leukemia cells such as HL-60, K562, U937 and Kasumi-1 were grown in RPMI 1640 with 
10% fetal bovine serum (FBS), while adherent cell, including A549, HepG2, HCT116, SW1990, 
and MDA-MB-231 were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% FBS. 
2.1.4.4.5 Human G9a expression level analysis 
In this study, G9a expression levels were analyzed both in cancer cell lines and human tissues. 
CCLE (Cancer Cell Line Encyclopedia, www.broadinstitute. org/ccle/home) and GENT (Gene 
Expression database of Normal and Tumor tissues, http://medical-genome.kribb.re.kr/GENT/) 
were the databases that provided information regarding gene expression in cancer cell lines and 
human tissues, respectively. 
2.1.4.4.6 Quantitative Real-Time PCR  
For quantitative real-time PCR (qRT-PCR), total RNA was extracted and reverse 
transcribed into cDNA. qRT-PCR was performed in ABI PRISM 7500 using SYBR Green PCR 
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Master mix (Takara). The mRNA expression level of G9a was normalized to the transcript level 
of GAPDH. 
2.1.4.4.7 Cell viability analysis  
Cell growth inhibition was detected by CCK8 assay (Dojindo). 1×104 cell suspensions were 
dispensed on a 96-well plate, and then pre-incubated for 4 hours in a humidified incubator. 
Compounds were dissolved in DMSO, diluted in DMEM culture medium for a concentration of 
10× stock solution, and added as 10 ul per well. After incubation for 48 hours, 10 uL of CCK8 
solution was added into the wells and the solution was allowed to incubate for 4 hours in a CO2 
incubator. Afterwards, the absorbance was measured at 450 nm. 
2.1.4.4.8 Flow cytometry assays 
Cell apoptosis was determined by dual staining with annexin V conjugated to phycoerythrin 
(PE) and 7-amino-actinomycin (7AAD). K562 cells were treated with 0, 2, 4, 6, 8, 10 µM of 
DCG066. After incubation for 24 hours, cells were collected and stained with annexin V-PE and 
7AAD (BD Pharmingen) for 15 minutes in the dark and analyzed by flow cytometry. Cells 
undergoing apotosis were identified as annexin V+ and/or 7AAD+ cells. 
Additionally, cells (1×106) were treated with DCG066 (0, 1, 2, 4 µM) or DMSO for cell cycle 
analysis. After 24 hours of incubation, cells were collected and washed with cold PBS twice, and 
then suspended in 300 ul PBS, fixed by 700 ul ethanol. The fixed cells were washed by PBS twice 
and re-suspeneded in PI/RNase Staining Buffer (BD Pharmingen) and then incubated for 15 
minutes before analysis. Flow cytometry experiments were performed using a LSR II cytometer 
(BD Pharmingen), and data were analyzed by using the FlowJo 7.6.1 software. 
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2.1.4.4.9 Histone extraction and Western blot 
Histones from cell lysates were extracted using trichloroacetic acid precipitation as described 
previously.[69] 1×107 cells were harvested by centrifugation at 800×g for 5 minutes, and 
suspended on ice in hypotonic buffer (10mM Tris-HCl pH 8.0, 1mM KCl, 1.5mM MgCl2, 1mM 
DTT, 1mM PMSF) for 30 minutes. The cell lysate was centrifuged at 13000×g for 10 minutes, and 
the supernatant was discarded. The lysate pellets were re-suspended using 0.2N H2SO4,
 mixing at 
rotor at 4 ℃ for 30 minutes, centrifuged at 13000×g for 10 minutes at 4 ℃ with the precipitation 
discarded. 50% trichloroacetic acid (TCA) was added to the supernatant dropwise, and then the 
resulting solution was centrifuged for 20 minutes. The pellets were washed twice in ice-cold 
acetone and then dissolved by adding H2O. Histone content was quantified by a Bradford assay 
and purity was tested by Coomassie blue staining. 
Extracted histone was denatured by SDS loading buffer. Anti-histone H3 antibody (rabbit), 
anti-histone H3 lysine 9 trimethyl antibody (mouse), anti-histone H3 lysine 9 trimethyl antibody 
(rabbit), and mono- and di-methyl arginine antibody (mouse) were purchased from Abcam. Anti-
histone H3 lysine 27 trimethyl antibody (rabbit) was purchased from Millipore.  
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2.2 Structure based design, synthesis and activity studies of small hybrid molecules as 
HDAC and G9a dual inhibitors 
The work presented in this chapter is reproduced with some modification as to fit the format with 
permission from the journal Oncotarget. My contributions as first author were the design, chemical 
synthesis of hybrid molecules, MALDI assay, and figure/manuscript preparation. 
Zang, Lanlan, Shukkoor M. Kondengaden, Qing Zhang, Xiaobo Li, Dilep K. Sigalapalli, Shameer 
M. Kondengadan, Kenneth Huang et al. "Structure based design, synthesis and activity studies of 
small hybrid molecules as HDAC and G9a dual inhibitors." Oncotarget 8, no. 38 (2017): 63187. 
ABSTRACT: Aberrant enzymatic activities or expression profiles of epigenetic regulations are 
therapeutic targets for cancers. Among these, histone 3 lysine 9 methylation (H3K9Me2) and 
global de-acetylation on histone proteins are associated with multiple cancer phenotypes including 
leukemia, prostatic carcinoma, hepatocellular carcinoma and pulmonary carcinoma. Here, we 
report the discovery of the first small molecule capable of acting as a dual inhibitor targeting both 
G9a and HDAC. Our structure based design, synthesis, and screening for the dual activity of the 
small molecules led to the discovery of compound 14 which displays promising inhibition of both 
G9a and HDAC in low micro-molar range in cell based assays. 
2.2.1 Introduction 
Epigenetic modifications describe post-translational modifications that occur on the 
protein without lasting impact on the base genomic code. Likewise, epigenetic 
modifications are reversible due to the manner in which they occur, making restoration of 
the epigenome to its normal function a crucial target in many disease models.[70-74] In 
particular, dimethylation of histone 3 at lysine 9 (H3K9Me2) and various acetylation marks 
on histones are directly correlated to the onset and advancement of multiple cancer 
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phenotypes, including leukemia, prostatic carcinoma, hepatocellular carcinoma and 
pulmonary carcinoma.[75-77] Recently, there has been much success in the development 
of small molecules targeting these post-translational modifications. Epigenetics is still a 
field much in its infancy considering the number of epigenetic targets.[9, 74, 75, 78] From 
this vast pool, epigenetic markers that related to leukemogenesis and tumorigenesis has 
shown to be a promising application of epigenetics. 
Cancer is a disease with complicated treatment options due to the multifactorial basis 
of initiation and progression. Therefore a treatment targeting multiple components instead 
of a single component could be a particular interest in cancer therapeutics.[79-84] To meet 
this need, developing new lead molecules which target cancer from various stages of 
disease development from either known inhibitors or de novo is essential for improving 
effectiveness and side effects/toxicity profile.[14, 85-89] Herein we report the design, 
synthesis and extensive biological evaluation of a class of small molecules targeting the 
enzymes histone deacetylases (HDACs) and histone methyltransferases(G9a), both are key 
posttranslational enzymes in cancer development. 
Histone deacetylases (HDACs) fall into the category of eraser enzymes, so termed due 
to their ability to reverse the acetylation modification employed by another enzyme histone 
acetyl transferases (HATs).[90] However, despite the name, histone deacetylases have a 
wide range of substrates included but not limited to strictly histones.[77] Aberrant activity 
of HDACs have been well documented in several cancer phenotypes, with HDAC 
inhibitors (HDACIs, Figure 2.9) proven as antineoplastic agents. HDACIs have multiple 
cell type-specific effects in vitro and in vivo, such as growth arrest, cell differentiation and 
apoptosis in malignant cells.[75, 91] HDACIs have been shown to induce apoptosis in both 
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solid and hematopoietic malignancies using both transcription dependent and transcription 
independent mechanisms.[92-94] While histone acetylation regulated by HDAC and their 
corresponding writer enzymes HATs, protein methylation is similarly regulated by protein 
lysine methyltransferases enzymes (PKMT), protein arginine methyltransferases (PRMT) 
and their corresponding demethylase enzymes.[70, 95] Our particular interest is the PKMT 
G9a (also known as KMT1C, EHMT2), which is a histone 3 lysine 9 (H3K9) specific 
methyltransferase that is overexpressed in many cancers including leukemia, hepatocellular 
carcinoma and pulmonary carcinoma. G9a is notable for its roles in cancer cell 
proliferation, whereas knockdown of G9a in prostate, lung, and leukemia cancer cells 
resulted in the inhibition of cell growth.[74, 96, 97] Presently, there are number of small 
molecules with different structural cores that have been found to inhibit G9a (Figure 2.9), 
which are also under consideration in clinical trials.[74, 98] In addition to catalyzing mono- 
and dimethylation of H3K9, G9a and its closely related protein GLP, also dimethylate 
lysine 373 of the tumor suppressor p53 to repress the transcriptional activity of p53.[99] 
Different modifications of chromatin associated with variable functions, with the 
extent of modifications and specific residue selected imparting different overall result. For 
example， hyper-acetylation of histone H3 and H4 both known to be activators associated 
with ongoing transcription.[100, 101] However, methylation of H3K9 and H3K27 are 
associated with gene silencing and repressive marks.[102] 
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     Figure 2.9. Examples for known HDAC inhibitors and G9a Inhibitors. [74, 77, 98, 103] 
Following these pathways of distinct and uncorrelated functionalities, we proposed 
that concurrent inhibition of G9a and HDAC may help histone protein to retain the 
transcriptional activity via targeting two pathways. First affecting the reduced formation of 
corepressor marks (H3K9Me2 and p53K373Me2) as a downstream effect of G9a inhibition, 
and secondly with a relaxed and acetylated chromatin promoted by the HDAC inhibition. 
We also hypothesize a potential competition between the HDAC and G9a enzyme because 
they share common substrate (H3K9 and p53K373), a substrate in its acetylated state cannot 
be further methylated, thereby causing an indirect inhibition of G9a. It should also be noted 
that HDACIs show only a moderate and limited biological response when applied as a 
mono treatment, with therapeutic effect significantly improved in combination with other 
anticancer agents.[14, 85, 104] Hence, the optimal deployment of these molecules may be 
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a combination with other epigenetic drugs, acting against the set of enzymes responsible 
for the setup and maintenance of epigenetic information.[105] 
2.2.2 Results and discussion 
Initial tests designed around assessing whether a synergistic effect would be observed in real 
when a combination of G9a inhibitor and HDAC inhibitor used in conjunction. Towards this goal, 
MDA-MB-231 and MCF-7 cell lines treated with either SAHA (1-100 µM), BIX-01294 (1-100 
µM), or a mixture of SAHA and BIX-01294 (1:1; 1-100 µM). As indicated in Figure 2.10 and 
table 2.3, when applied in combination, performance was enhanced towards MDA-MB-231 and 
comparable in MCF-7. Despite being two distinct molecules with different physiochemical 
properties, application of both displayed a significant improvement (approximately 34% lower 
EC50 to SAHA, and 13% lower EC50 to BIX-01294 in MDA-MB-231). Effectively, this provided 
the basis for incorporating both SAHA and BIX-01294 into a single moiety capable of preserving 
inhibitory activity against both targets. 
 
Figure 2.10. EC50 plot of BIX and SAHA combination study. 
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Table 2.3. Combination study of BIX-01294 and SAHA 
Inhibitor (10 µM) MDA-MB-231 MCF-7 
SAHA 2.874±0.84 8.124±4.98 
BIX-01294  2.155±0.88 8.103±1.99 
SAHA+BIX-01294  1.891±0.56 8.564±2.17 
 
Multi-target treatments are typically utilized two approaches, formulating two active 
moieties as a cocktail, or hybridizing properly selected active moieties into a single 
molecule. The first method heavily relies on both compounds having comparable solubility, 
or else fine-tuning of the formulation to ensure the desired bioavailability.[79, 82, 87, 106, 
107] In contrast, a dual-target drug doesn't have such issue with different solubility or 
bioavailability. However, hybrid compounds are challenging to design due to the 
difficulties in optimizing a pharmacophore from two dissimilar compounds that can retain 
multiple functionalities inside the body. There have been some notable successes in the 
latter regard, with few drugs already on the market with superior performance to their 
cocktail counterparts.[88] Currently available hybrid drugs target different stages of disease 
development despite their precursors targeting the same diseases.[85, 87, 107, 108] In light 
of these studies, we propose that a hybrid drug that instead targets components belonging 
to the same scheme in disease progression or has otherwise interdependent functionality 
would yield an improved synergistic effect. Herein we report the design, synthesis, 
screening and biological study of a lead molecule for further development as a drug 
candidate utilizing this principle. 
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2.2.2.1  Compound design and synthesis 
From the available data on G9a and HDAC in the forms of known inhibitors and their 
respective X–ray crystal structures, we observed several details regarding their prospective 
ligands. For instance, all HDAC inhibitors are comprised of three parts- a lipophilic cap 
connected to a hydrophilic Zn2+ binding group by an alkyl, or arylene linker, with the cap 
portion being different bulky groups. Likewise, current G9a inhibitors, except for the fungal 
metabolite chaetocin, are primarily derived from the parent compound BIX-01294. Since 
the discovery of BIX-01294, a clear majority of the G9a inhibitors to emerge based on the 
quinazoline core of BIX-01294. As the lipophilic quinazoline core resemble the lipophilic 
bulky cap for HDAC inhibitors, we reasoned that the G9a core could feasibly function as 
the core scaffold of a HDAC and G9a dual inhibitor. There have been notable success 
stories in regard of varying the cap or linker portion of the HDAC inhibitor, while the metal 
binding portion kept as a hydroxamic acid or an ortho-amino benzamide.[13, 14, 79, 88, 
109] Following this line of thinking, we added the linker and the hydroxamic acid at the 
C2, and C4 of quinazoline ring to obtain the desired hybrid molecules (Figure 2.11 A).This 
design was inspired by the fact G9a have many inhibitors with bulky side chains as in the 
case of E72, HDACIs can also afford a reasonable variety of lipophilic cores. Various 
analogs with different linker lengths and diverse groups at C6 and C4 cyclohexylamine 
positions were also designed. In Figure 2.11 B, quinazoline core is split to four quarters to 
discuss the SAR studies. 
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Figure 2.11. A) Design for Hybrid Molecules B) Structural representation of designed 
compounds (R = Linker + Hydroxamic acid). 
2.2.2.2  Synthesis 
The designed analogs were synthesized from two building blocks; commercially available 
2,4-dichloro-6,7-dimethoxyquinazoline (1) was used for the dimethoxyanalogs (Scheme 
2.2) and, 2-amino-4-methoxybenzoic acid (8) used for monomethoxyanalogs (Scheme 2.3). 
Initially, we synthesized only a few analogs of class III to assess the effectiveness of the 
HDAC substitution while opening the piperazine ring originally present at the prototype 
BIX-01294, this class was particularly intended to explore the SAR of R1. The bulky seven-
member ring was then replaced with an ethylene diamine and coupled with various esters 
of different chain lengths (three to seven carbons for investigating the optimal length for 
the HDAC inhibition) to produce compounds 4, 5, 6 and 7. To check the effect of bulky 
groups at the C4 position of the heterocyclic ring, an isopropyl group then introduced to 
the tertiary amine instead of the methyl group to produce the set of compounds 4a, 5a, 6a 
and 7a (Series IIIA, Scheme 2.2). While investigating the binding characteristics of known 
G9a/GLP inhibitors, the C6 methoxy group of quinazoline ring was hypothesized not to 
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contribute significantly to ligand-receptor interactions. Therefore, the methoxy at C6 was 
eliminated to find a balance for HDAC activity. Compounds in class II designed from this 
rationale. Compounds 13-17 have a 4-aminobenzyl piperidine at C4, while 13a-17a possess 
an isopropylpiperidin-4-amine (Scheme 2.3). Recent studies of UNC0965 wherein a biotin 
tag was applied to UNC0638 found that UNC0965 retained biological activity,[110] 
following this lead, C4 of quinazoline ring was explored. Compounds with the HDAC 
pharmacophore on the C4 carbon of quinazoline core termed as class I, with analogs 19 and 
20 retaining the C6 methoxy group, and 21 and 22 lacking the methoxy group (Scheme 
2.4). 
 
Scheme 2.2. Reagents and conditions: (i) 1-methylpiperidin-4-amine/1-isopropylpiperidin-4-
amine, DIPEA, DMF, rt, 3 h, 80-86%, (ii) tert-butyl (2-aminoethyl)carbamate, DIPEA, 160 
°CMicrowave, 10 min, 60-66%, (iii) TFA/DCM, 3 h, (iv) Monomethyl Suberate, EDCl, HOBt, 8 
h, (v) 50% NH2OH in water, MeOH, 60°C, 8 h , 30-38% over two steps. 
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Scheme 2.3. Reagents and conditions: (i) Urea, 200°C, 2 h, (ii) POCl3, reflux 16 h, 40% in two 
steps, (iii) 4-aminobenzylpiperidin/1-isopropylpiperidin-4-amine, DIPEA, DMF, rt, 3 h, 74% and 
86%, (iv) tert-butyl (2-aminoethyl)carbamate, DIPEA, 160 °C Microwave, 10 min, 64% and 68%, 
(v) TFA/DCM, 3 h, (vi) MonomethylSuberate, EDCl, HOBt, 8 h, 70% in two steps, (vii) 50% 
NH2OH in water, MeOH, 60 °C, 8 h , 30-40%. 
 
Scheme 2.4. Reagents and conditions: (i) 4-aminobenzylpiperidin, DIPEA, DMF, rt, 3 h, 90%, (ii) 
1-methyl-1,4-diazepane, DIPEA, 160 °C Microwave, 10 min, 74%, (iii) EtOH, Pd/C, H2, 8 h, (iv) 
Monomethylsuberate/monomethylpimelate, EDCl, HOBt, 8 h, (v) 50% NH2OH in Water, MeOH, 
60 °C, 8 h, 44% and 45%, (vi) NHBoc-ethylinediamine, DIPEA, DMF, rt, 3 h, 78%, (vii) 1-methyl-
1,4-diazepane, DIPEA, 160 °C Microwave, 10 min, 69%, (viii) TFA/DCM, 8 h, (ix) 
Monomethylsuberate/ monomethylpimelate, EDCl, HOBt, 8 h, (x) 50% NH2OH in water, MeOH, 
60 °C, 8 h , 29%-36%. 
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Scheme 2.2 compounds were synthesized from the commercially available starting material 1. An 
initial displacement reaction using a primary amine was used to introduce the C4 selective 
substitution, with the second displacement to introduce the linker at the C2 position following the 
microwave assisted reaction previously reported.[111] Boc-protected ethylene diamine was treated 
with compound 2 at 160 oC in a microwave for 10 min to yield product 3 with excellent yield. 
Afterward, the amine 3 was deprotected with TFA/DCM, and the free amine was treated with 
corresponding monomethyl esters (carbon chain 2-6) in the presence of coupling reagent EDCI 
and HOBt for about 8 hours to produce mono methyl ester substituted at the C2 position. The ester 
compounds further treated with hydroxylamine in water to get the corresponding hydroxamic acid 
derivatives, which were purified using reverse phase flash chromatography to obtain compounds 
4-7 and 4a-7a in good yield. Synthesis of compounds in Scheme 2.3 requires the C6 demethoxy 
core, and this was synthesized according to the reported procedure to yield 10.[112] Appropriate 
displacement and coupling reactions in this core as demonstrated in Scheme 2.3 afforded 
compounds 13-17 and 13a-17a. Compounds with the HDAC pharmacophore at the C4 position 
(Figure 2B) were synthesized from the starting material 1. As in Scheme 2.4, Pd/C hydragenolysis 
was used to eliminate the benzyl group and produce the free amine of 18 for the coupling of 
monomethyl esters to result in compounds 19-22.  
A parallel synthesis and testing strategy were used in establishing the primary SAR, with the clear 
rationalization of the structure and activity at each stage we could reduce the synthetic targets. 
Initially, we evaluated the G9a potential after the introduction of HDAC pharmacophore. A 
biochemical assay using MALDI-TOF was used to visualize the effects of the synthesized 
compounds on G9a enzymatic activity, we carried out a biochemical reaction involving target 
enzyme G9a, methyl donor SAM and substrate H3 peptide at a concentration of 400 nM, 10 µM 
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and 5 µM respectively.[113] After successfully optimizing the reaction conditions and reaction 
time to see at least 80% of the substrate converted to the methylated form (H3K9Me1 or 
H3K9Me2) with no tri-methylation, we tested BIX-01294 for an optimum level of inhibition and 
fixed the concentration as 5 µM for each inhibitor. 
 
Figure 2.12. Results of in vitro biochemical and cell-based assays. 
a) Methylation pattern observed via MALDI-TOF after incubating with inhibitor 14 and BIX-
01294 for 30 min, b) % ratio of the H3K9Me0, H3K9Me1 and H3K9Me2 after incubating 30 min 
with 14 and BIX-01294 versus no inhibitor, c) In-Cell Western (ICW) assay of 14 and BIX-01294 
in MDA-MB 231 cell lines, d) Result of homogenous histone deacetylase assay of 14 alongside 
SAHA in K562 cell lines. 
 
Most of the compounds retained G9a inhibition capabilities, indicated by the reduction in 
the ratio of the H3K9Me1 and H3K9Me2 peaks compared to the control reaction (Figure 
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2.12, see appendix B.1. Figure 0.2, Table 0.1). While fractionally less potent than parent 
BIX-01294, retention of inhibitory capabilities was nonetheless verification of the initial 
hypothesis. These result corresponded to the MALDI-TOF study done by a previously 
reported procedure.[113] With the knowledge that G9a activity preserved in the 
biochemical assay, next, we investigated the effect in the cell. H3K9Me2 cell 
immunofluorescence In-Cell Western (ICW) assay was used to assess G9a inhibition 
potential, and homogeneous cellular histone deacetylase assay used for measuring HDAC 
inhibition. 
Functional potency evaluation for G9a inhibition: For assessing the functional potency 
of the dual inhibitors, we evaluated all the compounds by H3K9Me2 cell 
immunofluorescence In-Cell Western (ICW) assays and the results shown in Table 2.4. The 
MDA-MB-231 cell line was used in this study as this cell line possesses robust H3K9Me2 
levels.[5] Our results suggested that compounds belonging to the class IV (southwest 
directing HDAC) exert a G9a activity comparable to the parent compound BIX-01294, but 
all other classes were significantly less potent. 
Functional potency evaluation for HDAC inhibition: The enzymatic activity of 
HDAC was measured in intact cells using the homogeneous cellular assay method.[91] A 
cell-permeable peptide Boc-K(Ac)-AMC used as the HDAC substrate, after deacetylation 
it is cleaved by trypsin to release the fluorescent 7-amino-4-methylcoumarin (AMC) and 
further quantified. Each compound candidate tested in both Hela and K562 cell lines, two 
compounds (13 and 14) showed significant HDAC inhibition (Table 2.5, see appendix B.1.  
 
47 
 
Table 2.4. H3K9Me2 cell immunofluorescence In-Cell Western (ICW) assay results (MDA-MB-
231 cell line) 
 
Compound G9a IC50 (µM) Compound G9a IC50 (µM) 
4 96.69±1.68 4a 74.21±1.94 
5 >100 5a 66.63±3.98 
6 >100 6a >100 
7 76.74±0.89 7a 54.55±3.05 
13 37.79±2.80 13a >100 
14 7.136±1.62 14a 46.83±1.97 
15 72.10±1.37 15a 46.97±3.33 
16 90.26±3.75 16a 45.71±1.76 
19 99.63±3.13 21 ND 
20 97.51±2.78 22 60.65±3.66 
BIX-01294 4.563±1.2 5b 87.39±5.44 
 
Table 2.5. Results of homogeneous cellular histone deacetylase assay 
 
Compound Hela IC50 (µM) K562 IC50 (µM) 
13 15.33±0.79 27.75±0.59 
14 13.80±1.22 5.735±1.23 
SAHA 5.044±0.53 2.056±0.59 
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Table 0.2 for full results). An evaluation of these structures indicated that only class III 
compounds displayed the desired activity, it was inconclusive if the R1 and R2 substitutions 
were responsible. Compound 5b, synthesized from 3b with a benzyl group at R1 and a 
methoxy at R2, did not show decent inhibition of HDAC compared with Compound 14. 
Loss of activity in 5b indicated two important strategies for designing HDAC inhibitors 
with quinazoline core; an aromatic ring at R2 is essential for HDAC activity while the 
methoxy group at C6 of quinazoline core almost destroys HDAC inhibition. Linker lengths 
vary from Compound 11 to 14, in which, compounds with 5 or 6 methylene groups between 
the lipophilic core and Zn binding domain found to be the best choice. Similarly, 
compounds 19-22 with the R1 substituted with the HDAC chain did not show promising 
activity, leaving 13 and 14 as the candidates for further study. Closer examination of the 
tested compounds indicated that HDAC activity is limited to compounds with a benzyl 
group at the 4-aminopiperidin ring (R1) along with no substitution at C6. 
Molecular Docking Analysis 
Molecular Docking analysis and molecular dynamics simulations were widely used 
to estimate the interactions between protein and small molecular compounds 
theoretically[114, 115]. Our assays found that 14 had good cellular potency for inhibition 
of both G9a and HDAC, so docking studies were used to examine the interactions of 14 
with the target proteins compared to known ligands using Schrödinger Suite 2014-3.[116] 
The crystal structure of human HDAC8 with MS-344 (PDB ID: 1T67) and human G9a with 
BIX-01294 (PDB ID: 3FPD) were employed as the templates for molecular docking 
studies.[113, 117] Initially we chose HDAC8 protein structure (PDB ID:1T69) for the 
docking study because it has SAHA (which we used as the control in cell based assays) as  
49 
 
Figure 2.13. Molecular docking study results. 
 A) Predicted binding mode of compound 14 on HDAC8 (PDB ID: 1T67), B) Predicted binding 
mode of compound 14 on G9a (PDB ID: 3FPD), C) Binding model of active compound 14 
(orange) as revealed from GLIDE docking in the HDAC8 catalytic site (PDB ID: 1T67). The green 
dashed lines represent hydrogen bonds. The turquoise sphere represents Zn cation and with a 
trigonal bipyramidal coordination geometry. The pink dashed lines indicate the two contacts 
between the ligand and Zn cation, with the mixed dashed lines representing interaction between 
Zn cation and amino acid residues. H-bond distances (Å) between heteroatoms of ligand and amino 
acid residues are as follows: Asp101 (1.90), His142 (2.02), His143 (3.64), Gly151 (3.68), Gly304 
(3.00), Tyr306 (2.17), D) Binding model of active compound 14 (orange) as revealed from GLIDE 
docking in the G9a catalytic site (PDB ID: 3FPD). The green dashed lines represent hydrogen 
bonds. H-bond distances (Å) between heteroatoms of ligand and amino acid residues are as 
follows: Asp1131 (1.66), Asp1135 (1.75, 1.81), Arg1137 (3.33), Glu1138 (3.98), Asp1140 (1.77), 
Arg1214 (2.68, 2.90). 
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the co-crystallized ligand, but our study revealed a lower GLIDE score and docking score 
than the expected (Appendix B.2.), so SP Glide algorithm was first validated by docking 
MS-344 and BIX-01294 from the complex back to the protein, ligand preparation was done 
using LigPrep with OPLS_2005. The search space was defined using Receptor Grid 
Generation in Glide, with the centroid of the ligand chosen to define the grid box. Standard 
precision mode was selected for validation docking, and default settings for scaling van der 
Waals radii were used. No constraints were defined for the docking runs. The docking pose 
with the highest score returned for MS-344 and BIX-01294 were compared with the starting 
protein complex. For subsequent molecular docking of compound 14 in the binding site of 
HDAC8 and G9a, LigPrep was used for energy minimizations of the molecule with the 
OPLS_2005 force field. Using the initial grids generated for HDAC8 and G9a, the standard 
precision docking was repeated for compound 14 as described above. 
Table 2.6 and 2.7 shows the results of docking along with the prominent interactions for 
compound 14 with HDAC8 and G9a. Figure 2.13 illustrated the predicted binding modes 
and the detailed protein−inhibitor interactions of HDAC8 and G9a with compound 14, 
respectively. Figure 2.13 A showed that the catalytic tunnel of HDAC8 was occupied by 
the aliphatic side chain of the inhibitor, while the hydroxamate group chelated the zinc ion 
and hydrogen bonds with residues in the catalytic tunnel. The zinc ion displayed a trigonal 
bipyramidal geometry and two points contacted with the ligand (Figure 2.13 A and 2.3 C). 
Docking studies suggested important structural/catalytic roles for Gly140, His142, Gly151 
and Gly304 in the active site and extending to Tyr306, Asp101. Moreover, 
compound14occupies the binding pocket in a similar posture as MS-344 in the catalytic 
site of HDAC8 (Appendix B.2).  
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Table 2.6. GLIDE docking results for MS-344 and compound 14 at the catalytic site of HDAC8 
(PDB ID:1T67) 
 
S. No. 
Ligand 
ID 
Docking 
Score 
GLIDE 
score 
Interactions 
Hydrogen Bonds Interaction 
with Zn2+ 
Backbone Side Chain 
1 MS-344 -7.931 -7.931 
His142,  
His143,  
Gly151,  
Gly304; 
Asp101, 
Tyr306; 
Ionic 
interaction 
2 14 -7.934 -8.369 
Gly140, 
His142,  
Gly151, 
Gly304; 
Asp101, 
Tyr306; 
Ionic 
interaction 
 
Table 2.7. GLIDE docking results for BIX-01294 and compound 14 at the catalytic site of G9a 
(PDB ID: 3FPD) 
 
S.No. 
Ligand 
ID 
Docking 
Score 
GLIDE 
Score 
Interactions 
Hydrogen Bonds 
Interaction 
with Zn2+ 
Backbone Side Chain 
1 
BIX-
01294 
-7.664 -8.134 Ala1134 
Asp1131,  
Asp1135, 
Asp1140; 
NA 
2 14 -7.321 -7.52 
Arg1137, 
Glu1138 
Asp1131, 
Asp1135,  
Asp1140, 
Arg1214; 
NA 
 
A similar study was performed to establish the binding characteristics of compound 
14 with G9a. The binding model of compound 14 showed that it shares common hydrogen 
bonding interactions with key residues of the catalytic domain in a mode comparable to 
BIX-01294 (Appendix B.2). Most notably, the piperidine ring substituted at quinazolin-4-
amine in compound 14 has hydrogen bonding interactions with Arg1137, Glu1138 
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residues, and the aliphatic chain was involved in some more hydrogen bonding interaction 
with the side chains of residues Asp1131, Asp1135, Asp1140 and Arg1214 (Figure 2.13 B 
and 2.13 D). 
Cell antiproliferation Assay 
Table 2.8. Inhibition of compounds 13 and 14 on the growth of cancer cells and normal cells 
 
Compound EC50 (µM) 
 MDA-
MB-231b 
MCF-7c A549d HEK293e 
13 89.33±1.23 79.43±2.72 >100a 56.96±1.12 
14 10.02±1.66 37.36±2.20 36.24±1.76 19.95±0.19 
SAHA 2.874±0.84 8.124±4.98 19.31±1.26 2.482±1.13 
BIX-
01294 
2.155±0.88 8.103±1.99 21.74±2.73 2.048±0.98 
a>100 in the cases where the IC50 did not reach at the highest tested concentration (100 
µM). 
bMDA-MB-231: breast cancer cell line; cMCF-7: breast cancer cell line; dA549: human 
lung cancer cell line; eHEK293 normal cell line; SAHA and BIX-01294 were used as the 
positive controls; Cells were exposed to the different inhibitors with various concentrations 
for 72h. Inhibition of cell growth by the listed compounds was determined by using CCK-
8 kit. Data shown as mean ± SD of triplicates. 
 
Cell anti-proliferation assays were performed to determine the toxicity of these 
inhibitors. Several cell lines (MDA-MB-231, MCF-7 and A549) were incubated and then 
treated with varying concentrations of the inhibitors for 72 h, respectively. After the first 
cell culture screening, it was determined that the inhibitors were more effective with breast 
cell lines (MDA-MB-231 and MCF-7) compared to other cell lines, particularly compound 
13 and 14 (Table 2.8, and appendix B.3). These compounds were further evaluated against 
the control cell line HEK293 to test their toxicity with a non-cancerous cell line. As seen 
in Table 6, both SAHA and BIX-01294 appear to be toxic to cancer and normal cells, but 
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compounds 13 and 14 displayed lower toxicity, particularly compound 14. 14 also showed 
improved anti-proliferation abilities in all cancer cell lines and reduced toxicity in normal 
cell line compared to 13. 
ADME Prediction Studies 
The same procedures and principals from the earlier in silico physico-chemical 
evaluations of known HDACIs were applied here to evaluate these novel dual 
inhibitors.[118, 119] ADMET module of Discovery Studio 3.1 was used to predict physical 
properties. Using Lipinski’s rule of five,[120] the octanol–water partition coefficient 
(AlogP98) should be less than 5. As seen in Table 2.9, the candidate compound 14 is well 
within accordance of the rule. In addition, other values also fell into the acceptable ranges 
of PSA-2D (7–200) and QplogS (−6.5 to 0.5), indicating 14 may possess good 
bioavailability. These parameters were also taken into consideration in identifying better 
inhibitors, suggesting that 14 has the characteristics desirable for a drug candidate. 
Table 2.9. ADME prediction results 
 
Entry M.W QPlogSc PSA PSA-2Db    AlogP98a 
14 515.654 -3.702 161.25 141.462 2.511 
SAHA 264.324 -2.139 102.256 81.037 1.838 
BIX-01294 476.62 -6.792 50.675 63.249 4.189 
 
aAlogP98 means atom-based LogP (octanol/water), bPSA-2D means 2D fast polar surface 
area. cQplogS means predicted aqueous solubility. 
2.2.3 Conclusions 
Considering the inherent deficiency of HDACIs as a monotherapy, in conjunction with 
the past success of incorporating the HDAC pharmacophore into many dual inhibitors, we 
hypothesized that the core metal ion binding hydrophilic segment could be coupled with 
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the lipophilic core of G9a inhibitors to increase the effectiveness. Both G9a and HDACs 
are therapeutic targets for cancer therapy and are both capable of targeting identical 
substrates (H3K9 and lysine 373 of p53). In search of a lead molecule featuring both HDAC 
and G9a inhibition, the H3 mimicking quinazoline core of G9a inhibitors used as a base 
scaffold. Next, several modifications at different sites introduced to cover most of the 
possible chemical space related to the position and chain length (linker gap between the 
metal binding portion and G9a core). From this design, we synthesized more than 20 
compounds and tested biochemically and in vitro to see if they displayed the desired dual 
activity. Our primary assessment of success was from MALDI-TOF evaluation of the 
H3K9 methylation profile, many of the compounds retained G9a inhibition potential. Cell-
based assays for all the compounds against several cell lines were used to determine their 
inhibition potential, and we found that 13 and 14 displays the desired dual activities 
comparable to the controls SAHA and BIX-01294. Cell toxicity of these compounds was 
determined using CCK-8, showing that compound 14 was both more effective and less 
toxic compared to 13. The ADMET module of Discovery Studio 3.1 also predicted that the 
compound 14 has excellent physico-chemical properties, making it a viable drug candidate. 
Discovery of these small molecules with dual activity towards two epigenetic targets, 
HDACs and G9a, will provide the route for developing similar compounds with high 
potency soon. It is also worth mentioning that compound 14 may also act as a valuable tool 
in investigating the multi-targeting strategy, and its possible impacts on epigenetic targets. 
As this is the first time this sort of work has been done in respect to these two targets, it 
may also provide the basis to understanding histone cross-talk among distinct epigenetic 
targets. With this broad prospective, we further plan for a detailed SAR study specifically 
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to compound 14 to provide a more potent dual inhibitor in conjunction with a mechanistic 
reasoning to understand the synergistic effect of inhibiting both HDACs and G9a 
methyltransferases. 
2.2.4 Experimental Section 
Materials and Methods 
Reagents were purchased from commercial suppliers Sigma-Aldrich, Alfa Aesar, TCI and Acros, 
and were used without further purification unless otherwise indicated. Anhydrous solvents (e.g., 
DMF, DIPEA, MeOH, DCM) were purchased from Sigma-Aldrich. The synthetic progress was 
monitored using silica gel 60 F254 thin layer chromatography plates (Merck EMD Millipore). 
Microwave reactions were performed using Initiator for organic synthesis. Column 
chromatography purifications were performed on an Isolera one system using SNAP columns with 
KP-Sil silica or Zip Si columns with KP-Sil normal phase silica cartridges (unless otherwise 
stated). The nuclear magnetic resonance spectra were recorded on a 400 MHz spectrometer by 
Topspin 3.1 with solvents of CDCl3 and CD3OD. Chemical shifts described in ppm. Coupling 
constants, when reported, are described in hertz (Hz). High-resolution mass spectra (HRMS) data 
were acquired using orbitrap elite mass spectrometer with an electrospray ionization (ESI) source. 
All the samples were run under FT control at 600000 resolution. All temperatures are described in 
°C. The purity of all final compounds was confirmed by RP-HPLC analysis, was >95% or 
mentioned in the synthetic procedure. Analytical high-performance liquid chromatography 
(HPLC) was performed using a Waters Agilent 1260 infinity, column used was Agilent eclipse 
plus C18 3.5 µM reverse phase 150 mm×4.6 mm chromatography column. Samples were detected 
using a wavelength of 254 nm. All samples were analyzed using acetonitrile (0.1% TFA): water 
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(0.1% TFA) 5-60% over 30 min and a ﬂow rate of 0.4 ml/min. Preparative HPLC was performed 
using the XBridge prep C18, 5 µM, 10×150 mm column and a flow rate of 1 ml/min.  
Chemical Synthesis 
H3 (1-20, ARTKQTARKSTGGKAPRKQL): Peptide was synthesized through Fmoc-Strategy. 
Automated peptide synthesis was performed on Liberty Blue Peptide Synthesizer. Peptide were 
synthesized under microwave-assisted protocols on Wang resins. The deblock mixture was 20% 
piperidine in DMF. The following Fmoc-Lys(Boc)-Wang resin from Nova biochem were 
employed. The Fmoc-protected amino acids were purchased from Chempep. Cocktail of 
TFA/TIS/Dodt/H2O (92.5:2.5:2.5:2.5) was used to cleave peptides off theresin. After cleavage, 
crude peptide was purified through a reverse phase C18 column (purchased from Agilent, Eclipse 
XDB-C18, 5 µm, 9.4*250mm). 
Procedure A: General procedure for compounds 2, 2a and 2b. 4-amino-piperidines (18.01 mmol) 
were added to a solution of 2,4-dichloro-6,7-dimethoxyquinazoline (2.11 g, 8.14 mmol in DMF 
20 ml), followed by the addition of N,N-diisopropylethylamine (1.5 ml, 8.62 mmol) and the 
resulting mixture was stirred at room temperature for 2 h until TLC showed that the starting 
material had disappeared. Water was added to the reaction mixture, and the resulting solution was 
extracted with ethyl acetate. The organic layer was washed with 0.5% acetic acid aqueous solution 
and brine, dried and concentrated to give the crude product, which was purified on flash column 
via eluting with hexane-ethyl acetate (20%) to get 3.0g of the desired compound, yield 80-86%. 
Spectral properties of the product were matched with the reported compounds. 
Procedure B: General procedure for compounds 3, 3a and 3b. Compound 2 (6.0 mmol) was 
dissolved in 8 ml of isopropanol. To this solution was added tert-butyl (2-aminoethyl) carbamate 
(1.92 g, 12 mmol) and DIPEA (1.5 ml, 7.2 mmol). The resulting solution was placed inside a 
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microwave at 160 oC for 10 min. After cooling, TLC indicated the reaction was completed. Solvent 
was removed under reduced pressure, the residue was dissolved in DCM, washed with the 
saturated NaHCO3 solution. The combined organic phase was dried over Na2SO4 and concentrated 
under reduced pressure. The residue was purified on silica gel column, eluting with 5% MeOH in 
DCM (containing 0.5% Et3N) to give 1.8 g of the Boc–protected amino compound as pale yellow 
solid, yield 60-66%.  
N2-(2-aminoethyl)-6,7-dimethoxy-N4-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine (3): 
Brown solid, 1.8 g, 66% yield. M.P. 109-107 oC, 1H NMR (400 MHz, CDCl3) δ 7.10 (s, 1H), 7.06 
(s, 1H), 6.19 (s, 1H), 4.33 – 4.20 (m, 1H), 3.91 (s, 6H), 3.17 (d, J = 5.4 Hz, 2H), 2.93 – 2.75 (m, 
4H), 2.50 (s, 2H), 2.30 (s, 3H), 2.14 (m, 4H), 1.78 – 1.60 (m, 2H), 1.42 (s, 9H). 13C NMR (100 
MHz, CDCl3) δ 159.5, 155.9, 154.8, 153.2, 148.9, 147.9, 107.1, 106.7, 101.3, 80.2, 56.6, 56.1, 
54.5, 46.8, 45.0, 39.2, 30.4, 27.8. HRMS (ESI): m/zcalcd for C23H36N6O4 [M + H]
+, 461.2876; 
found, 461.2862. 
N2-(2-aminoethyl)-6,7-dimethoxy-N4-(1-isopropylpiperidin-4-yl)quinazoline-2,4-diamine 
(3a): Brown solid, 1.7 g, 60% yield. M.P. 114-116 oC, 1H NMR (400 MHz, CDCl3) δ 7.23 (s, 1H), 
7.19 (s, 1H), 4.13 (s, 1H), 3.84 (s, 6H), 3.58 – 3.44 (m, 4H), 3.39 (d, J = 4.9 Hz, 2H), 3.32 (d, J = 
4.6 Hz, 2H), 2.96 – 2.83 (m, 2H), 2.11 (t, J = 11.3 Hz, 2H), 2.01 (d, J = 10.8 Hz, 2H), 1.74 – 1.59 
(m, 2H), 1.40 (s, 9H), 1.01 (s, 6H).13C NMR (100 MHz, CDCl3) δ 165.1, 158.8, 156.3, 154.5, 
145.6, 112.04, 108.9, 99.6, 80.8, 56.3, 55.9, 52.6, 49.9, 48.4, 41.4, 40.8, 31.7, 28.4. HRMS (ESI): 
m/zcalcd for C25H40N6O4 [M + H]
+, 489.3145; found, 489.3156. 
N2-(2-aminoethyl)-6,7-dimethoxy-N4-(1-benzylylpiperidin-4-yl)quinazoline-2,4-diamine 
(3b): Brown solid, 2.1 g, 64% yield. M.P. 130-132 oC, 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.14 
(m, 5H), 6.79 (s, 1H), 6.58 (s, 1H), 6.01 (s, 2H), 5.44 (s, 1H), 4.11 (d, J = 12.4 Hz, 1H), 3.84 (m, 
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6H), 3.52 (s, 2H), 3.40 – 3.37 (m, 2H), 3.32 (d, J = 4.6 Hz, 2H), 2.93 – 2.84 (m, 2H), 2.11 (t, J = 
11.3 Hz, 2H), 2.01 (d, J = 10.8 Hz, 2H), 1.75 – 1.59 (m, 2H), 1.38 (s, 9H).13C NMR (100 MHz, 
CDCl3) δ 165.1, 158.8, 156.3, 154.5, 145.6, 138.1, 129.2, 128.2, 127.1, 112.01, 108.9, 102.3, 78.9, 
63.0, 56.3, 55.9, 52.6, 49.9, 48.4, 41.4, 40.8, 31.7, 28.3. HRMS (ESI): m/zcalcd for C29H40N6O4 
[M + H]+, 537.3189; found, 537.3165. 
NH-Boc protection was removed to get the free amines of 3, 3a and 3b using TFA/DCM overnight, 
dried amine was used directly in next step without further purification. 
Procedure C: General procedure for compounds 4-7 and 4a-7a, to a stirred solution of 
corresponding monomethyl ester (0.25 mmol) in anhydrous CH2Cl2 (5 ml) was added EDCI (70 
mg, 0.35 mmol) followed by HOBt (50 mg, 0.35 mmol) at 0 °C. After 30 min, a solution of 
compound 3 (138 mg, 0.3 mmol) and DIEPA (0.1 ml, 0.5 mmol) in CH2Cl2 (2 ml) was added drop-
wise at 0 °C. The mixture was allowed to stir at room temperature and monitored by TLC. Upon 
completion, the organic layer was washed with saturated aqueous NaHCO3 solution followed by 
brine. The organic extracts were dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The crude product was purified by flash chromatography (MeOH/DCM up to 20%) to 
afford desired compounds as colorless oily liquid. HRMS (ESI): m/zcalcd for C27H42N6O5 [M + 
H]+, 531.3295; found, 531.3279. This intermediate in methanol (2.5 ml) was added a solution of 
hydroxylamine (1 ml, 50% in water). The resulting solution was stirred for 3 h at 60°C. Then 
solvent was removed under vacuum and the crude residue purified by flash chromatography using 
reverse phase silica gel column using H2O (0.1% HCOOH)/CH3CN (0.1% HCOOH) as eluent (0-
100 %). This afforded the expected derivatives as a yellow/brown sticky mass, 30-38% over 2 
steps.  
59 
N1-(2-((6,7-dimethoxy-4-((1-methylpiperidin-4-yl) amino) quinazolin-2-yl) amino) ethyl)-
N8-hydroxyoctanediamide (4): 44 mg, 33% yield. 1H NMR (400 MHz, MeOD) δ 7.81 (s, 1H), 
7.59 (s, 1H), 6.91 (s, 1H), 4.68 (s, 1H), 3.93 (s, 6H), 3.64-3.47 (m, 5H), 3.23 (d, J = 1.4 Hz, 4H), 
3.14 (m, 1H), 2.90 (d, J = 16.0 Hz, 3H), 2.36-2.28 (m, 2H), 2.21-2.07 (m, 5H), 1.64 – 1.49 (m, 
4H), 1.30 (s, 4H). 13C NMR (100 MHz, MeOD) δ 183.7, 167.5, 148.4, 128.3, 124.8, 124.0, 117.1, 
110.9, 104.0, 55.4, 54.7, 53.3, 52.8, 46.1, 42.1, 41.8, 38.2, 35.9, 32.3, 28.2, 25.4. HRMS (ESI): 
m/zcalcd for C26H41N7O5 [M + H]
+, 532.3247; found, 532.3248. HPLC purity 95.45% ; tR= 14.004 
N1-hydroxy-N8-(2-((4-((1-isopropylpiperidin-4-yl)amino)-6,7-dimethoxyquinazolin-2-
yl)amino)ethyl)octanediamide (4a): 49 mg, 35% yield. 1H NMR (400 MHz, MeOD) δ 7.76 (s, 
1H), 7.70 (s, 1H), 6.90 (s, 1H), 4.72 (s, 1H), 3.92 (s, 6H), 3.60 (m, 5H), 3.48 - 3.38 (m, 4H), 3.33 
(dd, J = 3.2, 1.6 Hz, 1H), 2.39-2.19 (m, 5H), 2.07 (t, J = 7.1 Hz, 2H), 1.56 (d, J = 5.5 Hz, 4H), 
1.41-1.28 (m, 9H). 13C NMR (100 MHz, MeOD) δ 171.6, 166.3, 156.7, 153.1, 147.4, 147.2, 142.2, 
135.7, 125.2, 124.7, 120.0, 117.3, 110.5, 104.1, 103.7, 57.9, 55.5, 45.0, 34.1, 32.1, 28.3, 25.0, 15.8. 
HRMS (ESI): m/zcalcd for C28H45N7O5 [M + H]
+, 560.3560; found, 560.3554. HPLC purity 
95.12% ; tR= 14.820. 
N1-(2-((6,7-dimethoxy-4-((1-methylpiperidin-4-yl)amino)quinazolin-2-yl)amino)ethyl)-N7-
hydroxyheptanediamide (5): 38 mg, 30% yield. 1H NMR (400 MHz, MeOD) δ 7.70 (s, 1H), 6.97 
(s, 1H), 4.69 (s, 2H), 3.96 (s, 6H), 3.85 (s, 1H), 3.67 – 3.49 (m, 4H), 3.47 (d, J = 5.7 Hz, 2H), 3.25 
(d, J = 13.5 Hz, 2H), 3.15 (d, J = 7.4 Hz, 1H), 3.05 – 2.83 (m, 4H), 2.31 (d, J = 11.1 Hz, 2H), 2.23 
– 2.06 (m, 5H), 1.64 – 1.52 (m, 3H), 1.35 (d, J = 6.9 Hz, 2H). 13C NMR (100 MHz, MeOD) δ 
174.8, 170.0, 163.8, 156.6, 156.0, 153.4, 147.3, 112.0, 108.9, 99.6, 56.8, 53.6, 46.0, 40.5, 38.7, 
37.4, 34.4, 30.4, 28.3, 25.2. HRMS (ESI): m/zcalcd for C25H39N7O5 [M + H]
+, 518.3091; found, 
518.3080. HPLC purity 95.21% ; tR= 14.402 
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N1-hydroxy-N7-(2-((4-((1-isopropylpiperidin-4-yl)amino)-6,7-dimethoxyquinazolin-2-
yl)amino)ethyl)heptanediamide (5a): 51 mg, 38% yield. 1H NMR (400 MHz, MeOD) δ 7.75 (s, 
1H),  7.61 (s, 1H), 6.94 (s, 1H), 4.73 (s, 1H), 3.94 (s, 6H), 3.61 (m, 5H), 3.48 (s, 2H), 3.42 – 3.23 
(m, 3H), 2.39-2.21 (s, 5H), 2.09 (t, J = 6.9 Hz, 3H), 1.60 (s, 4H), 1.38 (m, 8H). 13C NMR (100 
MHz, MeOD) δ 170.8, 167.7, 164.5, 155.5, 154.2, 152.0, 147.3, 110.8, 104.2, 98.1, 55.4, 53.4, 
52.6, 48.2, 47.1, 38.5, 37.1, 35.4, 31.9, 28.5, 25.6, 15.8. HRMS (ESI): m/zcalcd for C27H43N7O5 
[M + H]+, 546.3405; found, 546.3385. HPLC purity 93.80% ; tR= 14.991. 
N1-(2-((4-((1-benzylpiperidin-4-yl)amino)-6,7-dimethoxyquinazolin-2-yl)amino)ethyl)-N7-
hydroxyheptanediamide (5b): 55 mg, 37% yield. 1H NMR (400 MHz, MeOD) δ 7.67 (d, J = 1.9 
Hz, 1H), 7.44 (dt, J = 15.7, 7.9 Hz, 5H), 6.96 (s, 1H), 4.48 (s, 1H), 3.96 (dd, J = 12.2, 3.3 Hz, 7H), 
3.63 (s, 3H), 3.54 – 3.44 (m, 2H), 3.28 (d, J = 11.8 Hz, 2H), 2.72 (s, 2H), 2.32 – 2.16 (m, 5H), 
2.10 (t, J = 7.1 Hz, 1H), 1.94 (d, J= 13.8 Hz, 2H), 1.60 (ddd, J = 15.4, 12.7, 7.5 Hz, 4H), 1.41 – 
1.20 (m, 2H). 13C NMR (100 MHz, MeOD) δ 174.9, 171.4, 167.7, 159.4, 156.3, 156.0, 153.3, 
147.4, 136.1, 130.6, 130.4, 129.1, 128.7, 128.6, 103.6, 98.4, 97.9, 60.5, 55.5, 51.1, 40.1, 38.3, 35.3, 
28.5, 27.9, 25.0, 24.8. HRMS (ESI): m/zcalcd for C31H43N7O5 [M + H]
+, 594.3440; found, 
594.3460. HPLC purity 96.20% ; tR= 14.001. 
N1-(2-((6,7-dimethoxy-4-((1-methylpiperidin-4-yl)amino)quinazolin-2-yl)amino)ethyl)-N6-
hydroxyadipamide (6): 44 mg, 35% yield. 1H NMR (400 MHz, MeOD) δ 7.65 (s, 1H), 6.93 (s, 
1H), 4.69 (s, 1H), 3.95 (s, 6H), 3.60 (d, J = 14.8 Hz, 4H), 3.21 (m, 3H), 2.89 (d, J = 9.2 Hz, 4H), 
2.29 (m, 4H), 2.13 (s, 3H), 1.90 (dt, J = 13.6, 6.7 Hz, 1H), 1.64 (s, 4H), 1.39 (d, J = 6.6 Hz, 2H). 
13C NMR (100 MHz, MeOD) δ 170.8, 168.2, 159.3, 156.5, 156.2, 153.3, 147.3, 111.2, 108.6, 
103.0, 55.5, 52.9, 46.0, 41.8, 40.56, 38.2, 37.4, 31.8, 28.2, 24.6. HRMS (ESI): m/zcalcd for 
C24H37N7O5 [M + H]
+, 504.2934; found, 504.2911. HPLC purity 96.81% ; tR= 13.374 
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N1-hydroxy-N6-(2-((4-((1-isopropylpiperidin-4-yl)amino)-6,7-dimethoxyquinazolin-2-
yl)amino)ethyl)adipamide (6a): 46 mg, 35% yield. 1H NMR (400 MHz, MeOD) δ 7.77 (s, 1H), 
7.64 (s, 1H), 7.32 (s, 1H), 6.96 (s, 1H), 4.73 (s, 1H), 3.96 (s, 6H), 3.72 – 3.52 (m, 5H), 3.47 (s, 
2H), 3.37 (d, J = 15.2 Hz, 2H), 2.39 (d, J = 12.1 Hz, 2H), 2.17 (m, 6H), 1.63 (s, 4H), 1.43 (d, J = 
6.3 Hz, 6H). 13C NMR (100 MHz, MeOD) δ 174.5, 170.5, 168.0, 157.1, 156.0, 153.5, 147.3, 113.4, 
108.4, 89.7, 57.2, 55.8, 49.2, 49.5, 40.8, 39.7, 38.0, 32.5, 28.2, 24.7, 15.5. HRMS (ESI): m/zcalcd 
for C26H41N7O5 [M + H]
+, 532.3247; found, 532.3245. HPLC purity 96.95% ; tR= 14.164 
N1-(2-((6,7-dimethoxy-4-((1-methylpiperidin-4-yl)amino)quinazolin-2-yl)amino)ethyl)-N5-
hydroxyglutaramide (7): 40 mg, 33% yield. 1H NMR (400 MHz, MeOD) δ 7.68 (s, 1H), 7.63 (s, 
1H), 7.30 (s, 1H), 6.84 (s, 1H), 4.66 (s, 1H), 3.92 (s, 6H), 3.61 (s, 4H), 3.46 (s, 2H), 3.35 (d, J = 
15.4 Hz, 3H), 2.90 (m, 3H), 2.29 (m, 4H), 2.14 (d, J = 6.6 Hz, 4H), 1.91 (s, 2H). 13C NMR (100 
MHz, MeOD) δ 170.8, 168.2, 159.4, 159.3, 156.5, 153.3, 147.3, 136.1, 122.1, 111.2, 108.6, 103.7, 
55.5, 52.9, 46.1, 41.8, 40.0, 38.4, 38.2, 35.2, 31.8, 28.2, 24.6. HRMS (ESI): m/zcalcd for 
C23H35N7O5 [M + H]
+, 490.2778; found, 490.2756. HPLC purity 95.61% ; tR= 12.751 
N1-hydroxy-N5-(2-((4-((1-isopropylpiperidin-4-yl)amino)-6,7-dimethoxyquinazolin-2-
yl)amino)ethyl)glutaramide (7a): 50 mg, 38% yield. 1H NMR (400 MHz, MeOD) δ 7.67 (s, 1H), 
6.93 (s, 1H), 4.72 (s, 2H), 3.94 (s, 6H), 3.59 (d, J = 12.4 Hz, 5H), 3.47 (s, 2H), 3.36 (d, J = 13.9 
Hz, 2H), 2.37 (s, 2H), 2.22-2.12 (m,  6H), 1.63 (m, 4H), 1.44 (s, 6H). 13C NMR (100 MHz, MeOD) 
δ 173.1, 168.0, 158.5, 156.5, 153.3, 134.9, 147.5, 110.6, 103.7, 98.5, 57.8, 55.2, 40.1, 38.4, 35.7, 
32.4, 31.7, 28.5, 16.2, 15.8. HRMS (ESI): m/zcalcd for C25H39N7O5 [M + H]
+, 518.3091; found, 
518.3139. HPLC purity 93.38% ; tR= 13.670. 
Compounds 13-16 and 13a-16a 
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2,4-dichloro-7-methoxyquinazoline: Compound 10 was prepared according to the previously 
reported procedure,[112] 3.4 g of anthranilic acid (20 mmol) and 3.5 equiv. of urea were finely 
powdered using mortar and pestle and heated to 200 °C in a round-bottom flask open to the 
atmosphere. After 2 h, the mixture was cooled, triturated with water, and filtered to give the 
product as crude. Product was dried and used in next step directly. Molecular ion peak for 
C9H8N2O3 was found at 192.0773. Crude quinazoline-2,4-dione and 2.4 g of N,N-diethylaniline 
were mixed in 45 ml of phosphorus oxychloride, and the mixture was refluxed overnight under an 
argon atmosphere. The crude reaction mixture was concentrated, neutralized the excess of POCl3 
using NaHCO3 and extracted to EA, dried on Na2SO4 and evaporated, purified using flash column, 
eluting at 20% of EA/Hexane. White fluffy powder, 1.82 g, 40% overall yield. HRMS (ESI): 
m/zcalcd for C9H6Cl2N2 [M + H]
+, 228.9935; found, 228.9934.  
N-(1-benzylpiperidin-4-yl)-2-chloro-7-methoxyquinazolin-4-amine (11) and  2-chloro-N-(1-
isopropylpiperidin-4-yl)-7-methoxyquinazolin-4-amine (11a). 
Compound 11 and 11a were prepared according to the procedure A, using 1-methylpiperidin-4-
amine or 1-benzylpiperidin-4-amine. 11: Yellow powder, 74%. M.P. 134-136 oC,1H NMR (CDCl3, 
400 MHz) δ ppm 7.54 (d, J = 9.0 Hz, 1H), 7.27-7.34(m, 5H), 7.10 (d, J = 2.4 Hz, 1H), 7.04 (dd, J1 
= 9.0 Hz, J2 = 2.4 Hz, 1H), 5.61(d, J = 7.71 Hz, 1H), 4.23-4.33 (m, 1H), 3.88 (s, 3H), 3.57 (s, 2H), 
2.91 (d, J = 11.9 Hz, 2H), 2.24-2.30 (m, 2H), 2.08-2.13 (m, 2H), 1.59-1.69 (m, 2H). 13C NMR 
(CDCl3, 100 MHz) δ ppm 163.7, 129.8, 158.3, 153.3, 137.7, 129.3, 128.3, 127.3, 122.0, 117.9, 
107.2, 106.9, 62.9, 55.7, 52.0, 48.0, 31.9. HRMS (ESI): m/zcalcd for C21H23ClN4O [M + H]
+, 
383.1639; found, 383.1610. 
11a: Brownish yellow semi solid, 86%.1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 9.1 Hz, 1H), 
7.13 (s, 1H), 7.07 (d, J = 9.1 Hz, 1H), 4.28 (s, 1H), 3.92 (s, 3H), 2.88 (d, J = 11.0 Hz, 2H), 2.35 
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(s, 3H), 2.26 (t, J = 11.6 Hz, 2H), 2.17 (d, J = 12.2 Hz, 2H), 1.86 (s, 1H), 1.66 (m, 2H). HRMS 
(ESI): m/zcalcd for C15H19ClN4O [M + H]
+, 306.1247; found, 307.1323. 
N2-(2-aminoethyl)-N4-(1-benzylpiperidin-4-yl)-7-methoxyquinazoline-2,4-diamine (12) and 
N2-(2-aminoethyl)-7-methoxy-N4-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine (12a) 
Compounds 12 and 12a were obtained via Procedure B: 
12: Brown solid, 1.94 g, 64%. 1H NMR (400 MHz, CDCl3) δ 8.75 (s, 2H), 8.49 (d, J = 5.2 Hz, 
1H), 7.96 (s, 1H), 7.37 – 7.14 (m, 4H), 6.62 (d, J = 8.9 Hz, 2H), 5.56 (s, 1H), 4.22 (s, 1H), 4.06 – 
3.88 (m, 1H), 3.67 (d, J = 10.9 Hz, 3H), 3.51 (d, J = 9.7 Hz, 4H), 3.26 (s, 2H), 2.99 (dd, J = 14.9, 
7.4 Hz, 1H), 2.90 (s, 2H), 2.09 (d, J = 15.0 Hz, 4H), 1.91 (d, J = 12.4 Hz, 3H), 1.28 (d, J = 10.5 
Hz, 10H). HRMS (ESI): m/zcalcd for C28H38N6O3 [M + H]
+, 507.3084; found, 507.3047. 
12a: Brown solid, 1.75 g, 68%. 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 8.9 Hz, 1H), 6.84 (s, 
1H), 6.74 (d, J = 8.8 Hz, 1H), 5.55 (s, 2H), 4.18 (s, 1H), 3.88 (s, 3H), 3.61 (d, J = 3.9 Hz, 2H), 
3.39 (d, J = 4.8 Hz, 2H), 2.87 (d, J = 11.2 Hz, 2H), 2.34 (s, 3H), 2.21 (t, J = 11.3 Hz, 2H), 2.12 (d, 
J = 11.8 Hz, 2H), 1.66 (d, 10.4 Hz, 2H), 1.44 (s, 9H). HRMS (ESI): m/zcalcd for C22H34N6O3 [M 
+ H]+, 431.2771; found, 431.2767. 
Compounds 13-17 and 13a-17a were synthesized according to procedure C from the 
corresponding free amines, Yield varied from 30-40%, yellow/brown sticky solids were obtained 
after purification. 
N1-(2-((4-((1-benzylpiperidin-4-yl)amino)-7-methoxyquinazolin-2-yl)amino)ethyl)-N8-
hydroxyoctanediamide(13): 45 mg, 31% yield. 1H NMR (400 MHz, MeOD) δ 8.06 (s, 1H), 7.52 
(d, J = 13.6 Hz, 5H), 6.83 (d, J = 11.2 Hz, 2H), 4.62 (s, 1H), 4.34 (s, 2H), 3.89 (s, 3H), 3.70 – 3.40 
(m, 6H), 3.22 – 3.03 (m, 3H), 2.21 (m, 8H), 1.56 (s, 4H), 1.29 (s, 5H). 13C NMR (100 MHz, 
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MeOD) δ 175.0, 171.5, 165.1, 159.8, 154.0, 151.3, 141.9, 130.9, 129.7, 129.6, 128.8, 125.4, 113.7, 
102.9, 98.0, 59.9, 55.3, 50.7, 40.0, 38.3, 35.7, 32.2, 28.4, 28.3, 27.9, 25.4, 25.1. HRMS (ESI): 
m/zcalcd for C31H43N7O4 [M + H]
+, 578.3455; found, 578.3444. HPLC purity 95.41%; tR= 16.756. 
N1-hydroxy-N7-(2-((7-methoxy-4-((1-methylpiperidin-4-yl)amino)quinazolin-2-
yl)amino)ethyl)heptanediamide (13a): 44 mg, 33% yield. 1H NMR (400 MHz, CDCl3) δ 7.46 (s, 
1H), 6.85 – 6.49 (m, 2H), 4.20 (s, 1H), 3.87 (s, 3H), 3.70 – 3.46 (m, 4H), 2.95 (d, J = 10.6 Hz, 
2H), 2.36 (s, 3H), 2.23 (dd, J = 21.2, 12.2 Hz, 6H), 2.15 – 2.00 (m, 6H), 1.81 (d, J = 10.6 Hz, 3H), 
1.65 (s, 5H). 13C NMR (100 MHz, MeOD) δ 175.0, 168.6, 165.2, 153.8, 149.2, 134.8, 125.4, 113.7, 
108.7, 102.9, 98.0, 55.2, 52.8, 46.2, 42.2, 40.0, 38.2, 35.6, 32.2, 28.4, 28.3, 28.1, 25.3, 25.0. HRMS 
(ESI): m/zcalcd for C25H39N7O4 [M + H]
+, 502.3142; found, 502.3143. HPLC purity 95.75%; tR= 
13.767. 
N1-(2-((4-((1-benzylpiperidin-4-yl)amino)-7-methoxyquinazolin-2-yl)amino)ethyl)-N7-
hydroxyheptanediamide (14): 49 mg, 35% yield. 1H NMR (400 MHz, MeOD) δ 8.10 (d, J = 9.1 
Hz, 1H), 7.59 – 7.40 (m, 5H), 6.97 (d, J = 9.1 Hz, 1H), 6.90 (s, 1H), 4.60 (s, 1H), 4.18 (s, 2H), 
3.94 (s, 3H), 3.64 (d, J = 8.0 Hz, 2H), 3.46 (dd, J = 14.1, 8.1 Hz, 4H), 3.39 – 3.31 (m, 2H), 3.18 – 
2.96 (m, 2H), 2.23 (dd, J = 19.2, 11.7 Hz, 4H), 2.15 – 1.92 (m, 4H), 1.69 – 1.53 (m, 4H), 1.41 – 
1.27 (m, 2H). 13C NMR (100 MHz, MeOD) δ 175.0, 171.4, 167.8, 165.3, 159.9, 154.0, 141.9, 
131.2, 130.5, 129.1, 128.7, 125.3, 113.8, 103.0, 98.2, 60.5, 55.1, 51.0, 40.2, 38.2, 35.3, 32.0, 28.4, 
28.0, 25.0, 24.8. HRMS (ESI): m/zcalcd for C30H41N7O4 [M + H]
+, 564.3298; found, 564.3307. 
HPLC purity 95.02%; tR= 16.600. 
N1-hydroxy-N7-(2-((7-methoxy-4-((1-methylpiperidin-4-yl)amino)quinazolin-
2yl)amino)ethyl) heptanediamide (14a): 49 mg, 40% yield. 1H NMR (400 MHz, MeOD) δ 8.10 
(s, 1H), 7.17 (s, 1H), 6.94 (m, 1H), 4.62 (d, J = 12.4 Hz, 2H), 3.94 (s, 3H), 3.86 (s, 2H), 3.73 – 
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3.55 (m, 2H), 3.47 (s, 1H), 3.29 (m, 5H), 3.15 (dd, J = 14.9, 7.5 Hz, 2H), 2.97 – 2.77 (m, 4H), 2.45 
– 2.17 (m, 3H), 2.24 – 2.02 (m, 3H), 1.61 (s, 2H), 1.42 – 1.22 (m, 2H). 13C NMR (100 MHz, 
CDCl3) δ 178.5, 174.4, 166.0, 165.6, 159.2, 153.1, 129.78, 117.7, 115.8, 106.9, 59.6, 53.5, 50.7, 
46.8, 42.1, 39.7, 39.3, 36.0, 32.0, 29.8, 28.4. HRMS (ESI): m/zcalcd for C24H37N7O4 [M + H]
+, 
487.2907; found, 488.2962. HPLC purity 94.16%; tR= 13.232. 
N1-(2-((4-((1-benzylpiperidin-4-yl)amino)-7-methoxyquinazolin-2-yl)amino)ethyl)-N6-
hydroxyadipamide (15): 52 mg, 38% yield. 1H NMR (400 MHz, MeOD) δ 8.03 (s, 1H), 7.52 (m, 
6H), 6.78 (d, J = 10.3 Hz, 2H), 4.61 (s, 1H), 4.36 (s, 2H), 3.87 (s, 3H), 3.60 (m, 4H), 3.46 (m, 2H), 
3.38 (m, 3H), 2.49 – 1.78 (m, 8H), 1.64 (s, 4H). 13C NMR (100 MHz, MeOD) δ 171.25, 167.79, 
165.02, 159.78, 153.88, 139.89, 131.05, 129.70, 129.50, 128.93, 113.70, 111.3, 103.5, 66.8, 59.84, 
55.36, 50.73, 41.6, 39.2, 38.4, 35.38, 32.02, 27.80. HRMS (ESI): m/zcalcd for C24H37N7O4 [M + 
H]+, 550.3142; found, 550.3148. HPLC purity 96.48%; tR= 16.262. 
N1-hydroxy-N6-(2-((7-methoxy-4-((1-methylpiperidin-4-yl)amino)quinazolin-2-
yl)amino)ethyl)adipamide (15a): 41 mg, 35% yield.1H NMR (400 MHz, MeOD) δ 8.08 (s, 1H), 
6.87 (d, J = 13.0 Hz, 2H), 4.68 (s, 2H), 3.88 (d, J = 12.3 Hz, 3H), 3.82 – 3.69 (m, 1H), 3.62 (s, 
4H), 3.46 (s, 2H), 3.22 (m, 2H), 3.28 – 3.17 (m, 1H), 3.19 – 3.01 (m, 1H), 2.89 (d, J = 15.2 Hz, 
3H), 2.42 – 2.19 (m, 3H), 2.09 (d, J = 29.5 Hz, 2H), 1.90 (s, 1H), 1.62 (s, 3H), 1.38 (d, J = 6.5 Hz, 
2H). 13C NMR (100 MHz, MeOD) δ 173.7, 170.0, 167.9, 164.5, 159.2, 153.4, 141.4, 124.6, 113.0, 
102.3, 97.4, 54.4, 53.6, 52.2, 46.2, 45.5, 41.6, 39.3, 37.5, 34.3, 34.0, 27.5. HRMS (ESI): m/zcalcd 
for C23H35N7O4 [M + H]
+, 474.2829; found, 474.2807. HPLC purity 96.40%; tR= 12.879. 
N1-(2-((4-((1-benzylpiperidin-4-yl)amino)-7-methoxyquinazolin-2-yl)amino)ethyl)-N5-
hydroxyglutaramide (16): 52 mg, 39% yield. 1H NMR (400 MHz, MeOD) δ 8.01 (s, 1H), 7.51 
(d, J = 18.6 Hz, 5H), 6.76 (d, J = 17.4 Hz, 2H), 4.49 (d, J = 13.1 Hz, 3H), 3.86 (s, 3H), 3.53 (d, J 
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= 9.5 Hz, 5H), 3.22 (s, 3H), 2.23 (m, 6H), 1.93 (s, 4H). 13C NMR (100 MHz, MeOD) δ 174.1, 
170.8, 167.9, 165.0, 159.7, 153.6, 141.7, 131.0, 129.0, 129.8, 128.3, 125.4, 115.4, 113.6, 102.8, 
67.9, 59.9, 55.3, 50.7, 40.1, 38.3, 34.8, 31.7, 27.8, 21.6. HRMS (ESI): m/zcalcd for C23H35N7O4 
[M + H]+, 536.2985; found, 536.2998. HPLC purity 94.34% ; tR= 16.051. 
N1-hydroxy-N5-(2-((7-methoxy-4-((1-methylpiperidin-4-yl)amino)quinazolin-2-
yl)amino)ethyl)glutaramide (16a): 35 mg, 31% yield. 1H NMR (400 MHz, MeOD) δ 8.10 (s, 
1H), 6.87 (d, J = 11.2 Hz, 2H), 4.70 (s, 1H), 3.92 (s, 3H), 3.73 (dd, J = 12.9, 6.5 Hz, 1H), 3.66 (m, 
3H), 3.46 (s, 2H), 3.35 (d, J = 15.5 Hz, 2H), 3.23 (m, 1H), 2.88 (d, J = 14.5 Hz, 2H), 2.46 – 2.21 
(m, 4H), 2.15 (s, 2H), 1.90 (s, 2H), 1.37 (m, 4H). 13C NMR (100 MHz,) δ 175.8, 171.2, 166.0, 
165.2, 153.3, 151.3, 127.6, 113.2, 110.1, 103.0, 57.8, 54.6, 50.5, 46.9, 41.8, 39.2, 36.4, 33.6, 31.4, 
19.0. HRMS (ESI): m/zcalcd for C22H33N7O4 [M + H]
+, 460.2672; found, 460.2648. HPLC purity 
95.90%; tR= 12.615. 
N-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-
amine (18): Compound 18 was synthesized according to the previously reported procedure,[111] 
which was treated with Pd/C under H2 gas to get the free amine. HRMS (ESI): m/zcalcd for 
C21H32N6O2 [M + H]
+, 401.2264; found, 401.2642. This amine was directly used in procedure C 
while using monomethyl suberate ester to get 19 and monomethyl pimelate to obtain 20. 
8-(4-((6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-yl)amino)piperidin-1-yl)-
N-hydroxy-8-oxooctanamide (19): 48 mg, 34% yield over 2 steps. 1H NMR (400 MHz, MeOD) 
δ 7.68 (s, 1H), 7.20 (s, 1H), 4.66 (d, J = 12.0 Hz, 1H), 4.51 (s, 1H), 4.22 (s, 2H), 4.12 (d, J = 12.7 
Hz, 1H), 3.96 (m, 8H), 3.45 (s, 2H), 3.28 (d, J = 9.7 Hz, 3H), 2.83 (d, J = 7.7 Hz, 4H), 2.47 (dd, J 
= 15.0, 7.3 Hz, 2H), 2.36 (s, 2H), 2.16 (m, 4H), 1.65 (m, 6H), 1.40 (s, 5H). 13C NMR (100 MHz, 
MeOD) δ 172.6, 171.5, 167.5, 158.5, 155.8, 152.9, 147.6, 103.4, 102.7, 99.6, 56.3, 55.5, 55.4, 
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44.7, 43.7, 42.7, 40.7, 32.4, 32.2, 31.5, 30.6, 28.5, 28.3, 25.1, 25.0, 24.3. HRMS (ESI): m/zcalcd 
for C29H45N7O5[M + H]
+, 572.3516; found, 572.3530. HPLC purity 94.71%; tR= 15.347. 
7-(4-((6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-yl)amino)piperidin-1-yl)-
N-hydroxy-7-oxoheptanamide(20): 62 mg, 45% yield over two steps. 1H NMR (400 MHz, 
MeOD) δ 7.72 (s, 1H), 7.23 (s, 1H), 4.66 (d, J = 12.1 Hz, 1H), 4.52 (s, 1H), 4.26 (s, 2H), 4.12 (d, 
J = 12.0 Hz, 2H), 3.96 (d, J = 14.8 Hz, 8H), 3.49 (d, J = 9.9 Hz, 4H), 2.86 (dd, J = 25.3, 14.7 Hz, 
4H), 2.64 – 2.29 (m, 4H), 2.27 – 1.92 (m, 4H), 1.83 – 1.50 (m, 6H), 1.50 – 1.34 (m, 2H). 13C NMR 
(100 MHz, MeOD) δ 172.5, 171.4, 167.2, 158.5, 155.9, 152.5, 147.7, 137.0, 103.5, 102.7, 99.2, 
56.18, 55.6, 55.5, 49.4, 45.9, 44.6, 43.5, 42.4, 40.2, 32.4, 32.1, 31.4, 30.6, 28.2, 25.0, 24.8, 24.0. 
HRMS (ESI): m/zcalcd for C28H43N7O5[M + H]
+, 558.3404; found, 558.3387. HPLC purity 
96.04%; tR= 14.311. 
Compounds 21 and 22  
Compound 10 was treated with NHBoc ethyline diamine as the procedure A to get the intermediate 
11b, which was further treated with 1-methyl-1,4-diazepane in accordance to procedure B to yield 
18a, followed by procedure C, using monomethyl suberate or monomethyl pimelate to get 21 and 
22.  
tert-butyl (2-((2-chloro-7-methoxyquinazolin-4-yl)amino)ethyl)carbamate (11b): 78% yield. 
1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 9.0 Hz, 2H), 7.08 – 6.88 (m, 2H), 5.39 (s, 1H), 3.85 (s, 
3H), 3.67 (d, J = 3.9 Hz, 2H), 3.57 – 3.37 (m, 2H), 1.40 (s, 9H). HRMS (ESI): m/zcalcd for 
C16H21ClN4O3+ [M + H]
+, 353.1380; found, 353.1372. 
tert-butyl(2-((7-methoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-yl)amino)ethyl) 
carbamate (18a): 69% yield. 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 8.9 Hz, 1H), 6.95 (s, 1H), 
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6.85 (s, 1H), 6.63 (s, 1H), 5.52 (s, 1H), 4.04 – 3.93 (m, 2H), 3.86 (s, 3H), 3.62 (d, J = 4.9 Hz, 2H), 
3.44 (d, J = 4.5 Hz, 3H), 2.73 (s, 2H), 2.69 – 2.51 (m, 2H), 2.37 (s, 3H), 2.03 (s, 2H), 1.41 (s, 9H). 
HRMS (ESI): m/zcalcd for C22H34N6O3[M + H]
+, 431.2771; found, 431.2746. 
N1-hydroxy-N8-(2-((7-methoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4 
yl)amino)ethyl)octanediamide (21): 36 mg, 29% yield over 2 steps. 1H NMR (400 MHz, MeOD) 
δ 7.97 (d, J = 8.7 Hz, 1H), 7.16 (s, 1H), 7.02 (d, J = 8.6 Hz, 1H), 4.28 (s, 2H), 3.94 (s, 3H), 3.87 
(s, 2H), 3.74 (d, J = 5.6 Hz, 3H), 3.60 – 3.48 (m, 4H), 3.42 (s, 2H), 2.89 (d, J = 7.3 Hz, 3H), 2.39 
(s, 2H), 2.21 (t, J = 7.0 Hz, 4H), 1.55 (m, 4H), 1.29 (s, 4H). 13C NMR (100 MHz, MeOD) δ 175.5, 
167.49 164.98 159.76 153.4, 124.9, 114.1, 103.6, 99.8, 55.3, 55.1, 48.2, 48.0, 47.8, 47.6, 47.4, 
47.2, 46.9, 46.0, 43.5, 42.6, 41.3, 37.5, 35.6, 34.0, 28.5, 28.4, 25.4, 24.7, 24.0. HRMS (ESI): 
m/zcalcd for C25H39N7O4[M + H]
+, 502.3142; found, 502.3128. HPLC purity 96.21%; tR= 13.810. 
N1-hydroxy-N7-(2-((7-methoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-
yl)amino)ethyl)heptanediamide (22): 43 mg, 36% yield over 2 steps. 1H NMR (400 MHz, 
MeOD) δ 7.98 (d, J = 9.1 Hz, 1H), 7.14 (d, J = 1.9 Hz, 1H), 7.00 (m, 1H), 4.27 (s, 2H), 3.93 (s, 
5H), 3.88 (s, 1H), 3.88 – 3.66 (m, 4H), 3.52 (m, 5H), 3.42 (s, 2H), 2.90 (s, 3H), 2.39 (s, 1H), 2.24 
(dd, J = 10.9, 7.1 Hz, 5H), 1.84 (dd, J = 13.7, 6.5 Hz, 2H). 13C NMR (100 MHz, MeOD) δ 174.99, 
171.13, 168.17, 164.87, 159.67, 153.28, 125.03, 114.13, 103.56, 99.82, 55.19, 43.67, 42.61, 41.15, 
37.62, 35.26, 31.88, 24.93, 24.60. HRMS (ESI): m/zcalcd for C24H37N7O4[M + H]
+, 488.2985; 
found, 488.2960. HPLC purity 96.80%; tR= 13.370. 
7-(benzyloxy)-N-(1-isopropylpiperidin-4-yl)-6-methoxy-2-(4-methyl-1,4-diazepan-1-
yl)quinazolin-4-amine (24) was synthesized from 1a, by following procedure A  (23) and 
procedure B (24), then benzyl group was removed using Pd catalyzed hydrogenolysis, mixture of 
compound 24 (600 mg, 1.2 mmol) and 10 wt% Pd(OH)2/C (90 mg) in ethanol (100 ml) was stirred 
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for 40 h at room temperature under hydrogen balloon. The reaction mixture was filtered and 
concentrated to provide the debenzylated product 4-((1-isopropylpiperidin-4-yl)amino)-6-
methoxy-2-(4-methyl-1,4-diazepan-1-yl) quinazolin-7-ol (25)as brownish yellow solid, 90 %.  
N-hydroxy-7-((4-((1-isopropylpiperidin-4-yl)amino)-6-methoxy-2-(4-methyl-1,4-diazepan-
1-yl)quinazolin-7-yl)oxy)heptanamide (26): Procedure D, Ethyl heptanoate (80 µl, 0.4 mmol) 
was added to the ice cold solution of compound 24 (200 mg, 0.4 mmol) in DMF and K2CO3 (280 
mg, 2 mmol), reaction mixture was warmed to room temperature and then at 60 oC. After 6 h 
reactions, mixture was evaporated to get the residue and dissolved in DCM and washed with brine, 
organic layer was vacuum dried and eluted in flash column using reverse phase silica at 40 % 
ACN/H2O to get the intermediate ester, which was then dissolved in 2 ml of MeOH and treated 
with 50% NH2OH/water mixture (1 ml) overnight to afford the targeted product. Reaction mixture 
was dried and purified using reverse column and further by HPLC using ACN (0.1% HCOOH) 
/H2O (0.1% HCOOH) as eluent. 94 mg, 40% overall yield. 
1H NMR (400 MHz, MeOD) δ 7.61 (s, 
1H), 7.06 (s, 1H), 4.14 (s, 3H), 3.97 (d, J = 14.7 Hz, 6H), 3.50 (s, 4H), 3.15 (s, 3H), 3.05 (s, 3H), 
2.74 – 2.57 (m, 3H), 2.38 (s, 3H), 2.22 – 2.03 (m, 3H), 1.90 (d, J = 14.1 Hz, 3H), 1.63 (d, J = 8.4 
Hz, 4H), 1.48-1.42 (m, 3H), 1.40-1.31 (m, 6H). 13C NMR (100 MHz, MeOD) δ 170.9, 164.2, 
158.0, 155.5, 152.0, 146.6, 110.9, 108.5, 101.5, 70.3, 57.4, 56.8, 56.6, 53.1, 46.4, 44.3, 32.4, 29.8, 
29.2, 28.8, 26.8, 25.1, 24.1, 20.3. HRMS (ESI): m/zcalcd for C30H49N7O4 [M + H]
+, 572.3924; 
found, 572.3925. HPLC purity 96.80%; tR= 13.370. 
8-((4-((1-benzylpiperidin-4-yl)amino)-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-7-yl)oxy)- 
N-hydroxyoctanamide (30): Targeted analog 30 was synthesized from the anthranillic acid 
starting material. 7-(benzyloxy)-N-(1-benzylpiperidin-4-yl)-2-(4-methyl-1,4-diazepan-1-
yl)quinazolin-4-amine (27): prepared according to the procedure A and B. 1H NMR (400 MHz, 
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CDCl3) δ 7.90 (d, J = 3.6 Hz, 1H), 7.26-7.18 (m, 5H), 7.12 (s, 1H), 6.98 (d, J = 3.9, 1H), 5.87 (s, 
1H), 4.39-4.12 (m, 5H), 3.92 (s, 3H), 3.63 (s, 2H), 3.20 (d, J = 4.6 Hz, 2H), 3.04 (d, J = 2.4 Hz, 
2H), 2.52 (d, J = 2.4 Hz, 2H), 2.28 (s, 3H), 1.82-1.66 (m, 6H). 13C NMR (100 MHz, CDCl3) δ 
163.0, 159.0, 158.6, 138.4, 129.1, 128.2, 127.0, 122.2, 112.1, 104.8, 104.3, 63.1, 58.8, 57.2, 55.3, 
52.4, 48.2, 46.6, 45.9, 45.8, 32.0, 27.6. MALDI-TOF: m/z for C27H36N6O [M + H]
+ is 461.9. 
4-((1-benzylpiperidin-4-yl)amino)-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-7-ol (28): Aryl 
demethylation using BBr3 was employed.[121] BBr3 solution in DCM (1 ml, 1M) was added to 
the ice cold solution of compound 27 (450 mg, 1 mmol), resulting solution was allowed to be in 
normal room temperature and stirred the reaction mixture under inert atmosphere. Reaction was 
monitored using mass spec (MALDI-TOF), after completion of the reaction at about 48 h, water 
was added to the mixture and basified with NaHCO3, extracted with DCM, washed with brine and 
dried to obtain a pale yellow solid and used for next steps without purification. MALDI-TOF: m/z 
for C26H34N6O[M + H]
+ is 447.8, ratio of the product was over 90% to starting material. 
8-((4-((1-benzylpiperidin-4-yl)amino)-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-7-yl)oxy)- 
N-hydroxyoctanamide (30): Procedure D using 28 as the starting material, afforded the desired 
intermediate as colorless solid. HRMS (ESI): m/zcalcd for C35H50N6O3[M + H]
+, 603.4022; found, 
603.4031. Subsequently, compound 29 was dissolved in 2 ml of MeOH and treated with 50% 
NH2OH/water mixture (1 ml) overnight to afford the targeted product. Reaction mixture was dried 
and purified using reverse column and further by HPLC using ACN/H2O as eluent. Fractions 
collected were concentrated and lyophilized to get brown powder, 54 mg, 23% yield over two 
steps. 1H NMR (400 MHz, MeOD) δ 8.10 (d, J = 9.2 Hz, 1H), 7.65 – 7.53 (m, 4H), 7.06 (d, J = 
2.2 Hz, 1H), 6.94 (d, J = 8.9 Hz, 1H), 3.94 (d, J = 9.0 Hz, 2H), 3.80 (s, 2H), 3.72 – 3.59 (m, 4H), 
3.50 (s, 2H), 3.22 (s, 3H), 2.48 (s, 2H), 2.34 (d, J = 14.2 Hz, 3H), 2.15 (s, 2H), 2.05 (s, 4H), 1.96 
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(s, 5H), 1.86 (s, 2H), 1.68 (s, 2H), 1.46 (s, 4H). 13C NMR (100 MHz, MeOD) δ 175.5, 167.4, 164.9, 
159.7, 153.4, 140.3, 129.1, 128.2, 127.0, 124.9, 114.1, 109.0, 103.6, 68.7, 63.7, 55.3, 55.1, 46.0, 
43.5, 42.6, 41.3, 34.0, 28.5, 28.4, 25.4, 24.7. HRMS (ESI): m/zcalcd for C33H47N7O3 [M + H]
+, 
590.3819; found, 590.3832. HPLC purity 96.26%; tR= 14.192. 
Molecular Docking Analysis 
Protein Preparation and Grid Generation: The coordinates for the HDAC8/MS-344 complex 
(PDB ID: 1T67) and G9a/BIX-01294 complex (PDB ID: 3FPD) were downloaded from the RCSB 
Protein Data Bank. In these structures, MS-344 and BIX-01294 are bound to HDAC8, G9a 
respectively. The PDB protein-ligand structures were processed with the Protein Preparation 
Wizard in the Schrödinger suite. The protein structure integrity was checked and adjusted, and 
missing residues and loop segments near the active site were added using Prime. The receptor was 
prepared for docking by the addition of hydrogen atoms and the removal of co-crystallized 
molecules except for Zn2+, as it is near to the active site in the case HDAC. Active site water 
molecules outside 5.0 Å from the ligand were removed. The bound ligands were used to specify 
the active site. A 3D box was generated around each ligand to enclose the entire vicinity of active 
site. The receptor grid for each target was prepared with the help of OPLS_2005 force field. The 
grid center was set to be the centroid of the co-crystallized ligand, and the cubic grid had a size of 
20 Å.  
Ligand Preparation: The 2D ligand structures were prepared using ChemBioDraw Ultra 12.0, 
and the 3D structures were generated by Schrödinger suite. Schrödinger’s LigPrep program was 
used to generate different conformations of ligands. All possible protomers and ionization states 
were enumerated for 14 and bound ligands using Ionizer at a pH of 7.4. Tautomeric states were 
generated for chemical groups with possible prototropic tautomerism.  
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Molecular Docking: molecular docking studies were performed by using a GLIDE docking 
module of Schrödinger suite. It performs grid-based ligand docking with energetics and searches 
for positive interactions between ligand molecules and a typically larger receptor molecule, usually 
a protein. Finally, prepared ligands were docked into the generated receptor grids using Glide SP 
docking precision. The results were analyzed based on the GLIDE docking score and molecular 
recognition interactions. All the 3D figures were obtained using Schrödinger Suite 2014-3. 
Cloning, Protein Expression and Purification 
Mouse histone methyltransferase G9a (969-1263) cDNA was amplified from the cDNA of 
BALB/c mouse thymus, and the fragment was sub-cloned into a vector with a 6His-sumo tag. The 
mouse G9a (mG9a) was expressed in Escherichia coli BL21 (DE3) by the addition of 1 mM 
isopropyl-1-thio-D-galactopyranoside (IPTG) and incubated overnight at 16 °C. 
The 6His-sumo mG9a (969-1263) protein was purified using the following procedure: harvested 
cell pellet was re-suspended in 20 mM Tris (pH 8.0), 500 mM NaCl, 0.1% β-mercaptoethanol, and 
1 mM PMSF. Cells were lysed by sonicating for 15 s with 6 s intervals for a total time of 15 min 
on an ice bath. The supernatant of cell lysate was loaded onto a Ni+ affinity column (Invitrogen) 
then washed with buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 20 mM imidazole, 0.1% β-
mercaptoethanol, and 1 mM PMSF). The 6His-sumo tag was cleaved from the column by adding 
Ubiquitin-like-specific protease 1 (ULP-1) at 4 °C for 12 h. Wash buffer was then run through the 
Ni+ column again and the elution buffer collected. Subsequently, advanced protein purification 
was done by HiTrap Q HP sequential Superdex 200 10/300 GL. Elute of every step was analyzed 
by SDS PAGE, stained by Coomassie brilliant blue (CBB). 
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MALDI-TOF-MS 
The in vitro inhibition of G9a by the synthesized compounds were measured by MALDI-TOF 
mass spectrum (Bruker MALDI TOF/TOF Analyzer). 400 nM purified G9a, 5 µM synthesized 
histone H3 (1-21) and 10 µM non-radioactive S-adenosyl methionine (Sigma) were added in 
reaction buffer (50 mM HEPES pH 8.0, 5 µg/ml BSA and 0.1% β-Mercaptoethanol) with or 
without inhibitors (5 µM). The reaction was incubated at room temperature for 30 minutes and 
stopped by TFA. 1 µl of the sample was mixed with CHCA matrix and m/z peaks were obtained 
at reflection positive mode. The results of mass spectrum were analyzed using the Bruker flex 
analysis software, a detailed description of data processing is provided in appendix B.1. 
Cell Based Assays 
Cell lines information: 
MDA-MB-231(breast cancer cell line), MCF-7 (breast cancer cell line), A549 (human lung cancer 
cell line), K562 (human immortalized myelogenous leukemia cell line), Hela (human cervical 
cancer cell line), HEK293 (normal cell line). 
Reagents: CCK-8, Trichostatin A and trypsin were purchased from Sigma. 
Cell line: MDA-MB-231, A549 cell lines were grown at 37 °C/ 5% CO2 in Dulbecco’s Modified 
Eagle’s Medium (from Sigma) supplemented with 10% fetal bovine serum and 2% 200 mM L-
glutamine and 0.5% antibiotic-antimycotic solution (from Sigma). 
Hela, K562 cell lines were grown at 37 °C/5% CO2 in RPMI 1640 medium (Gibco) supplemented 
with 10% fetal bovine serum and 0.5% antibiotic-antimycotic solution. 
MCF-7 cell line was grown at 37 °C/ 5% CO2 in Eagle’s Minimum Essential Medium 
supplemented with 10% fetal bovine serum and 0.5% antibiotic-antimycotic solution. 
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HDAC Activity Assay 
The manual assay was developed by Thomas’s group.[122] HeLa cells were seeded into white 96-
well cell culture plates (corning costar 3596) at a density of 8000-10000 cells/well (total volume 
81 µl culture medium) and incubated under standard cell culture conditions(37 °C，5% CO2). 
After 24 h, 9 µl inhibitors with different concentration were added to the HeLa cells and incubation 
was continued for 3 h under cell culture conditions. After this treatment period, 10 µl of a 2 mM 
stock solution of the substrate Boc-K(Ac)-AMC was added into the 96 well plates with Hela cells 
and inhibitors. Cell culture plates were incubated under standard cell culture conditions for an 
additional 3 h before addition of 100 µl/well lysis/developer buffer mix (50 mM Tris–HCl, pH 8.0, 
137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1 vol% Nonidet-P40, 2.0 mg/ml trypsin, 10 µM TSA). 
After final incubation for 3 h under cell culture conditions, fluorescence was measured at excitation 
of λex = 355 nm and emission of λem = 460 nm on the Perkin–Elmer Wallac Victor V 1420 
multilabel plate reader (Perkin–Elmer, Wellesley, USA). A549 and K562 cell lines used the same 
method, respectively. IC50s were calculated using GraphPad Prizm statistical package with 
sigmoidal variable slope dose response curve fit. 
G9a H3K9me2 Cellular Assay 
Cells were seeded at 8000-10000 cells (100 µl) in black-walled 96-well plates (Thermo 165305) 
and exposed to various inhibitor concentrations for 48 h. After the incubation, the media was 
removed and 100 µl fixation and permeabilization solution (2% formaldehyde in PBS) for fixation 
was added for 30 min. And then use 200 µl 0.1% Triton X100 in PBS washing solution to wash 
(allow wash to shake on a plate shaker for 5 min). After five washes, cells were blocked for 1 h 
with 150 µl blocking buffer to each well (1% BSA in PBS) (allow blocking at room temperature 
with moderate shaking on a plate shaker). After 1 h, remove the blocking buffer from the blocking 
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step and add primary antibody in blocking buffer to cover the bottom of each well. (Three out of 
four replicates were exposed to the primary H3K9me2 antibody, Abcam no. 1220 at 1/500 dilution 
in 1% BSA, PBS for overnight, one replicate was reserved for the background control (only 
blocking buffer). The wells were washed five times with 0.1% Tween 20 in PBS, then secondary 
IR800 conjugated antibody (LiCor) and cell tag 700 stain added for 1 h. (incubate for 1 h with 
gentle shaking at room temperature, protect plate from light during incubation). After 5 washes 
with 0.1% Tween 20 in PBS, remove wash solution completely from wells. Turn the plate upside 
down and tap or blot gently on paper towels to remove traces of wash buffer. The plates were read 
on an Odyssey CLX (LiCor) scanner at both 800 nm (H3K9me2 signal) and 700 nm (cell tag 700 
stain signal) channels. IC50s were calculated using GraphPad Prizm statistical package with 
sigmoidal variable slope dose response curve fit. 
Toxicity Assay 
A549, MDA-MB-231, MCF-7 and HEK293 cells were seeded at 8000-10000 cells (100 µl) in 
white 96-well plates and pre-incubate the plate for 24 h under standard cell culture conditions, 
respectively. And then the cells were exposed to the different inhibitors with various 
concentrations for 72 h. Finally, 10 µl of CCK-8 kit solution was added to each well and incubated 
for 3-4 hours under standard cell culture conditions, and the 96 well plates were measured the 
absorbance at 450 nm using Perkin–Elmer Wallac Victor 3V 1420 multi label plate reader (Perkin–
Elmer, Wellesley, USA). EC50s were calculated using GraphPad Prizm statistical package with 
sigmoidal variable slope dose response curve fit. 
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3 CANCER DIAGNOSTICS 
3.1. DNA encoded library of Globo series glycans for early stage detection of cancer 
ABSTRACT: DNA encoded libraries (DEL) are used with immense success in screening small 
molecules for drug discovery. The concept of DEL is even more beneficial for glycans since these 
complex molecules are extremely difficult to detect itself and often require secondary methods. 
However, the split and pool method used in DEL is not adaptable in glycans because of the 
synthetic challenges. Alternatively, we propose here a single step encoding of glycans by click 
chemistry using predefined structure-based DNA code specific to each glycan. DNA-Glycan 
conjugates then pooled to get DNA encoded glycan library (DEGL) and used in multiplex 
detection of glycan binding proteins. As a proof of principle study, we synthesized blood glycans 
and globo glycans and demonstrated glycan specific DNA encoding, conjugation chemistry, 
selection and detection using PCR, qPCR and Next Generation Sequencing. Selectivity, specificity 
and sensitivity of the method were also evaluated and compared with the conventional methods. 
Overall, DEGL provide a highly sensitive solution phase assay, uses femtomoles of sample, and 
unprecedented throughput and sample capacity when Next Generation Sequencing platforms are 
used. 
 
 
Key Words: DNA encoded glycan library, Glyco-PCR, Carbohydrate oligonucleotide conjugates. 
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3.1.1. Introduction:  
Glycans and glycoconjugates are one of the most abundant biomolecules, playing 
important roles in several biological events such as molecular recognition, adhesion, pathogenesis, 
and inflammation.[123] Expression patterns of complex carbohydrates are widely altered in 
cancer, retrovirus infection, atherosclerosis, thrombosis, diabetes, neurodegeneration, arthritis and 
other diseases.[124] Glycan structures also play a critical role in host defense mechanism as they 
form a major portion of the antigenic structures, along with other microbe-derived molecules, 
which are recognized by host immune cells and mount an immune response.[125] Hence, the 
structural consequences of the interactions of oligosaccharides with receptors of interest are one 
of the major focuses of pharmaceutical research now. [124, 126]  
Nature has provided a systematic, template driven, coded system that has greatly facilitated 
scientific understanding of nucleic acids and proteins.  Similar natural organizing principles do not 
exist for the incredibly complex myriad carbohydrates (glycans), which also lack UV/ fluorescent 
properties hence fallen behind. Furthermore, even with the recent advances in solid phase 
automated synthesis and enzymatic synthesis which eased the difficulties in obtaining a variety of 
glycans, materials available for experimentation remain extremely precious, especially for 
complex glycans. Hence, the development of a highly versatile and ultra-sensitive detection 
technology is particularly important in the field of carbohydrate research for the characterization 
of glycan-protein interactions.   
Microarrays and ELISA are the most used methods in glycomics now although with their 
limitations; microarray has the disadvantage of requiring specific instrumentations and not 
mimicking the biological environment while ELISA is not suitable for high throughput 
analysis.[125, 127-129] In another pioneering work named multiplex glycan bead array (MGBA) 
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by Jin-Xiong She’s group in collaboration with our group, recently reported the use of colored 
Luminex beads for the multiplex detection of glycan binding proteins,[130] which is certainly 
improved in magnitude and throughput, but still require instrumentation specifically for this use.   
Alternatively, we assumed DNA-encoded glycan libraries (DEGLs) as a potential replacement or 
adjunct to the existing technologies. Encoding a small molecule with a piece of DNA enhances the 
detection limit of the small molecules many-fold by polymerase chain reaction (PCR).[131] 
Although the concept of DNA encoding was introduced in 1992, it has gained momentum recently 
with the advancement in DNA next generation sequencing (NGS) technologies and involved in 
many of the discovery of new lead molecules.[132-134]  The technology also referred as DEL, 
generally adopt split and pool library synthesis, which is practically suited for the construction of 
libraries spanning millions to billions of small molecules.[135] However, the split and pool synthesis 
which heavily depend on the aqueous phase coupling reactions is not suitable in the highly 
complicated glycan synthesis. Hence, we need an alternate approach for the affordable use of DNA 
encoding in glycomics.  In this work, we describe an affordable approach to use the enormous 
potential of DNA encoding in functional glycomics via structure-based DNA coding of glycans 
and single step click conjugation of DNA code and glycans. 
Kwon and coworkers showed the feasibility of using DNA tag in glycomics; their work 
coined Glyco-PCR, successfully demonstrated detection glycan-binding proteins (GBP) using 
DNA conjugated glycans with high sensitivity.[136, 137] Although, the method asserted the ultra-
sensitive detection by DNA amplification, it hasn’t addressed how a large pool of glycan is 
analyzed with an affordable cost. More recently, DNA encoded library involving glycan were 
synthesized by biocatalysis and split and pool,[138] again it is limited to very limited number of 
glycans. However, the glycosyltransferases enzymes available to facilitate such an approach is 
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limited, which means the DNA encoding of glycan via split and pool will be restricted to the 
enzyme specificity. To overcome this and enhance the scope of DNA Encoded Glycan Library 
(DEGL), single step tagging of glycans previously synthesized by enzymatic or chemical methods 
with a relatively big DNA fragment remains the only option. Though custom synthesis of such 
DNA sequences is possible and pragmatic for small DEGLs, it would be a cost-prohibitive option 
when dealing with hundreds of sugars, and hence compromising on the enormous potential of high 
throughput analysis.  These challenges are certainly inevitable but can be minimized if we could 
develop a broadly acceptable protocol exclusively for glycans, from the synthesis of DEGL to final 
data analysis. A universal protocol will allow manufacturers to catalog DNA codes for different 
glycans and sell at a lower price. This is particularly reasonable in glycans since the number of 
biologically significant glycans characterized so far is less than twenty thousand.[139] It is worthy 
to note here that, cataloging DNA codes for glycans can also achieved by selecting random DNA 
codes, but we wanted to use the full potential of what DNA manipulation has to offer in functional 
glycomics; which is only possible when DNA code is somehow corelated to the glycan in question. 
For instance, structurally defined DNA code will ensure minimum errors in selection and 
sequencing, since it is more likely to have same glycan epitopes selected against a target than a 
totally different glycan structure. The same principle can also be applied to other closely related 
technologies like probe-based assays and DNA arrays. In order to the ubiquitous use of DNA 
codes, we require systematic selection of DNA codes, highly feasible DNA-glycan conjugation 
chemistry, and well-characterized detection procedures.  Here, we address all three issues, firstly, 
an in-house software program was developed (available at http://131.96.145.142:8000/cgi-bin/form.py) 
for generating a DNA code specifically for each glycan. Next, the DNA code amended with 
primers and 5’ hexynyl modification was 'click' conjugated with the corresponding azido-glycan, 
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and finally, selection and detection methods were optimized.  As a proof of principle application 
study, DEGL of Globo series glycans were synthesized and applied in detecting cancer-specific 
antiglycan antibody VK9. Certain Globo-series glycans are overexpressed in some cancers and 
proven as biomarkers for the early detection of breast cancer and ovarian cancer.[25, 140-142] 
Recent developments in the Globo-H based immunotherapy also require highly sensitive methods 
to quantitatively detect the antiglobo H antibodies for monitoring therapy and in clinical 
trials.[143-145]  
3.1.2. Results and Discussion 
3.1.2.1. Systematic coding of glycans 
Our first aim was to develop a unique DNA coding method that would be consistent with 
the existing representation of glycans, so that any glycans known or yet to be characterized can 
get a unique name in DNA terms. Unlike peptides, proteins, and genetic materials, representation 
of carbohydrates brings many challenges. A detailed and accurate depiction of glycans should 
feature composition, sequence, branching position, possible modifications, and anomeric 
configuration. Kornfeld et al. first proposed the use of symbols to depict carbohydrates,[146] and 
this approach has since replaced the IUPAC naming,[147] with modifications adapted to fit the 
entire glycome.[148, 149] All these approaches are based on different shapes and color codes to 
represent the building blocks (Figure 3.1), which gave us the idea of using nucleotide bases to 
represent the building blocks. The number of shapes and colors we could use for the representation 
are infinite, but only four nucleotide bases A, T, G, and C available for DNA coding. Hence, we 
depended on permutation and combination approach to cover the whole glycome. The number of 
sugar monomers are more than one hundred, and they can be incorporated into the oligosaccharide 
in multiple ways, making glycan structural information more complex. These inherent difficulties 
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prompted us to develop a dedicated program that could sort the structural information to coding 
vocabulary and transform IUPAC names to single-stranded DNA code. For natural adaptation of 
the codes into functional glycomics, the codes should be of minimum length but still code all the 
information and enabling PCR amplification.  
Structure-based coding must have a controlled vocabulary of the structural components.  
For attaining this goal, similar to the Consortium of Functional Glycomics (CFG) representations, 
initially, we split the structural information of the carbohydrate into the components and the 
structure (Figure 3.1). Then we gathered all monomers into library A and different linkages to 
library B. Next, the monomers in the library A assigned with a unique four-letter code. There are 
256 possible combinations with the four letters A, T, G, and C. More than 70 monomers were- 
 
                                   Figure 3.1. Different representation of glycans 
 
added to this library (Appendix C.1, Table 0.5), effectively using about 70 randomly-generated 
codes. Similarly, all linkages library B were coded with 3 letters. Thirty-six linkages are currently 
in this library with further space for future modifications (Appendix C.1, Table 0.6). Many glycans 
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feature functional group modifications as part of the structure, and to add this information we 
added a third library (library C, Appendix C.1, Table 0.7). More than 100 modifications were 
identified and added to the library and assigned four letter codes which were not used in the library 
A. Any special characters like ‘(’ used in the IUPAC input were also incorporated with specific 
codes. Finally, we consolidated these libraries into a Python-based program, and several rounds of 
evaluations performed with diverse glycan structures. A sample library of 100 glycans was tested, 
and the program successfully delivered codes for all the glycans tested (Appendix C.1, Table 0.9). 
A sequence length between 25 to 120 bases ideally fit the PCR applications and, among the 100 
glycans randomly selected most of them fell in this limit, but few glycans had sequence length 
smaller or higher than the range specified. Through the careful observation of the sample pool, we 
identified many of the repeating fragments in the glycans (e.g., six sugar core structure of N-
glycans). Hence, we assumed taking this as a single block would reduce the overall length of the 
codes of long glycans, and a fourth library (library D, Appendix C.1, Table 0.8) was added to the 
program featuring many of the most common building blocks found in the glycans. For the glycans 
possessing a code smaller than the 25 bases, a random sequence of 20-base DNA was added to the 
code with a special mention in the program to avoid misinterpretation. These two modifications 
allowed us to keep the sequence length within the desired limits.  
3.1.2.2. Glycan codes to functional glycomics 
 Once a reliable DNA code was established, we synthesized the blood group antigens A, B and O 
with an azide linker by adopting chemo-enzymatic strategies. These glycans then conjugated to 
the 5’-hexyne modified DNA codes (IDT, Coralville, IA) corresponding to the antigens via click 
chemistry to get the glycan-DNA conjugates for the initial studies (Figure 3.2a, Experimental 
section Figure 3.8). Blood group antigens were chosen because of two reasons, the abundant 
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antibody presence, and any specificity and selectivity studies could be achieved easily with these 
structurally similar glycans.  
The success of the DEGL lies in the utility of applying the DNA codes to the standard PCR and 
qPCR protocols. It is crucial to have the glycan-coupled DNA (G+DNA) achieve similar PCR 
efficiency to the native DNA, so we compared the G+DNA conjugates with the corresponding 
native DNA strands to verify the efficiency of amplification in both PCR and qPCR. PCR was 
performed on DNA and G+DNA templates using standard thermal cycles with varying annealing 
temperatures. Gel electrophoresis analysis implied both DNA and G+DNA amplified well in the 
range of 52-60 ºC (Experimental section, Figure 3.7).  Next, we examined the qPCR detection 
limit of the G+DNA conjugates; both DNA and G+DNA conjugates were serially diluted to 
provide different concentrations of templates, with final concentrations ranging from 2.4 nM to 16 
pM. Standard curve qPCR was carried out to obtain the corresponding critical threshold value (Ct), 
which is used to compare the concentration of the templates in the qPCR reaction mixture, with a 
low Ct indicating high template concentration. Ct values of the conjugates from 2.4 nM to 16 pM 
concentrations were observed in the range of 5-25, while the negative control (no template control, 
NTC) gave a Ct value above 30 (Figure 3.2b). A standard plot of the Ct value vs log concentration 
of the DNA and G+DNA conjugate fit well within a linear relationship indicating the successful 
application of G+DNA for quantitative detection up to pico molar level (Experimental section 
3.13).  
Encouraged by the result obviously suggesting the detection of glycans from even a picomolar 
level, we proceeded to the final goal, screening of glycans against glycan binding proteins. DEGs 
can be used either as a screening tool against the known concentration of proteins or a detection 
tool to identify glycan-binding molecules. We did two sets of experiments for validating these two 
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aspects of DEGs; initially, we demonstrated the detection of specific glycan binding proteins by 
using the familiar blood glycan-antibody interactions. All three G+DNA conjugates (G1+A DNA, 
G2+B DNA, and G3+O DNA, with G1, G2 and G3 representing A, B, and O glycan antigens, 
respectively) were interrogated with the commercially-procured human blood antibodies (IgM). 
Concentrations of 5 µM, 2.5 µM, and 1 µM of the G+DNA were incubated with 2 µL of the 
antibodies; unbound DNA was eliminated either by filtration with 100k cut off centrifuge tubes or 
precipitation with magnetic protein L beads. The filtrate/eluent hence obtained then subjected to 
qPCR assay, and Ct values of the G+DNA then compared with the Ct values of negative control 
wherein antibody was omitted from the incubation. Ct difference of more than 10 points was 
observed at all three G+DNA concentrations (Experimental section, Figures 3.14-3.17), indicating 
the successful application of DEG in screening. 
 In another experiment, we evaluated the use of DEGs in the detection of glycan-binding proteins, 
a mixture of all three antibodies (1:1:1) interrogated with each of the G+DNA conjugates (2.5 uM) 
separately. As seen in Figure 3.2c, Ct values of 8.4 and 7.7 respectively for G1+A DNA and G2+B 
DNA infer the high affinity binding of A and B glycans with their corresponding antibodies Ab A 
and Ab B. But, a similarly tested G3+O DNA showed relatively higher Ct value but still less than 
that of the no antibody controls indicating weak interaction of antigens with the Ab O (Figure 
3.2c). This result implies that DEGs are ideal for the selective detection even from a mixture of 
closely related target proteins.  We also tested the specificity of the method, for this aim, we 
investigated a single G+DNA (G2+B DNA) against the three antibodies, and a clear amplification 
was visible only when both Ab B and G2+B DNA were in the mix. All the remaining tests were 
poorly amplified (Figure 3.2d). This result proved that the amplification was indeed from the target 
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specific binding of glycan, and there was no significant interference of nonspecific binding of 
DNA and target proteins. 
 
Figure 3.2. DNA encoded blood glycans and their detection by qPCR. 
a) DNA Encoded Blood Glycans, b) qPCR limit of detection comparison of glycan DNA conjugate 
and pure DNA, c) Each G+DNA conjugate selected against the mixture of antibodies composing 
equal concentration of Ab A, Ab B and Ab O, d) G2+B DNA selected against each antibody 
separately. 
 
3.1.2.3 DNA Encoded Glycan Library of globo series glycans and multiplex analysis using 
Next Generation Sequencing  
After successfully demonstrating blood antigens selection and amplification by PCR and 
qPCR, we wanted to apply the technology to the next generation sequencing platforms. Hence, we 
designed a DNA Encoded Glycan Library (DEGL) of globo series glycans (Figure 3.3). Globo-
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glycans are characterized as glycosphingolipids, and their expression pattern is well correlated 
with cancer metastasis and progression. Aberrant expression of immunogenic globo glycans 
triggers the production of the anti-glycan antibodies targeting these epitopes. These antibodies are 
generally observed in the sera even before cancer progresses to the late stages and effectively act 
as biomarkers for certain types of cancer including breast, lung, prostate and ovarian cancer.[26, 
150, 151] Globo-H and its truncated analogs Gb5, Gb4, Gb3, and Gb2 were synthesized from the 
enzymatic extension of chemically synthesized Gb-2. To test the terminal epitope specificity alone, 
Bb4, Bb3 and Bb2 were also synthesized via chemo-enzymatic strategy (Procedure is described in 
experimental section). All these glycans were then conjugated to the corresponding DNA codes 
via click chemistry as described previously.  
 
Figure 3.3. Globo glycan structure and representation of globo-glycan conjugates. 
 
ELISA of globo series glycans and DNA Encoded Glycan Library of globo series glycans 
Initially we validated the selected system with the conventional ELISA to confirm the 
antibody binding capacity and specificity of the glycans. Since sugars have low binding affinity 
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for unmodified plastic surfaces, the binding protein, streptavidin, was used to capture biotinylated 
sugars (synthesis is given in experimental section). Simultaneously, we also tested DEGL using 
ELISA to see the effect of different presentation of glycans. For this assay, we coated the DEGL 
onto plastic surfaces directly by the help of Pierce DNA coating solution. Both naked glycan and 
DEGL was tested against VK9, which is a mouse IgG anti-Globo H monoclonal antibody. In the 
ELISA of biotinylated sugars, VK9 has very high binding intensities to GbH and Bb4 and very 
low binding to Bb3 (Figure 3.4a). However, DEGL ELISA also showed week binding for Bb2 
along with the strong binding with GbH and Bb4 (Figure 3.4b). This result bolstered our earlier 
observation that immobilized glycans on a surface may not provide accurate information of the 
binding. We rationalize this difference in pattern to the different presentation of glycan epitope, 
all of the four glycans have the same terminal epitope of Fuc a1-2 Gal(b1-3 GalNAc), which is 
recognized by VK9 antibodies,[152] but a long DNA tag on the DEGL will give more space to the 
glycan antigens binding with the antibody, while normal ELISA would block the binding of the 
short glycans of Bb3 and Bb2. This kind of interferences will be further negligible when a DNA 
encoded glycan library is used, because the antigen-antibody interaction takes place in a more 
biologically significant solution phase. 
 
Figure 3.4. ELISA detection of glycans and glycan-DNA conjugates. 
a) ELISA of glycans conjugated with biotin immobilized on avidin coated surface against VK9. 
b) ELISA of glycans+DNA codes immobilized via pierce DNA coating solution against VK9. 
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qPCR detection GbH against VK9 antibody 
After validating the DEGL, we tested the GbH+DNA with the monoclonal anti globo-H 
antibody VK9 using the protein A/G protocol, and the qPCR results for two different 
concentrations (2.5 µM and 5 µM of GbH+DNA incubated with 2 µL of VK-9 antibody) are given 
in the Figure 3.5.  As expected, a concentration dependent binding was observed as indicated by 
the Ct values (7 and 19 for 5 µM and 14 and 21 for 2.5 µM).  
 
Figure 3.5. qPCR detection GbH against VK9 antibody. 
 
Detection of glycan binding antibodies present in the cancer plasma 
After gaining the confidence from the globo-H and VK-9 interrogation studies, we 
conducted an elaborate study using all the globo series glycan against two breast cancer plasma 
samples (sanguine bioscience BC1 and BC2) and compared the Ct values of each glycan 
conjugates with the sample treated with both healthy serum (HS) and no serum (NS). The results 
show that only GbH, Bb4 and Bb3 had significant amplification with the Ct values less than 8, 
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while other glycan conjugates show relatively less amplification (Figure 3.6). These results are 
consistent with the micro array based methods reported by Chi-Huey Wong group.[26] Though 
this approach accurately differentiated the cancer plasma from the healthy plasma based on the 
presence of glycan binding antibodies, it is not convenient to test every glycan conjugate separately 
and it is not practical when several plasma samples are needed to be tested. But these difficulties 
can be easily overcome by employing next generation sequencing (NGS), which allow multiplex 
detection of the glycan conjugate from a large cohort of plasma samples with one additional step 
of barcode indexing. Hence NGS technology allow the high throughput detection of hundreds of 
plasma samples with even thousands of glycans in the DEGL. 
 
Figure 3.6. Ct value plot of different globo series glycan conjugates interrogated with breast 
cancer plasma (BC1 and BC2), health serum (HS) and no serum (NS). 
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NGS experiments: 
 
 
Figure 3.7. Protocol for the multiplex detection of glycan binding to the target. 
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Next, we wanted to translate the results to more promising NGS based parallel screening. Initially 
we tested the different concentrations of DEGL with different concentrations of VK9 antibody 
using the PCR and qPCR assays. We incubated 1 uM, 500 nM, 100 nM and 10 nM samples with 
0.5 µL, 1 µL, and 2 µL of the VK9 antibody, and unbound glycans were washed out after 
precipitating the bound glycan-VK9 complex on protein A/G beads. Each assay was compared to 
the same amount of DEGL with no VK9 negative control. Then, washed beads were used as the 
template for the NGS analysis. Briefly, beads were diluted to 20 µL, and from this, 2 µL was used 
for the initial PCR amplification (18 cycles). PCR products were then purified using AM pure 
beads (Beckman Coulter) according to the manufacturer’s protocol and used for the NGS fusion 
PCR to incorporate the index codes and ion-torrent NGS adapters. Now about 150 bp DNA codes, 
it was again purified using AM pure beads, and all barcoded samples were run through an Agilent 
Bioanalyzer for quality control. Samples were then pooled in equimolar concentration and adjusted 
to the desired 26 pM for the NGS, analyzed using ion-PGM semiconductor sequencer. Data were 
analyzed using ‘FASTAPTAMER’ software, which is a custom designed software for the analysis 
of sequence count and read per million of aptamers after selection.[153] Unfortunately, the 
sequencing results (note provided) were not good enough to discriminate the antibody samples 
with the no antibody samples. We assumed this could be due to the high sensitivity of the 
sequencing method, and even the smallest of nonspecific DNA binding to the protein A/G beads 
(Ct values from qPCR suggest minor nonspecific binding) was affecting the overall performance 
of the assay. Hence, we decided to skip the procedure involving the beads and instead used biotin 
tagged secondary antibody specific to VK9. After incubation, the complex of DEGL+VK9+anti-
VK9-biotin was separated using the magnetic streptavidin beads and washed several times to 
remove any unbound DEGL from the mixture (Figure 3.7). Downstream processing of beads was 
92 
performed as described above, and we compared the relative enrichment of all the library members 
in comparison with the no VK9 negative control. As shown in Figure 3.8, only Globo-H, the 
antigen specific to the monoclonal antibody VK9 and its truncated analog Bb4 is enriched 
compared to the rest of glycans indicating the efficiency of NGS method in detecting the glycans 
from a mixture.  Even though the results were consistent over several runs, there was some random 
amplification in no serum controls as seen in the case of BB2 in figure 3.8. We assumed this might 
be due to the nonspecific binding of DNA to any of the components in the selection procedure, for 
instance binding to the secondary antibody or magnetic beads.  
 
Figure 3.8. Multiplex detection of DEGL against VK9 antibody using NGS method. 
 
Single stranded DNAs has the tendency to form the secondary structure, which may be the 
cause for binding like aptamers. To minimize this, we then hybridized the DNA conjugated 
glycans with their complimentary strand ssDNA to get the dsDNA, double strand DNA forms the 
helix and generally void of any binding. Next, dsDNA glycan library is incubated against the VK9 
and selection and sequencing has done according to the same procedure. Yet, the random 
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amplification in the negative control was still observed but this time the amplified DNA was Gb3 
DNA (result not shown). The random amplification of two different sequences in two experiments 
indicate that DNA might be selectively amplified after the selection due to any PCR bias and not 
because of nonspecific binding we initially assumed. To solve this, we added a control sequence 
immediately after the selection to all the samples, which will act both act as an internal standard 
and a supplemented template in negative control. With this modified method we further carried 
out the selection and sequencing of Globo-H series DEGL against the VK9 antibody. The results 
shown in the figure 3.9 clearly indicate the selective enrichment of GbH glycan along with the 
BB4 glycan in a lesser extent. 
 
Figure 3.9. Selection of globo series glycan library against VK9 antibody. Graph is plotted as the 
ratio of enrichment of each DNA sequence of DEGL treated with antibody against no antibody 
control in triplicate (Error bar is of standard error). 
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Detection of natural antiglycan antibodies 
 
Antiglycan antibodies are one of the major class of naturally occurring antibodies in the serum. 
Several antiglycan antibodies are known against the tumor specific glycans and glycans associated 
with autoimmune diseases, and there is a notable interest in pursuing them as potential biomarkers 
for such diseases.[154-156] To demonstrate the feasibility of detecting naturally occurring 
antiglycan antibodies via DEGL and NGS method, we further choose the blood glycan system 
which we earlier validated using PCR and qPCR. DEGL library was expanded with the addition 
of blood A and blood B glycans and selected the 10-glycan library against various blood groups. 
Figure 3.10, shows the selective enrichment of blood A antigen signal because sera of people 
having B blood group comprises substantial number of natural antibodies against the A antigen 
but no antibodies against the antigen B. 
 
Figure 3.10. Multiplex detection of DEGL against natural antiglycan antibody of blood B 
antibody using NGS method. Graph is plotted as the ratio of enrichment of each DNA sequence 
of DEGL treated with antibody against no antibody control in triplicate (Error bar is of standard 
error). 
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Comparing the different methods available to study the functions of glycans are not easy, 
they are largely dependent on assay platform, glycans and GBPs used in the assays and several 
other parameters like glycan presentation, incubation time, buffers and wash time etc.[129] Even 
the variability is significant in same platform technology, as of the glycan arrays from different 
group with different fabrication and assay protocol.[157] Our findings with the DEGL involving 
PCR, qPCR and NGS were positively corelated with the existing methods in selectivity, specificity 
and sensitivity (Table 3.1). DEGL requires femtomoles of glycans for the multiplex detection of 
glycan specific antibodies in the NGS assays, which is almost same as the glycans required in the 
microarray method which uses the minimum sample among the various methods.[129] Our 
method’s relative low sensitivity to the other methods in the table is most likely due to the 
monovalent presentation of glycan to the binding proteins unlike the multivalent presentations in 
ELISA, glycan arrays and MGBA. But, such presentations of glycan can be easily attained with 
the DEGL and hence a higher sensitivity could be attained.  
Most notable feature to highlight with the DEGL is its potential as method of high 
throughput and high capacity in sample handling. Moreover, unlike the ELISA, Glycan array or 
MGBA which are mono-dimensional and reads the optical density or florescence of the dye 
conjugated secondary antibody for the glycan detection, DEGL is multi-dimensional in glycan 
detection. DNA encoding brings tremendous possibility in detection and selection procedures as 
evidenced by the diverse methods opted by various research groups for the selection of small 
molecules.[158] Apart from the simple PCR, qPCR and NGS approaches, many groups have 
developed technologies that can detect binders specifically for each proteins from a mixture of 
targets or even from the cell lysates.[159, 160] Billions and trillions of compounds are screened 
against target proteins for drug development purpose, hence the number of glycans in the DEGL 
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is virtually unlimited.[135] On another side, with the proper selections of barcoding and 
sequencing platforms it is possible to screen about 800 assays in a single run. Also, fabrication of 
DEGL is simple chemical reaction widely used by chemist and biologists and very flexible to 
incorporate the multivalent presentation of glycans, which may be critical for many weak or 
medium binding glycans. One drawback of the assay is the time taken from the incubation to the 
sequencing result; it requires a full day of preparation before placing the sample for sequencing, 
which take almost five hours for the delivery of data. All together the DEGL screening take about 
two days to complete and it may be not suited for the quickest results, especially in certain clinical 
application. However, we think our glycan specific coding based on the structure could facilitate 
the use of multiplex qPCR using several probes for the diagnostic and vaccine monitoring.  
Table 3.1 Comparison of different platform technologies[26, 129, 154] 
 
 DEGL ELISA MGBA Glycan Arrays 
Glycan* 100 fmol 2500 fmol 1000 fmol 60 fmol 
Antibody** 500 ng 10 fmol/mL 250 fmol/mL 700 fmol/mL 
Serum Dilution*** 1:20 1:400 1:500 1:500 
*from references 26 and 129, ** reference 129, *** from references 26 and 154 
3.1.3. Conclusion 
Advancement of the technologies in DNA synthesis and sequencing has extended the scope of 
DNA beyond genetics. For example, DNA encoded libraries of small molecules in drug screening 
and lead optimization is a priority of research in major pharmaceutical companies. We recognized 
the importance of applying DEL technologies to functional glycomics, because this field is 
otherwise restricted by low sensitivity detection techniques and extreme difficulty in obtaining 
samples. Applying the highly sensitive PCR based detection will enhance the reach of functional 
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glycomics to sub-nanogram samples and allow tandem high throughput screening. For the 
encoding purpose, we described here a unique method to code each glycan, analogous to the 
codons of protein synthesis, which accounted for extensive structural information. The program 
which is available (http://131.96.145.142:8000/cgi-bin/form.py) for the use of the research 
community is aimed at providing a uniformity in the codes for every single glycan in future DEGL 
applications. A structure specific code also helps researchers to develop target specific qPCR probe 
to analyze the binding of specific glycan or a group of glycans having the same structural motifs 
without requiring a NGS. We also elaborated methods for the DNA-Glycan conjugation and 
various selection protocols and information retrieval. Finally, as a proof of principle application 
study, we synthesized DEGL consisting of the globo series glycans and demonstrated their 
application in detecting the antiglycan antibodies. Looking forward to the future, we believe, 
DEGL platform described here would give access to many researchers across the globe to use 
DNA code to decipher plethora of information regarding how glycans talk in biological 
significance. To lead the effort, we are extending the scope of our collection of DNA encoded 
glycans to several important classes and make them available for other researchers. This way with 
the contributions from several groups, it would probably pave the way for next generation of 
functional glycomics. 
3.1.4. Experimental section 
Materials 
All chemicals and biological reagents were purchased from Thermo Fisher unless 
otherwise mentioned. Maxima SYBR Green/ROX qPCR Master Mix, Platinum Pfx DNA 
Polymerase were purchased from Life Technologies (Carlsbad, CA). Micro Bio-Gel P-30 
Chromatography Columns were purchased from Bio-Rad (Hercules, CA). Tris[(1-Benzyl-1H-
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1,2,3-Triazol-4-yl) methyl] amime (TBTA) Click chemistry Ligand were purchased from TCl 
(Tokyo,Japan). MicroAmp 96 well Fast PCR Reaction Plate, MicroAmp Optical Adhesive Film, 
MicroAmp Fast Reaction Tubes, Strips were purchased from Applied Biosystems (Foster City, 
CA). All oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA). 
UDP-GlcNAc, UDP-GalNAc, UDP-Gal, and GDP-Fucose were prepared using one-pot 
multienzyme system as reported previously.[161, 162] β1–3-N-acetylglucosaminyltransferase 
(LgtA) and β1–4-galactosyltransferase (LgtB) from Neisseria meningitides were prepared as 
reported previously.[163, 164]  β1–3-N-acetylglucosaminyltransferase (LgtD) and α1–4-
galactosyltransferase (LgtC) were prepared as reported previously.[165] α1,2-FucT (HmFucT) 
from Helicobacter mustelae[166] was cloned into pET-28a vector and expressed in E.coli BL21 
(DE3). β1-3-N-acetylgalactosaminyltransferase (GTA) and β 1-3-galactosyltransferase (GTB) 
from human[167] were cloned into pET-28a vector and expressed in E.coli BL21 (DE3). The 
purified proteins were concentrated and desalted with 10 kDa molecular weight cut-off (Millipore, 
MWCO) spin filters for further use. GloboH-related oligosaccharides were prepared by following 
the previous protocol with minor changes.[26] Primary antibodies used is mouse anti-Globo H 
monoclonal antibody VK-9 (IgG; eBioscience™, Catalog #:14-9700-82). The secondary 
antibodies used were Biotin-conjuagted Goat anti-mouse IgG(H+L) and HRP-conjugated goat 
anti-mouse IgG(H+L) (ThermoScientific, Catalog #:A16066). Beads used were streptavidin 
conjugated magnetic beads (Dynabeads™ MyOne™ Streptavidin T1, Invitrogen, Catalog 
#:65601), Pierce Protein A/G Magnetic Beads (ThermoScientific, Catalog #:88803) and 
Agencourt AMPure Beads (Beckman Coulter). Taq DNA polymerase, NHS-PEG4-Biotin and 
Pierce DNA Coating Solution were all purchased from ThermoScientific. 
 
99 
DNA Sequences 
Table 3.2. DNA codes used in the study 
 
Name 5’Mod Sequence 3’Mod 
Oligo O 5’Hexynyl AATGATACGGCGACCACCGAAGAAAAGACGATCTAA
GCTCTACGATGTAAGACACGTCTGAACTCCAGTCAC 
None 
Oligo A 5’Hexynyl AATGATACGGCGACCACCGAACGCAACTTTAGAAAA
GAAAACGATCTAAGATCTACGATGTAACACGTCTGAAC
TCCAGTCAC 
None 
Oligo B 5’Hexynyl  AATGATACGGCGACCACCGAACGAAACTTTAGAAAA
GAAAACGATCTAAGCTCTACGATGTAAGACACGTCTGA
ACTCCAGTCAC 
None 
Gb-H 5’Hexynyl AATGATACGGCGACCACCGAAAGAAAAGACGATCTA
CGCTCTACGAATAACGATGTAAGACACGTCTGAACTCC
AGTCAC  
None 
Gb-5 5’Hexynyl AATGATACGGCGACCACCGAAACGATCTACGCTCTAC
GAATAACGATGTAAGACACGTCTGAACTCCAGTCAC 
None 
Gb-4 5’Hexynyl AATGATACGGCGACCACCGAACGCTCTACGAATAACG
ATGTAAGACACGTCTGAACTCCAGTCAC 
None 
Gb-3 5’Hexynyl AATGATACGGCGACCACCGAAACGAATAACGATGTA
AGACCCCAGTCAGGCCTAACGTACACGTCTGAACTCCA
GTCAC 
None 
Gb-2 5’Hexynyl AATGATACGGCGACCACCGAAACGATGTAAGACCCC
AGTCAGGCCTAACGTACACGTCTGAACTCCAGTCAC 
None 
100 
Bb-4 5’Hexynyl AATGATACGGCGACCACCGAAAGAAAAGACGATCTA
CGCTCTACGA CACGTCTGAACTCCAGTCAC 
None 
Bb-3 5’Hexynyl AATGATACGGCGACCACCGAAAGAAAAGACGATCTA
CGCCCCCAGTCAGGCCTAACGTACACGTCTGAACTCCA
GTCAC 
None 
Bb-2 5’Hexynyl AATGATACGGCGACCACCGAAAGAAAAGACGACCCC
AGTCAGGCCTAACGTACACGTCTGAACTCCAGTCAC 
None 
FW 
Primer 
None AATGATACGGCGACCACCGAA None 
RV 
Primer 
None GTGACTGGAGTTCAGACGTG 
 
None 
 
* For all 5’ to 3’ DNA Sequences BOLD is the forward primer and BOLD ITALIC is the 
reverse primer binding site. 
 
Preparative scale synthesis of blood antigen ABO and globo series glycans 
 
 
2 was prepared from 1 using LgtA from Neisseria meningitides.  In detail, a reaction mixture in 
a final volume of 50 ml containing 50 mM Tris-HCl, 425 mg of 1 (1 mmol), 607 mg of UDP-
GlcNAc (1 mmol), 5 mM of Mg2+, 8 mg of LgtA was carefully shaken at 37°C to allow the 
formation of 2. The reaction was monitored by TLC (EtOAc/MeOH/H2O/HOAc=5:2:1.4:0.4). 
Once the reaction was no longer move forward, equal volume ethanol was added to remove 
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proteins and the solution was concentrated in vacuo. After purification by using Bio-Gel P-2 
column. 530 mg of 2 was obtained in 85% yield regarding 1. 
 
3 was prepared from 2 using LgtB from Neisseria meningitides.  In detail, 503 mg of 2 was 
dissolved in a 80 ml of reaction mixture containing 50 mM Tris-HCl, 12 mM of UDP-Gal, 5 mM 
of Mg2+, 10 mg of LgtB. The reaction was carefully shaken at 37°C for overnight to allow the 
formation of 3. The reaction was monitored by TLC (EtOAc/MeOH/H2O/HOAc=5:2:1.4:0.4). 
Once reaction finished, equal volume ethanol was added to precipitate proteins and the supernatant 
was concentrated in vacuo. After purification by using Bio-Gel P-2 column. 432 mg of 3 was 
obtained in 76% yield regarding 2. 
4 
(blood O-antigen) was prepared 3 using FucT from Helicobacter mustelae. In detail, reaction was 
performed in a final volume of 35 ml mixture containing 50 mM Tris-HCl (pH 8.0), 277 mg of 3 
(10 mM), 5 mM of Mg2+, 15 mM of GDP-Fucose, and 4 mg of FucT. 20 units of alkaline 
phosphatase were added into reaction system to hydrolyze the newly formed GDP to improve the 
reaction yield. The reaction was carefully shaken at 37°C for overnight and monitored by TLC 
(EtOAc/MeOH/H2O/HOAc=5:2:1.4:0.4). Once reaction finished, the product was purified by 
using Bio-Gel P-2 column. 211 mg of 4 was obtained in 64 % isolated yield regarding 3. Product 
was confirmed by MALDI-TOF-MS analysis.  
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5 (blood A-antigen) was prepared from blood O-antigen using GTA from human. In detail, 
reaction was performed in a final volume of 14 ml mixture containing 20 mM Tris-HCl (pH 8.0), 
66 mg of 4 (5 mM), 3 mM of Mg2+, 7 mM of UDP-GalNAc, and 5 mg of GTA. The reaction was 
carefully shaken at 37°C for overnight for the formation of 5. The reaction was monitored by TLC 
(isopropanol/NH4OH/H2O = 7:3:2). Once reaction finished, the product was purified by using 
Bio-Gel P-2 column. 45 mg of 5 was obtained in 56 % isolated yield regarding 4. Product was 
confirmed by MALDI-TOF-MS analysis.  
 
 
6 (blood B-antigen) was prepared from blood O-antigen using GTB from human. In detail, 
reaction was performed in a final volume of 14 ml mixture containing 20 mM Tris-HCl (pH 8.0), 
66 mg of 4 (5 mM), 3 mM of Mg2+, 7 mM of UDP-Gal, and 5 mg of GTB. The reaction was 
carefully shaken at 37°C for overnight for the formation of 6. The reaction was monitored by TLC 
(isopropanol/NH4OH/H2O = 7:3:2). Once reaction finished, the product was purified by using 
Bio-Gel P-2 column. 39 mg of 6 was obtained in 51 % isolated yield regarding 4. Product was 
confirmed by MALDI-TOF-MS analysis. 
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Synthesis of Globo-H and related glycans 
 
 
2 was prepared from 1. In detail, a reaction mixture in a final volume of 10 ml containing 50 
mM Tris-HCl, 85 mg of 1 (2 mmol), 153 mg of UDP-Gal (2.5 mmol), 5 mM of Mg2+, 2 mg of 
LgtC was carefully shaken at 37°C to allow the formation of 2. The reaction was monitored by 
TLC (EtOAc/MeOH/H2O/HOAc=5:2:1.4:0.4). Once the reaction was no longer move forward, 
equal volume ethanol was added to remove proteins and the solution was concentrated in vacuo. 
After purification by using Bio-Gel P-2 column. 99 mg of 2 was obtained in 86% yield regarding 
1. 
 
 
In a reaction mixture of 5 ml volume, 50 mM Tris-HCl, 59 mg of 2 (1 mmol), 5 mM of Mg2+, 
98 mg of UDP-GalNAc (1.5 mmol), 2 mg of LgtD were added. the reaction was carefully shaken 
at 37°C overnight to allow the formation of 3. Once the reaction finished, equal volume ethanol 
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was added to remove proteins and the solution was concentrated in vacuo. After purification by 
using Bio-Gel P-2 column, 63 mg of 3 was obtained in 80% yield regarding 2. 
 
 
4 was prepared from 3. A 5 ml of reaction mixture containing 50 mM Tris-HCl, 5 mM of Mg2+, 
47 mg of 3 (0.6 mmol), 65 mg of UDP-Gal (1 mmol), and 5 mg of LgtD was carefully shaken at 
37°C overnight to allow the formation of 3. 5 unit of alkaline phosphatase was added to hydrolyze 
the formation of UDP to improve the reaction yield. After purification by using Bio-Gel P-2 
column, 36 mg of 4 was obtained in 62% yield.  
 
GloboH (5) was prepared from 4. A reaction mixture containing 50 mM Tris-HCl, 5 mM of 
Mg2+, 29 mg of 4 (0.3 mmol), 32 mg of GDP-Fuc (1 mmol), and 2 mg of FucT was carefully 
shaken at 37°C overnight to allow the formation of GloboH. 5 unit of alkaline phosphatase was 
added to hydrolyze the byproduct GDP to improve the reaction yield. After purification by using 
Bio-Gel P-2 column, 24 mg of GloboH was obtained in 71% yield.  
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In a 10 ml of reaction mixture, 50 mM Tris-HCl, 53 mg of 6 (2 mmol), 5 mM of Mg2+, 158 mg 
of GDP-Fucose (2.5 mmol), 3 mg of FucT were added. the reaction was carefully shaken at 37°C 
overnight to allow the formation of 7. Once the reaction finished, equal volume ethanol was added 
to remove proteins and the solution was concentrated in vacuo. After purification by using Bio-
Gel P-2 column, 61 mg of 7 was obtained in 75% yield. 
 
 
 
10 was synthesized from 8 by two reaction steps. In a 5 ml of reaction mixture, 50 mM Tris-
HCl, 5 mM of Mg2+, 61 mg of 8 (2 mmol), 153 mg of UDP-Gal (2.5 mmol), 4 mg of LgtD were 
added. the reaction was carefully shaken at 37°C overnight to allow the formation of 9. Once the 
reaction finished, equal volume ethanol was added to remove proteins and the solution was 
concentrated in vacuo. After purification by using Bio-Gel P-2 column, 77 mg of 9 was obtained 
in 83% yield regarding 8. In second reaction step, 77 mg of 9 was incubated in a 5 ml of 50 mM 
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Tris-HCl with 5 mM of Mg2+, 47 mg of 9 (1 mmol), 127 mg of GDP-Fucose (2 mmol), and 3 mg 
of FucT. The reaction was carefully shaken at 37°C overnight to allow the formation of 10. Once 
the reaction finished, equal volume ethanol was added to remove proteins and the solution was 
concentrated in vacuo. After purification by using Bio-Gel P-2 column, 69 mg of 10 was obtained 
in 57% yield regarding to 8. 
 
 
 
14 was prepared from 11 stepwisely. In a 10 ml of reaction system, 50 mM Tris-HCl, 5 mM of 
Mg2+, 53 mg of 11 (2 mmol), 163 mg of UDP-GalNAc (2.5 mmol), and 2 mg of LgtD were added. 
The reaction was performed at 37°C overnight to allow the formation of 12. 12 was purified by 
Bio-Gel P-2 column (75 mg, 81% yield). Then, 75 mg of 12 was dissolved in 10 ml water 
containing 50 mM Tris-HCl, 5 mM of Mg2+. 122 mg of UDP-Gal (2 mmol) and 7 mg of LgtD 
were added. In addition, 5 units of alkaline phosphatase was added to hydrolyze the byproduct 
GDP to improve the reaction yield. The reaction was performed at 37°C. 13 was obtained after P-
2 gel purification. In last reaction step, 32 mg of 13(0.5 mmol) was dissolved in 5 ml of water 
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containing 50 mM Tris-HCl, 5 mM of Mg2+. 1.5 mg of FucT and 48 mg of GDP-Fuc(0.75 mmol) 
was added to start the reaction at 37°C. 2 units of alkaline phosphatase was added to hydrolyze the 
byproduct GDP to improve the reaction yield. 14 was purified by P-2 column (28 mg, 73% yield). 
Gradient PCR and Tm Determination 
Initially a gradient PCR was performed to figure out the optimal melting temperature to be 
used in the further quantitation experiments. Platinum Pfx DNA Polymerase was used for the PCR, 
approximately 26 µg of template, 1 µL of primers (10 µM), 1mm dNTP, 10X amplifying buffer, 
MgSO4, Polymerase and nuclease free water was used for a typical 25 µL reaction. Standard 
thermocycling condition were used with different temperature in the melting phase (95°C for 10 
min, X°C for 30s, 95°C for 15s, 13 cycles) wherein X represents the melting phase and temperature 
gradient from 50 oC - 60 oC were tested during this phase. The amplified PCR products were 
analyzed using 4% agarose gel electrophoresis. Tm determined using this method was used for 
qPCR.  
Component 25 µl 50 µl Final Concentration 
10X Amplifying Buffer 5 10 -  
MgSO4 1 2 -  
dNTP(10mM) 0.75 1.5 0.3mM  
Forward Primer(10uM) 0.75 1.5 0.3uM  
Reverse Primer(10uM) 0.75 1.5 0.3uM  
Template(1uM) 1 2 0.04  
Polymerase 0.3 0.5 -  
Nuclease Free Water 15.4 31 -  
 
 
108 
 
                                Figure 3.11. Gradient PCR for Tm determination. 
 
Figure 3.12. Click conjugation of 5’-hexynyl DNA and azido modified glycans. 
 
Synthesis of glycan DNA conjugates: Glycan(Antigen)- DNA Conjugates were synthesized 
using Azido-Alkyne cycloaddition click reaction. The 5’-/5Hexynyl-terminated DNA was 
procured from the commercial suppliers (IDT) with standard desalting purified. Desalted DNA 
was HPLC purified before click conjugation. All glycans were synthesized via chemo enzymatic 
method with the azido propyl linker at the reducing end as described above.  
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Click reaction procedure: 5’-Hexynyl-terminated DNA (500 µM, 20 µL), azido glycan (1.5 mM, 
30 µL), 2M TEA buffer (pH 7, 20 µL, final concentration of 0.2 M), 5 mM of freshly prepared 
Ascorbic acid solution (20 µL, final concentration 0.5mm), 10 mm of copper-TBTA in 55% 
DMSO (10 µl, final concentration 0.5 mm) and 50 volume % DMSO (100 µl) were mixed together 
in a tube. The reaction mixture was vortexed and kept at room temperature for overnight. The 
reaction mixture was purified using Micro Bio-Gel P-30 Chromatography Columns (20 base pair 
cut-off). The concentration of the Glycan (Antigen)-DNA Conjugates was determined by 
absorbance at 260/280 using Nanodrop (ThermoFisher).  
Any presence of residual unreacted DNA was further tested by PCR amplification and gel 
electrophoresis. Recovered reaction mix was incubated with the specific antibody for two hours 
and washed with the washing buffer, and later eluted with the elution buffer. Both wash and elution 
buffers were collected and performed a PCR. Gel analysis of the PCR product did not show a band 
in the wash buffer (residual unreacted DNA) but a strong band was seen in elution buffer indicating 
all DNA is coupled with the azido sugar (Figure 3.11) 
 
 
Figure 3.13. Gel analysis of ‘clicked’ DNA. 
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Figure 3.14. Glycan structures used for the conjugation with alkyne DNA and alkyne biotin 
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Figure 3.15. Structure of Glycan DNA conjugates. 
 
Characterization of DNA+Glycan conjugates 
DNA codes for each glycans were purified by HPLC before used in click reaction, 
Preparative HPLC purification was achieved using following conditions; Agilent 1200 HPLC 
system, Xbridge semi prep C18 column, 5 uM, 10X 150 mm; Solvent A : pH 7.0 TEAA buffer 0.1 
M, Solvent B: 20% CAN in solvent A; 5% B to 95% B over 30 minutes with a flow rate of 1.2 
mL/minute. After click reaction, products were purified and concentrated and analyzed by HPLC. 
Analytical method: Agilent 1200 HPLC or Shimadzu LC20AT, Eclipse Plus C18, 3.5 uM, 4.6 X 
112 
100 mm column; Solvent A : pH 7.0 TEAA buffer 0.1 M, Solvent B: 20% CAN in solvent A; 5% 
B to 95% B over 30 minutes with a flow rate of 0.6 mL/minute. 
PCR comparison of DNA and G+DNA 
A PCR comparison was conducted between pure DNA and G+DNA to make sure that the 
DNA can be used for further PCR reaction after conjugation with glycan. PCR was conducted 
under the same conditions as stated under Gradient PCR and Tm Determination and analyzed using 
4% agarose gel electrophoresis. 
 
Figure 3.16. PCR comparison of pure DNA and glycan conjugated DNA. 
 
qPCR Methods 
General qPCR protocol for a typical 12.5 µL reaction: The glycan(Antigen)- DNA Conjugates 
were added to 6.25 µL 2X Maxima SYBR Green/ ROX qPCR Master Mix with 1 µL primers 
(Forward Primer – 500 nM and Reverse Primer- 300 nm). qPCR was performed with Applied 
Biosystems Stepone System (50 oC for 2 mins (Holding), 95oC for 10 mins (Holding), 95 oC for 
15 s, 60oC for 10 s ,72 OC for 10 s for 40 cycles). 
A : DNA 100  
      Ladder 
B: Control 
C : Control 
D : DNA_A 
E : DNA_A 
F: G+DNA_A 
G: G+DNA_A 
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Ct or threshold cycle, is a measurement of signal intensity for qPCR experiments. In a 
qPCR experiment, PCR is performed in presence of a fluorogenic intercalating dye (SYBR Green 
in our case). The dye intercalates with double-stranded DNA, as more double-stranded DNA is 
produced in each PCR cycle the dye increases the fluorescence intensity. Once the fluorescence 
intensity reaches a threshold level, the cycle number is recorded by the instrument as Ct value. 
Therefore, sample having large amount of DNA will have a lower Ct value compared to those 
samples containing relatively less amount of DNA. 
Standard curve plot of DNA and G+DNA 
To prove the consistency over concentration for both pure DNA and G+DNA, a qPCR 
standard curve reaction was conducted over a series of 8 different concentrations (2.4 nM, 1.2 nM, 
600 nM, 206 nM, 130 nM, 64 pM, 32 pM, and 16 pM) with standard thermocycling conditions 
stated above. 
Component Volume(in uL) 
2x Maxima SYBR Green/ROX qPCR 
master mix  
6.25 
Forward Primer(500nm) 1 
Reverse Primer(300nm) 1 
Template(Gradient as stated above) 1 
Nuclease Free Water 3.25 
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Figure 3.17. Standard curve plot of pure DNA (B DNA) and glycan conjugated B DNA. 
 
Immunoprecipitation of Antibody-Antigen-DNA Conjugates 
10 µL of glycan(antigen)-DNA Conjugate (5 µM) was incubated with 2 µL of antibody (if 
plasma is used then 2 µL of plasma is diluted to 8 µL using water) for 2 hours at room temperature. 
After two hours, the reaction volume was made up to 100 µL using TBST buffer and added to 20 
µL of prewashed A/G protein bead and incubated for one hour at room temperature with occasional 
shaking at an interval of 15 mins. After one hour the beads were washed thoroughly for 7 times 
using TBST buffer. After washing the beads were reconstituted in 20 µL of TBST buffer. The 
beads (2 µL) were directly used as template for qPCR analysis. 
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DNA encoded glycans for the detection of glycan binding proteins 
 
                          Figure 3.18. G1+A DNA for the detection of A antibodies. 
10 µL of three different concentration (5 µM, 2.5 µM and 1 µM) incubated with 2 µL of Blood 
Group A Antigen Antibody HE-193 (MA1-19693). IP and qPCR was performed as described 
previously. 
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                            Figure 3.19. G2+A DNA for the detection of B antibodies. 
10 µL of three different concentration (5 µM, 2.5 µM and 1 µM) incubated with 2 µL of Blood 
Group B Antigen Antibody HEB-29 (MA1-19691). IP and qPCR was performed as described 
previously. 
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                      Figure 3.20. G3+O DNA for the detection of O antibodies. 
10 µL of three different concentration (5 µM, 2.5 µM and 1 µM) incubated with 2 µL of Blood 
Group ABH Antigen Antibody HE-10 (MA1-19694). IP and qPCR was performed as described 
previously. 
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Figure 3.21. Ct value of different concentrations of G+DNA when incubated with the specific 
antibody. 
 
Selectivity and specificity analysis of DEGL  
Glycan-DNAs with the mixture of antibodies A, B and O (G+DNA Vs ABO Abs 1:1:1):  
Antibody mixture was prepared by mixing 2 µL each of Blood Group A Antigen Antibody 
HE-193 (MA1-19693), Blood Group B Antigen Antibody HEB-29 (MA1-19691) and Blood 
Group ABH Antigen Antibody HE-10 (MA1-19694). Then, 10 µL of each glycan conjugates (2.5 
µM) were incubated with 2 µL of antibody mix separately. Immunoprecipitation and qPCR 
0
5
10
15
20
25
30
35
40
Ct value of G+DNA vs specific antibody
G3+O DNA vs Ab OG2+B DNA vs Ab BG1+A DNA vs Ab A
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analysis was performed as described above. A no antigen control with none conjugated DNA (A 
DNA, 2.5 µM) is used in immunoprecipitation and a no template control was used in qPCR. 
G2+B DNA vs A, B, and O antibodies: In this experiment, 10 µL of G2+B DNA (2.5 µM) was 
incubated with 2 µL of each antibody. A no antibody control is used in immunoprecipitation and 
a no template control was used in qPCR. Immunoprecipitation and qPCR analysis was performed 
as described above. 
Globo-H vs VK-9: The immunoprecipitation procedure for Globo-H with VK9 were same as 
stated in Immunoprecipitation of Antibody-Antigen- DNA Conjugates. The volume of antibody 
used was 2 µL and Globo-H was 10 µL (2.5 µM). 
ELISA experiment.  
The 96-well plate (Costar Polystyrene High Binding Plate 3590) was coated with 100 ml 
of 10 ug/ml Streptavidin (Sigma) in 0.01 M PBS (pH 7.4) at 4oC overnight. The coated plate was 
then washed with 150 ul of 0.05% Tween-20/PBS buffer (pH 7.4) (PBST) for three times and then 
add 100ul Biotinylated sugar (synthesized via click reaction, Figure S1) for capturing. After 30 
minutes, the plate was washed. For DNA-sugar ELISA, the only difference is to coat the DNA-
sugar onto plastic surfaces directly at the help of Pierce DNA Coating Solution for overnight. Then 
the plate was blocked with 2% (w/v) BSA in PBST for 2 hrs. After washed with another 150 ul 
PBST for 3 times, 100 ul VK9 (a mouse IgG anti-Globo H monoclonal antibody) with a series of 
dilution was added for incubation at room temperature for 2 hrs. After washed with 200 ul PBST 
for 6 times, HRP-goat anti-mouse IgG(H+L) was added to the plate at a dilution as recommended 
for 1 hr at room temperature. After washed with another 200 ul PBST for 6 times, 100 ul TMB 
solution was added to the plate and then stopped by 100 ul 1 M phosphoric acid. The plate was 
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then read at OD450 with a plate reader (PerkinElmer, 2030 Multilabel Reader Victor). The result 
is calculated by minus OD450 value of control (no antibody).  
 
 
Figure 3.22. MALDI TOF analysis of GH and biotinylated-GbH. 
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NGS experiment 
NGS Protocol 
1. Selection: 10 ul of 100nM DEGL was incubated with 2ul (1ug) Vk-9 antibody (Globo 
H Monoclonal Antibody, eBioscience; Catalog Number: 14-9700-82) for 2 hrs at 37oC. After 2 
hrs 0.2 ul of Biotin Conjugated Goat Anti-Mouse IgG Secondary Antibody (Thermofischer 
Scientific; Catalog Number:31800), 40 ul of Sheared Salmon Sperm DNA (Thermofischer 
Scientific; catalog Number: AM9680) and 50 ul of TBST buffer (0.1 % Tween 20, 0.1% BSA) 
was added and incubated at 37oC for 1 hr. 20ul of Streptavidin Magnetic beads (Dynabeads Myone 
Streptavidin T1; Catalog Number: 65601) was prewashed using PBS as per user instructions. After 
1 hr the solution was incubated with prewashed Streptavidin beads for 30 mins at 37oC. The beads 
were washed 7 times using 100 ul TBST buffer. The washed beads were then diluted in 20 ul of 
TBST buffer.  
2. Library Preparation: 1ul of washed streptavidin beads were used for amplification using 
template primers with Taq polymerase (Thermofischer Scientific; Catalog Number: EP0402) for 
18 cycles. The PCR product was purified using Agencourt AMPure XP Magnetic beads (30% 
PEG) as per user instructions. The purified PCR product was amplified again using NGS adapters 
(30 Cycles) and purified using Agencourt AMPure XP Magnetic beads. The purified product’s 
concentration was measured using Agilent 2100 Bioanalyzer. An equimolar solution of 26pM was 
prepared which was loaded in Ion Chef for the Chip Preparation and sequencing by Ion PGM. 
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4. CONCLUSION 
Cancer is the most lethal and feared disease of this century. The disease has several causes 
including gene mutation, abnormal protein production and external factors like lifestyle and 
environmental factors.[168, 169] These multifactorial dispositions have delineated the overall lack 
of success in cancer therapy compared to other diseases like heart disease and diabetes. 
Traditionally cancer is treated with the chemo therapeutic agents and more recently with the 
targeted small molecules and immune therapy.[3, 4, 8, 170] Chemotherapeutic agents target 
rapidly dividing cells lacking any specificity, hence it eliminates cancer cells and other fast-
growing tissues alike. Researchers quest to minimizing this off- target effect yielded the first 
targeted therapy for cancer in early 1990s.[3] Ever since, the war against cancer is led by the small 
molecules targeting several important proteins in cancer development and metastasis.[3, 6, 9-12, 
78, 85, 87, 171-175] In another side, it is evident that cancer diagnosis at initial stages of disease 
development is critical for the therapy.[1, 20, 23, 176-178]. Diverse strategies are applied for the 
early detection of cancer by searching the cancer biomarkers in the body, yet a very conclusive 
non-invasive method for the detection is still not met. 
Our search of inhibitors targeting epigenetic enzyme G9a yielded a series of compounds 
as potential inhibitors through structure based virtual screening. Among these compounds, a new 
G9a inhibitor, DCG066, was confirmed by in vitro biochemical and cell-based enzyme assays. 
DCG066 has a novel molecular scaffold unlike other G9a inhibitors presently available. Like 
G9a’s histone substrate, DCG066 can bind directly to G9a and inhibit methyltransferase activity 
in vitro. DCG066 displays low cytotoxicity in leukemia cell lines with elevated levels of G9a 
expression, including K562. This work presents DCG066 as an inhibitor of G9a with a novel 
structure, providing both lead in G9a inhibitor design and a means for probing the functionality of 
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G9a. We also designed hybrid molecules targeting G9a and HDAC, two epigenetic enzymes 
involved in many cancers. Detailed SAR study of compounds featuring pharmacophores of both 
G9a inhibitors and HDAC inhibitors identified compound 13 and 14 with dual inhibition of targets 
in sub micromolar level. The activity of the compounds confirmed by cellular and biochemical 
assays and the molecules have drug like physico-chemical properties. Hence has the potential to 
developed as a lead molecule for targeted therapy of cancer. 
We also elaborated here a robust method for the detection of glycan specific antibodies 
relevant to cancer prognosis. Glycans are an important class of cancer markers and not been used 
to the potential owing to the complexity in their detection and analysis. We solved this critical 
issue by conjugating the glycans with a structure-based DNA code and further analyzed the DNA 
glycan conjugate in the DNA way, i.e. by using the molecular biology methods PCR, qPCR and 
next generation sequencing. We demonstrated the detection of anti-glycan antibodies in cancer 
plasm using the DNA encoded glycan library (DEGL) of globo series glycans. 
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APPENDICES  
Appendix A Supporting information for Discovery of novel small molecule inhibitors of 
lysine methyltransferase G9a and their mechanism in leukemia cell lines 
Appendix A.1. Characterization of compounds 
 
HPLC (DCG066)  
 
 
 
Figure A.1.  HPLC of DCG066 
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1H NMR of DCG066 
 
 
145 
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13C NMR of DCG066 
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Spectral data of compound 7 
1H NMR  
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13C NMR  
 
Shukkoor_KL05 #279-515 RT: 2.07-2.90 AV: 29 NL: 1.26E8
T: FTMS + p ESI Full ms [200.00-1000.00]
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Appendix B. Supporting information for Structure based design, synthesis and activity 
studies of small hybrid molecules as HDAC and G9a dual inhibitors 
Appendix B.1. Supporting information for assays 
MALDI-TOF study of methylation 
MALDI-TOF based experiment was performed according to the protocol developed by 
Chang etal.[113] MALDI spectrums were collected using Bruker flex control software and 
analyzed by flex analysis. After labelling each cluster peaks of H3K9Me0, H3K9Me1 and 
H3K9Me2 for all of the tested concentrations, area under the cluster (AUC) were extracted by 
using the same flex analysis software. % abundance of each peak was calculated by following 
formula, 
A = % Abundance of (H3K9Me0) = area of H3K9Me0/ (area of H3K9Me0+area of 
H3K9Me1 + area of H3K9Me2)  
B = % Abundance of (H3K9Me1) = area of H3K9Me1/ (area of H3K9Me0+area of 
H3K9Me1 + area of H3K9Me2) 
C = % Abundance of (H3K9Me2) = area of H3K9Me2/ (area of H3K9Me0+area of 
H3K9Me1 + area of H3K9Me2). 
This was repeated for each spectra (3 multiples for each samples). 
G9a catalyze dimethylation of H3K9 and hence formation of H3K9Me2 was considered as 
the product formation and H3K9Me0 and H3K9Me1 is considered substrate not modified to the 
final product. Hence here % conversion to product is also C, from this to get the %maximal activity 
(%MA), C was compared to the % conversion when no inhibitor was used (D). 
Finally % inhibition was found by subtracting %MA(i)  from 100 
Example: % methylation levels and % inhibition when used 5 µM compound 14 
A = 13.09 
B = 61.18 
150 
C = 25.72 
% conversion when no inhibitor was used D = 84.43 (average of six measurements) 
%MA = 100 * 25.72/84.43 
           = 30.46 
Finally % inhibition = 100 – 30.46  
                                  = 69.54% 
Average of 3 values were reported in the Figure S1 and Table 1. 
 
 
Figure B.1. A sample MALDI-TOF image used for the % inhibition analysis 
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Table B.1. MALDI-TOF methylation study of inhibitors at 5 µM concentration for 30 min 
 
CPD# Inhibition (%) CPD# Inhibition (%) 
4 26.96±12.15 4a 11.22±3.68 
5 65.02±1.95 5a 47.55±9.32 
6 26.64±11.34 6a 50.65±16.51 
7 19.58±20.95 7a 15.01±15.73 
13 24.91±17.42 13a 62.00±14.44 
14 29.68±23.32 14a 69.55±3.43 
15 69.12±24.54 15a 47.85±12.88 
16 40.32±13.81 16a 40.32±13.81 
19 10.71±25.88 20 14.62±15.81 
21 22.75±26.72 22 40.26±15.33 
5b 38.01±4.99 BIX-
01294 
77.68±5.73 
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HDAC assay results 
Table B.2. Cell based homogenous HDAC assay results 
 
CPD# IC50-HDAC 
 Helac A549d K562e 
4 NAa NA NA 
4a NA NA NA 
5 NA NA NA 
5a NA NA NA 
6 NA NA NA 
6a NA NA NA 
7 NA NA NA 
7a NA NA NA 
13 15.33±0.79 >100 27.75±0.59 
13a >100 >100 >100 
14 13.80±1.22 >100 5.735±1.23 
14a >100b >100 >100 
15 >100 >100 >100 
15a >100 >100 >100 
16 >100 >100 >100 
16a >100 >100 >100 
19 >100 >100 >100 
20 >100 >100 >100 
21 >100 >100 >100 
22 >100 >100 >100 
BIX NA NA NA 
SAHA 5.044±0.53 >100 2.056±0.59 
NAa not active up to the highest concentration tested (the highest concentration of all compounds 
is 100 µM; 
>100b in the cases where the IC50 did not reach at the highest tested concentration (100 
µM); 
cHela: human cervical cancer cell line; dA549: human lung cancer cell line; eK562: human 
immortalized myelogenous leukemia cell line; SAHA was used as the positive control. Data are 
shown as mean ± SD of triplicate. 
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Appendix B.2. Molecular docking study results 
HDAC (PDB ID:1T69) protein interactions study 
Initially we chose HDAC8 protein structure (PDB ID:1T69) for the docking study because 
it has SAHA (which we used as the control in cell based assays) as the co-crystallized ligand, but 
our study revealed a lower GLIDE score and docking score than the expected, and so we did a 
similar study on another HDAC8 protein structure 1T67 and found a higher binding scores and 
chose this for later study.   
Table B.3. Glide docking study results for compound 14 and SAHA at the catalytic site of 
HDAC8 (PDB ID: 1T69) 
 
S
NO. 
Ligand 
Id 
Glide 
score 
Dockin
g score 
INTERACTIONS 
 H- bonds π-π 
 
Interaction 
with Zn2+ 
atom 
  
 Backbone Side chain 
1 SAHA -5.794 -5.794 His142, His143, 
Gly151, Gly304 
Asp101, 
Tyr306 
Phe152 + 
2 14 -8.858 -8.471 Gly140, His142, 
Gly151, Gly206, 
Phe207, Pro209, 
Gly304 
Asp101, 
Tyr306 
- + 
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Superimposed images of 14, MS-344 with HDAC8 (PDB ID: 1T67) and 14, BIX-01294 with 
G9a (PDB ID: 3FPD) 
 
Figure B.2. Binding analysis image of compound 14 and SAHA with HDAC8 (PDB ID: 1T69). 
 
                 FigureB.3. Super imposed ligands with their corresponding target enzyme.  
A) Superimposition of cocrystallized MS-344 (gray), best docked pose of 14 (orange) in the 
catalytic site of HDAC8 (PDB ID: 1T67), B) Superimposition of BIX-01294 (gray), best docked 
pose of 14 (orange) in the catalytic site of G9a (PDB ID: 3FPD). 
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 Appendix B.3. Cytotoxicity study results 
Table B.4.. Detailed results of cytotoxicity study 
 
CPD# EC50(µM) 
MDA-MB-231c MCF-7d A549e 
4 >100b >100 NAa 
4a >100 >100 NA 
5 >100 >100 NA 
5a >100 >100 NA 
6 >100 >100 NA 
6a >100 >100 NA 
7 >100 >100 NA 
7a >100 >100 NA 
13 89.33±1.23 79.43±2.72 >100 
13a >100 >100 NA 
14 10.02±1.66 37.36±2.20 36.24±1.7
6 
14a 82.32 >100 NA 
15 95.15 >100 NA 
15a 77.62 >100 NA 
16 38.15 57.29 >100 
16a 90.54 >100 NA 
19 >100 >100 NA 
20 >100 >100 NA 
21 >100 >100 NA 
22 >100 >100 NA 
26 31.28±3.30 >100 NA 
30 24.01±3.64 >100 NA 
5b 12.29±3.27 74.57±1.81 NA 
BIX-01294 2.155±0.88 8.103±1.99 21.74±2.7
3 
SAHA 2.874±0.84 8.124±4.98 19.31±1.2
6 
NAa, not active up to the highest concentration tested (the highest concentration of all compounds 
is 100 µM. 
>100b in the cases where the IC50 did not reach at the highest tested concentration (100 
µM). 
cMDA-MB-231: breast cancer cell line; dMCF-7: breast cancer cell line; eA549: human 
lung cancer cell line; SAHA and BIX-01294 are used as the positive controls; 
Cells were exposed to the different inhibitors with various concentrations for 72 h, Inhibition of 
cell growth by the listed compounds was determined by using CCK-8 kit. Data are shown as mean 
± SD of triplicate. 
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Appendix B.4. Mass, NMR, HPLC spectra of compounds  
HPLC of compound 14 
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Shukkoor_MS-17 #490-576 RT: 1.82-2.00 AV: 8 NL: 2.55E8
T: FTMS + p ESI Full ms [180.00-800.00]
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Shukkoor_17A #392-574 RT: 2.07-2.55 AV: 22 NL: 1.53E8
T: FTMS + p ESI Full ms [180.00-800.00]
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Shukkoor_MS-021-C #350-728 RT: 1.14-2.10 AV: 36 NL: 2.24E7
T: FTMS + p ESI Full ms [180.00-800.00]
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Shukkoor_MS-21A #471-611 RT: 1.58-1.93 AV: 15 NL: 1.89E8
T: FTMS + p ESI Full ms [180.00-800.00]
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273.6729 is the target peak[M+2H]2+ 
546.3385 is the target peak[M+H]+ 
 
5a 
5a 
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Shukkoor_MS-024 #453-562 RT: 1.73-1.96 AV: 10 NL: 1.26E8
T: FTMS + p ESI Full ms [180.00-800.00]
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Shukkoor_MS-24_A #382-515 RT: 1.77-2.13 AV: 14 NL: 2.09E7
T: FTMS + p ESI Full ms [180.00-800.00]
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Shukkoor_MS-025 #458-564 RT: 1.77-2.01 AV: 10 NL: 4.38E7
T: FTMS + p ESI Full ms [180.00-800.00]
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Shukkoor_MS25A #427-764 RT: 1.55-2.57 AV: 32 NL: 1.29E7
T: FTMS + p ESI Full ms [180.00-800.00]
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Shokkoor_082614_MS47 #419-973 RT: 1.49-3.27 AV: 59 NL: 2.40E7
T: FTMS + p ESI Full ms [120.00-600.00]
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Shukkoor_MS-050_140911101028 #328-515 RT: 1.77-2.17 AV: 17 NL: 4.40E8
T: FTMS + p ESI Full ms [200.00-1000.00]
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Shukkoor_MS-051A #281-464 RT: 2.01-2.49 AV: 17 NL: 6.11E7
T: FTMS + p ESI Full ms [200.00-1000.00]
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Qing_Qing-5 #589-676 RT: 1.94-2.19 AV: 13 NL: 2.30E8
T: FTMS + p ESI Full ms [100.00-600.00]
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Qing_Qing-6 #573-742 RT: 1.87-2.52 AV: 46 NL: 7.80E8
T: FTMS + p ESI Full ms [100.00-600.00]
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Qing_Qing-7 #672-863 RT: 2.17-2.72 AV: 29 NL: 2.01E8
T: FTMS + p ESI Full ms [100.00-600.00]
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Qing_Q44 #487-635 RT: 1.97-2.34 AV: 19 NL: 4.50E8
T: FTMS + p ESI Full ms [180.00-800.00]
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Qing_Q45 #543-712 RT: 2.02-2.46 AV: 21 NL: 3.40E8
T: FTMS + p ESI Full ms [180.00-800.00]
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Qing_Q20 #542-607 RT: 2.14-2.29 AV: 6 NL: 5.26E7
T: FTMS + p ESI Full ms [100.00-600.00]
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251.6608 is the target 
peak[M+2H]2+ 
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Qing_Q41 #548-657 RT: 2.14-2.39 AV: 10 NL: 2.51E7
T: FTMS + p ESI Full ms [180.00-800.00]
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739.6024
z=1
497.2340
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711.5713
z=1
766.5273
z=1
488.2958 is the target peak[M+H]+ 
244.6517 is the target peak[M+2H]2+ 
 14a 
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Qing_Q42 #501-658 RT: 2.09-2.46 AV: 15 NL: 1.66E7
T: FTMS + p ESI Full ms [180.00-800.00]
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Qing_Q43 #566-657 RT: 2.21-2.39 AV: 8 NL: 1.37E8
T: FTMS + p ESI Full ms [180.00-800.00]
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460.2648 is the target peak[M+H]+ 
230.6360 is the target peak[M+2H]2+ 
16a 
16a 
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Qing_79 #305-555 RT: 2.16-2.85 AV: 23 SB: 179 0.01-2.10 , 2.72-4.99 NL: 5.37E6
T: FTMS + p ESI Full ms [200.00-1000.00]
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Qing_090214 #94-223 RT: 1.83-2.63 AV: 32 NL: 5.70E5
T: FTMS + p ESI Full ms [200.00-1000.00]
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Appendix C Supporting information for DNA encoded library of Globo series glycans for 
early stage detection of cancer 
Appendix C.1. HPLC spectra of DNA and Glycan DNA conjugates 
 
 
 
HPLC of A DNA+ Antigen A click reaction 
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HPLC of B DNA+ Antigen B click reaction 
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O+S 
 
 
HPLC of O DNA+ Antigen O click reaction 
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GbH+S 
 
HPLC of GbH DNA used in click reaction after HPLC purification 
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Gb5+S 
 
Gb4+S 
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Gb3+S 
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Gb2+S HPLC fraction collection (peak 2 is used in the study) 
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BB3+S 
 
 
Bb3+S collection (peak two is used for study) 
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BB2+S 
 
Bb2+S collection (peak two is used for study) 
HPLC of complimentary DNA used in hybridization 
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Appendix C.2. Coding Dictionaries and Examples 
Sugar Dictionary (Carb Dict): 
Table B.5.  Monosaccharides and their codes (library A) 
 
S.N
o 
Sugar 
Monomer 
Sugar Name DNA Code(as in dictionary) 
1. All 
 
Allose 
 
AAAA 
 
 2. AllNAc 
 
N-Acetyl-
Allosamine 
 
AAAC 
 
3. AllN 
 
Allosamine 
 
AAAG 
 
4. AllA 
 
Alluronic 
Acid 
 
AAAT 
 
5. Alt 
 
Altrose 
 
AACA 
 
6. AltNAc 
 
N-Acetyl-
Alltrosamine 
 
AACC 
 
7. AltN 
 
Alltrosamine 
 
AACG 
 
8. AltA 
 
Alturonic 
Acid 
 
AACT 
 
9. Glc 
 
Glucose 
 
AAGA 
 
10. GlcNAc 
 
N-Acetyl-
Glucosamine 
 
AAGC 
 
11. GlcN 
 
Glucosamine 
 
AAGG 
 
12. GlcA 
 
Glucoronic 
Acid 
 
AAGT 
 
13. Man 
 
Mannose 
 
AATA 
 
14. ManNAc 
 
N-Acetyl-
Mannosamine 
 
AATC 
 
15. ManN 
 
Mannosamin
e 
 
AATG 
 
16. ManA 
 
Man uronic 
Acid 
 
AATT 
 
17. G µL 
 
Gulose 
 
ACAA 
 
18. GulNAc 
 
N-Acetyl-
Gulosamine 
 
ACAC 
 
19. GulN 
 
Gulosamine 
 
ACAG 
 
20. GulA 
 
Guluronic 
Acid 
 
ACAT 
 
21. Ido 
 
Idose 
 
ACCA 
 
22. IdoNAc 
 
N-Acetyl-
Idosamine 
 
ACCC 
 
23. IdoN 
 
Idosamine 
 
ACCG 
 
24. IdoA 
 
Idouronic 
Acid 
 
ACCT 
 
25. Gal 
 
Galactose 
 
ACGA 
 
26. GalNAc 
 
N-Acetyl-
Galactosamine 
 
ACGC 
 
27. GalN 
 
Galactosami
ne 
 
ACGG 
 
28. GalA 
 
Galacturonic 
Acid 
 
ACGT 
 
29. Tal 
 
Talose 
 
ACTA 
 
30. TalNAc 
 
N-Acetyl-
Talosamine 
 
ACTC 
 
31. TalN 
 
Talosamine 
 
ACTG 
 
32. TalA 
 
Taluronic 
Acid 
 
ACTT 
 
33. Tag 
 
Tagatose 
 
ATCG 
 
34. TagA 
 
Tagaturonic 
Acid 
 
ATCT 
 
35. Hep 
 
Heptose 
 
ATCG 
 
36. DDManH
ep 
 
D-Glycero-
DMannoHeptose 
 
ATGG 
 
37. Dha 
 
3-deoxy-D-
lyxo-heptulosaric 
acid 
 
ATGT 
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38. LDManH
ep 
 
L-glycero-D-
mannoheptose 
 
ATTA 
 
39. Fuc 
 
Fucose 
 
AGAA 
 
40. FucNAc 
 
N-acetyl-L-
fucosamine 
 
AGAC 
 
41. FucN 
 
Fucosamine 
 
AGAG 
 
42. Qui 
 
Quinovose 
 
AGAT 
 
43. QuiNAc 
 
N-acetyl-D-
quinovosamine 
 
ATAA 
 
44. QuiN 
 
Quinovosami
ne 
 
ATAC 
 
45. Rha 
 
Rhamnose 
 
ATAG 
 
46. RhaNAc 
 
N-acetyl-L-
rhamnosamine 
 
ATAT 
 
47. RhaN 
 
Rhamnosami
ne 
 
ATCA 
 
48. Tyv 
 
Tyvelose 
 
ATTC 
 
49. Oli 
 
Olivose 
 
ATTG 
 
50. Par 
 
Paratose 
 
ATTT 
 
51. Dig 
 
Digitoxose 
 
CAAA 
 
52. 6dAlt 
 
6-deoxy-L-
altrose 
 
CAAC 
 
53. 6dTal 
 
6-deoxy-D-
talose 
 
CAAG 
 
54. Abe 
 
Abequose 
 
CAAT 
 
55. Api 
 
Apiose 
 
CACA 
 
56. Col 
 
Colitose 
 
CACC 
 
57. Neu5Ac 
 
N-
acetylneuraminic 
acid 
 
AGGC 
 
58. Neu5GC 
 
N-
glycolylneuraminic 
acid 
 
AGGG 
 
59. Kdn 
 
3-Deoxy-D-
glycero-D-galacto-
nonulosonic acid 
 
AGGT 
 
60. Kdo 
 
3-Deoxy-D-
manno-octulosonic 
acid 
 
ATCC 
 
61. Mur 
 
Muramic 
acid 
 
CACG 
 
62. MurNAc 
 
N-
etylmuramic acid 
 
CACT 
 
63. MurNGc 
 
N-
glycolylmuramic 
acid 
 
CCAA 
 
64. Sia 
 
Sialic Acid 
 
CCAG 
 
65. Neu 
 
Ne r inic 
i  
 
CCAC 
 
66. Fru 
 
Fructose 
 
ATGA 
 
67. Sor 
 
Sorbose 
 
ATGC 
 
68. Psi 
 
Psicose 
 
ATAA 
 
69. Rib 
 
Ribose 
 
GGGG 
 
70. Ara 
 
Arabinose 
 
ATAT 
 
71. Xyl 
 
Xylose 
 
ATCA 
 
72. Lyx 
 
Lyxose 
 
ATCT 
 
73. Bac 
 
Bacillosamin
e 
 
CCAT 
 
74. R 
 
For 
extending the short 
nucleotide 
sequences. 
CCCCAGTCAGGCCTAAC
GTA 
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Linkages Dictionary (Link Dict) 
Table B.6. Linkages/branching and their codes (library B) 
 
S.No Linkage DNA 
Code(as in 
Dictionary) 
1. a1-1 
 
AAT 
 
2. a1-2 
 
AAG 
 
3. a1-3 
 
AAC 
 
4. a1-4 
 
ATA 
 
5. a1-5 
 
AGA 
 
6. a1-6 
 
ACA 
 
7. a1-7 
 
ATT 
 
8. a1-8 
 
ATC 
 
9. a2-1 
 
GTA 
 
10. a2-2 
 
GTC 
 
11. a2-3 
 
GGT 
 
12. a2-4 
 
GGC 
 
13. a2-5 
 
GGA 
 
14. a2-6 
 
GTT 
 
15. a2-7 
 
GAC 
 
16. a2-8 
 
GAT 
 
17. b1-1 
 
ATG 
 
18. b1-2 
  
TCA 
 
19. b1-3 
 
TCT 
 
20. b1-4 
 
TGT 
 
21. b1-5 
 
TCC 
 
22. b1-6 
 
TTA 
 
23. b1-7 
 
TTC 
 
24. b1-8 
 
GAA 
 
25. a? 
 
GCC 
 
26. b? 
 
CAA 
 
27. ?1 
 
CAC 
 
28. ?2 
 
CTC 
 
29. ?3 
 
CCA 
 
30. ?4 
 
GGG 
 
31. ?5 
 
CCT 
 
32. ?6 
 
AGG 
 
33. ?7 
 
CCG 
 
34. ?8 
 
CGC 
 
35. ?? 
 
AGT 
 
36. ) 
 
AAA 
 
37. ( 
 
TTT 
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Modification Dictionary (Mod Dict): 
                                Table B.7. Modifications and their codes (library C) 
 
S
.No 
Compoun
d 
Mod
ification 
D
NA Code 
(as in 
Dictionary
) 
1
. 
Anhydro
us 
 
[2Y] AGCA 
  
 
2
. 
 [4Y] 
 
A
GCC 
 
3
. 
 [7Y] 
 
A
GCG 
 
4
. 
 [8Y] 
 
A
GCT 
 
5
. 
 [?Y] 
 
CC
CA 
 
6
. 
Hydroxyl 
 
[2O
H] 
 
A
GTA 
 
7
. 
 [4O
H] 
 
A
GTC 
 
8
. 
 [7O
H] 
 
A
GTG 
 
9
. 
 [8O
H] 
 
A
GTT 
 
1
0. 
 [?O
H] 
 
C
AGA 
 
1
1. 
Pyruvate 
 
[2V] 
 
C
AGC 
 
1
2. 
 [4V] 
 
C
AGG 
 
1
3. 
 [7V] 
 
C
AGT 
 
1
4. 
 [8V] 
 
C
ATA 
 
1
5. 
 [?V] 
 
C
ATC 
 
1
6. 
Sulphate 
0 
[2S] 
 
C
ATG 
 
1
7. 
 [4S] 
 
C
ATT 
 
1
8. 
 [7S] 
 
C
GAA 
 
1
9. 
 [8S] 
 
C
GAC 
 
2
0. 
 [?S] 
 
C
GAG 
 
2
1. 
Phosphate 
 
[2P] 
 
C
GAT 
 
2
2. 
 [4P] 
 
C
GGA 
 
2
3. 
 [7P] 
 
C
GGC 
 
2
4. 
 [8P] 
 
C
GGG 
 
2
5. 
 [?P] 
 
C
GGT 
 
2
6. 
n-glycolyl 
 
[2J] 
 
C
GTA 
 
2
7. 
 [4J] 
 
C
GTC 
 
2
8. 
 [7J] 
 
C
GTG 
 
2
9. 
 [8J] 
 
C
GTT 
 
3
0. 
 [?J] 
 
CT
AA 
 
3
1. 
n-acetyl 
 
[2N
Ac] 
 
CT
AC 
 
3
2. 
 [4N
Ac] 
 
CT
AG 
 
3
3. 
 [7N
Ac] 
 
CT
AT 
 
3
4. 
 [8N
Ac] 
 
CT
GA 
 
3
5. 
 [?N
Ac] 
 
CT
GC 
 
3
6. 
o-acetyl 
 
[2Ac
] 
 
CT
GG 
 
3
7. 
 [4Ac
] 
 
CT
GT 
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3
8. 
 [7Ac
] 
 
CT
TA 
 
3
9. 
 [8Ac
] 
 
CT
TC 
 
4
0. 
 [?Ac
] 
 
CT
TG 
 
4
1. 
Carboxylat
e 
 
[2C
OOH] 
 
CT
TT 
 
4
2. 
 [4C
OOH] 
 
G
AGA 
 
4
3. 
 [7C
OOH] 
 
G
AGC 
 
4
4. 
 [8C
OOH] 
 
G
AGG 
 
4
5. 
 [?C
OOH] 
 
G
AGT 
 
4
6. 
Inositol 
 
[2IN
] 
 
G
CAA 
 
4
7. 
 [4IN
] 
 
G
CAC 
 
4
8. 
 [7IN
] 
 
G
CAG 
 
4
9. 
 [8IN
] 
 
G
CAT 
 
5
0. 
 [?IN
] 
 
G
CGA 
 
5
1. 
pentyl 
 
[2EE
] 
 
G
CGC 
 
5
2. 
 [4EE
] 
 
G
CGG 
 
5
3. 
 [7EE
] 
 
G
CGT 
 
5
4. 
 [8EE
] 
 
G
CTA 
 
5
5. 
 [?EE
] 
 
G
CTC 
 
5
6. 
octyl 
 
[2E
H] 
 
G
CTG 
 
5
7. 
 [4E
H] 
 
G
CTT 
 
5
8. 
 [7E
H] 
 
GT
GA 
 
5
9. 
 [8E
H] 
 
GT
GC 
 
6
0. 
 [?E
H] 
 
GT
GG 
 
6
1. 
deactylated
-n-actyl 
 
[2Q] 
 
GT
GT 
 
6
2. 
 [4Q] 
 
TA
AA 
 
6
3. 
 [7Q] 
 
TA
AC 
 
6
4. 
 [8Q] 
 
TA
AG 
 
6
5. 
 [?Q] 
 
TA
AT 
 
6
6. 
N-Sulfate 
 
[2Q
S] 
 
TA
CA 
 
6
7. 
 [4Q
S] 
 
TA
CC 
 
6
8. 
 [7Q
S] 
 
TA
CG 
 
6
9. 
 [8Q
S] 
 
TA
CT 
 
7
0. 
 [?QS
] 
 
TA
GA 
 
7
1. 
Pyruvate 
Acetal 
 
[2P
YR] 
 
TA
GC 
 
7
2. 
 [4P
YR] 
 
TA
GG 
 
7
3. 
 [7P
YR] 
 
TA
GT 
 
7
4. 
 [8P
YR] 
 
TA
TA 
 
7
5. 
 [?PY
R] 
 
TA
TC 
 
7
6. 
N-
methylcarbomoyl 
 
[2E
CO] 
 
TA
TG 
 
7
7. 
 [4E
CO] 
 
TA
TT 
 
7
8. 
 [7E
CO] 
 
TC
GA 
 
7
9. 
 [8E
CO] 
 
TC
GC 
 
8
0. 
 [?EC
O] 
 
TC
GG 
 
8
1. 
Phosphoch
oline 
 
[2PC
] 
 
TC
GT 
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8
2. 
 [4PC
] 
 
TG
AA 
 
8
3. 
 [7PC
] 
 
TG
AC 
 
8
4. 
 [8PC
] 
 
TG
AG 
 
8
5. 
 [?PC
] 
 
TG
AT 
 
8
6. 
Phosphoeth
nlamine 
 
[2PE
] 
 
TG
CA 
 
8
7. 
 [4PE
] 
 
TG
CC 
 
8
8. 
 [7PE
] 
 
TG
CG 
 
8
9. 
 [8PE
] 
 
TG
CT 
 
9
0. 
 [?PE
] 
 
TG
GA 
 
9
1. 
Methyl 
 
[2M
E] 
 
TG
GC 
 
9
2. 
 [3M
E] 
 
TG
GG 
 
9
3. 
 [4M
E] 
 
TG
GT 
 
9
4. 
 [7M
E] 
 
TT
GA 
 
9
5. 
 [8M
E] 
 
TT
GC 
 
9
6. 
 [?M
E] 
 
TT
GG 
 
9
7. 
Sulphate 
 
[3S] 
 
TT
GT 
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Core Dictionary (Core Dict): 
Table B.8. Core structure and their codes (Library D) 
 
S.No Sugar blocks for Secondary 
naming 
       CFG 2D 
structure 
Long Nucleotide Len
gth 
Assigned short 
DNA code  
1
. 
Man b1-4 GlcNAc b1-
4( Fuc a1-6) GlcNAc  
 AATATGTAAGCTGTTTTAGAAAC
AAAAAAGC 
31 GTACA  
2. Man a1-6Man b1-
4 GlcNAc b1-4 GlcNAc  
AATAACAAATATGTAAGCTGTAA
GC 
25 GTACT  
3. Gal b1-4 GlcNAc b1-4  
 
ACGATGTAAGCTGT 14 GTCCT  
203 
4. Gal a1-3 Gal b1-
4 GlcNAc b1-2 
 
ACGAAACACGATGTAAGC
TCA 
21 GTACC  
5. Gal a1-3 Gal b1-
4 GlcNAc b1-3 
 
ACGAAACACGATGTAAGC
TCT 
21 GTTAT  
6. Gal b1-3 GlcNAc b1-4  
 
ACGATCTAAGCTGT 14 GTTCA  
7. Man a1-3 Man a1-6 
 
AATAAACAATAACA 14 GTTTG  
8. GalNAc b1-4 GlcNAc b1-2  
 
ACGCTGTAAGCTCA 14 GTTTC  
9. Fuc a1-3 GlcNAc b1-2  
 
AGAAAACAAGCTCA 14 GTTGT  
10. Fuc a1-2 Gal b1-4( Fuc a1-
3) GlcNAc b1-2 
 
AGAAAAGACGATGTTTTAGAAA
ACAAAAAGCTCA  
34 GGATT  
204 
11.  Fuc a1-2 Gal b1-
4 GlcNAc b1-2  
 
AGAAAAGACGATGTAAGCTCA 21 GTTGC  
12. Gal b1-4( Fuc a1-
3) GlcNAc b1-4 
 
ACGATGTTTTAGAAAACAAAAAG
CTGT 
27 GTGAG  
13. GalNAc b1-4 GlcNAc b1-6 
 
ACGCTGTAAGCTTA 14 GTGTC  
14. Gal b1-4 GlcNAc b1-6 
 
ACGATGTAAGCTTA 14 GTGCG  
15. NeuAc a2-3 Gal b1-
4 GlcNAc b1-4  
 
AGGCGGTACGATGTAAGCTGT 21  GTGGA  
16. NeuAc a2-3 Gal b1-
4 GlcNAc b1-6 
 
AGGCGGTACGATGTAAGCTTA 21 GTGGT  
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Coding Examples:  
Table B.9. Examples of DNA encoding of glycans using the program 
Structure Long Nucleotide Lengt
h 
Short 
Nucleotide 
Lengt
h 
 
acgctgttttagaaaagaaaaagctgtaataaactttacgct
gttttagaaaagaaaaagctgtaataacaaaaaatatgtaa
gctgttttagaaacaaaaaagc 
105 acgctgttttagaaaagaaaa
agctgtaataaactttacgctg
ttttagaaaagaaaaagctgt
aataacaaaagtaca 
79 
 
acgatgtaagctgtaataaactttacgatgtaagctgtaata
acaaaaaatatgtaagctgttttagaaacaaaaaagc 
79 gtacgaataaactttacgatgt
aagctgtaataacaaaagtac
a 
44 
 
 
acgatgtaagctgtaataaactttaagctgtaataacaaaa
aatatgtaagctgttttagaaacaaaaaagc  
72 gtacgaataaactttaagctgt
aataacaaaagtaca 
37 
206 
 
acgatggttcttttacgatgggttaaaaaagctgtaagctca
aataaactttacgatgggttaacgatgggtcttttacgatgg
gttaaaaaagctgtaagctcaaataacaaaatttatcatcaa
aaaatatgtaagctgttttagaaacaaaaaagc 
159 acgatggttcttttacgatggg
ttaaaaaagctgtaagctcaa
ataaactttacgatgggttaac
gatgggtcttttacgatgggtt
aaaaaagctgtaagctcaaat
aacaaaatttatcatcaaaagt
aca 
133 
 
acgaaacacgatgtaagctcatttacgaaacacgatgtaa
gctgtaaaaataaactttacgaaacacgatgtaagctcaaa
taacaaaaaatatgtaagctgttttagaaacaaaaaagc  
120 gaaacacgatgtaagctc
atttacgaaacgtacgaaaaa
taaactttgtaccaataacaaa
agtaca 
69 
 
acgaaacacgatgtaagctcatttacgatgtaagctgtaaa
aataaactttacgaaacacgatgtaagctcaaataacaaaa
aatatgtaagctgttttagaaacaaaaaagc 
113 acgaaacacgatgtaagctc
atttgtacgaaaaataaacttt
gtaccaataacaaaagtaca 
62 
207 
 
acgaaacacgatgtaagctcaaataaactttacgaaacac
gatgtaagctcaaataacaaaaaatatgtaagctgttttaga
aacaaaaaagc 
93 gtaccaataaactttacgaaa
cacgatgtaagctcaaataac
aaaagtaca 
51 
 
acgaaacacgatgtaagctcaaataaactttacgatgtaag
ctcaaataacaaaaaatatgtaagctgttttagaaacaaaa
aagc  
86 gtaccaataaactttacgatgt
aagctcaaataacaaaagta
ca 
44 
 
acgaaacacgatgtaagctcaaataaactttaagctcaaat
aacaaaaaatatgtaagctgttttagaaacaaaaaagc 
79 gtaccaataaactt
taagctcaaataacaaaagta
ca 
37 
 
acgaaacacgatgtaagctcaaataaactttaataacaaaa
aatatgtaagctgttttagaaacaaaaaagc 
72 gtaccaataaactttaataaca
aaagtaca 
30 
 acgaaacacgatgtaagctcttttacgaaacacgatgtaa
gcttaaaaacgatgtaagctcaaataaactttacgaaacac
gatgtaagctcaaataacaaaaaatatgtaagctgttttaga
aacaaaaaagc 
134 gttattttacgaaac
acgatgtaagcttaaaaacg
atgtaagctcaaataaactttg
taccaataacaaaagtaca 
76 
208 
 
acgatgtaagctcatttacgatctaagctgtaaaaataaact
ttacgatgtaagctcatttacgatgtaagcttaaaaaataac
aaaaaatatgtaagctgttttagaaacaaaaaagc 
119 acgatgtaagctc
atttgttcaaaaaataaacttta
cgatgtaagctcatttacgat
gtaagcttaaaaaataacaaa
agtaca 
84 
 
acgatgtaagctcatttacgatgttttagaaaacaaaaagct
gtaaaaataaactttacgatgtaagctcaaataacaaaaaa
tatgtaagctgttttagaaacaaaaaagc 
112 acgatgtaagctcatttgtga
gaaaaataaactttacgatgt
aagctcaaataacaaaagta
ca 
64 
 
acgatgtaagctcatttacgatgtaagctgtaaaaataaact
ttacgaaacacgatgtaagctcaaataacaaaaaatatgta
agctgttttagaaacaaaaaagc 
106 acgatgtaagctcatttgtac
gaaaaataaactttgtaccaa
taacaaaagtaca 
55 
 
acgatgtaagctcatttacgatgtaagctgtaaaaataaact
ttacgatgtaagctcatttacgatgtaagcttaaaaaataac
aaaaaatatgtaagctgttttagaaacaaaaaagc 
119 acgatgtaagctcatttgtac
gaaaaataaactttacgatgt
aagctcatttacgatgtaagct
taaaaaataacaaaagtaca 
84 
209 
 
acgatgttttagaaaacaaaaagctcaaataaactttaataa
actttaataacaaaaaataacaaaaaatatgtaagctgtttta
gaaacaaaaaagc 
98 acgatgttttagaaaacaaaa
agctcaaataaactttaataaa
ctttaataacaaaaaataaca
aaagtaca 
72 
 
acgatgttttagaaaacaaaaagctcaaataaactttacgat
gtaagctcaaataacaaaaaatatgtaagctgttttagaaa
caaaaaagc 
92 acgatgttttagaaaacaaaa
agctcaaataaactttacgat
gtaagctcaaataacaaaagt
aca 
66 
 
acgatgttttagaaaacaaaaagctcaaataaactttaataa
caaaaaatatgtaagctgttttagaaacaaaaaagc 
78 acgatgttttagaaaacaaaa
agctcaaataaactttaataac
aaaagtaca 
52 
 
acgatctaagctgtaagcagttttaagcagtaaaaataaac
tttaataagtaataaacaaaaatatgtaagctgttttagaaac
aaaaaagc 
92 gttcaaagcagttttaagcag
taaaaataaactttaataagta
ataaacaaagtaca 
57 
210 
 
acgatgttttagaaaacaaaaagctcatttacgatgtaagct
gtaaaaataaactttacgatgtaagctcaaataacaaaaaa
tatgtaagctgttttagaaacaaaaaagc 
112 acgatgttttagaaaacaaaa
agctcatttgtacgaaaaata
aactttacgatgtaagctcaa
ataacaaaagtaca 
77 
 
acgatgttttagaaaacaaaaagctcatttacgatgttttag
aaaacaaaaagctgtaaaaataaactttacgatgttttagaa
aacaaaaagctcaaataacaaaaaatatgtaagctgtttta
gaaacaaaaaagc 
138 acgatgttttagaaaacaaaa
agctcatttgtgagaaaaata
aactttacgatgttttagaaaa
caaaaagctcaaataacaaa
agtaca 
90 
 
acgatgttttagaaaacaaaaagctcaaataaactttacgat
gttttagaaaacaaaaagctcaaataacaaaaaatatgtaa
gctgttttagaaacaaaaaagc 
105 acgatgttttagaaaacaaaa
agctcaaataaactttacgat
gttttagaaaacaaaaagctc
aaataacaaaagtaca 
79 
211 
 
acgatgtaagctcaaataaactttacgatgtaagctcattta
cgctgtaagcttaaaaaataacaaaaaatatgtaagctgttt
tagaaacaaaaaagc  
99 acgatgtaagctcaaataaac
tttacgatgtaagctcatttgtg
tcaaaaataacaaaagtaca  
64 
 
acgatgtaagctcaaataacatttacgatgtaagctcattta
cgctgtaagcttaaaaaataaacaaaaatatgtaagctgttt
tagaaacaaaaaagc 
99 acgatgtaagctcaaataaca
tttacgatgtaagctcatttgtg
tcaaaaataaacaaagtaca 
64 
 
acgatgtaagctcaaataaactttacgctgtaagctcattta
cgatgtaagcttaaaaaataacaaaaaatatgtaagctgttt
tagaaacaaaaaagc 
99 acgatgtaagctcaaataaac
tttgtttctttacgatgtaagctt
aaaaaataacaaaagtaca 
64 
 
acgatgtaagctcaaataaactttaggggttacgatgtaag
ctcaaataacaaaaaatatgtaagctgttttagaaacaaaa
aagc 
86 acgatgtaagctcaaataaac
tttaggggttacgatgtaagct
caaataacaaaagtaca 
60 
212 
 
acgatgtaagctcaaataaactttaataaagaataaacaat
aacaaaaaatatgtaagctgttttagaaacaaaaaagc 
79 acgatgtaagctcaaataaac
tttaataaagaataaacaataa
caaaagtaca 
53 
 
acgatgtaagctcaaataaactttaataaactttaataacaa
aaaataacaaaaaatatgtaagctgttttagaaacaaaaaa
gc 
85 acgatgtaagctcaaataaac
tttaataaactttaataacaaa
aaataacaaaagtaca 
59 
 
acgatgtaagctcaaataaactttacgctgtaagctcaaat
aacaaaaaatatgtaagctgttttagaaacaaaaaagc 
79 acgatgtaagctcaaataaac
tttgtttcaataacaaaagtac
a 
44 
 
acgatgtaagctcaaataaactttaagctcaaataacaaaa
aatatgtaagctgttttagaaacaaaaaagc 
72 acgatgtaagctcaaataaac
tttaagctcaaataacaaaag
taca 
46 
 
acgatgtaagctcaaataaactttacgatgtaagctcaaat
aacaaaaaatatgtaagctgttttagaaacaaaaaagc 
79 acgatgtaagctcaaataaac
tttacgatgtaagctcaaataa
caaaagtaca 
53 
213 
 
acgatgtaagctcaaataaactttacgatgtaagctcattta
cgatgtaagcttaaaaaataacaaaaaatatgtaagctgttt
tagaaacaaaaaagc 
99 acgatgtaagctcaaataaac
tttacgatgtaagctcatttgtg
cgaaaaataacaaaagtaca 
64 
 
acgatgtaagctcaaataaactttacgatgtaagctcattta
cgaaacacgatgtaagcttaaaaaataacaaaaaatatgt
aagctgttttagaaacaaaaaagc 
106 acgatgtaagctcaaataaac
tttacgatgtaagctcatttac
gaaacgtgcgaaaaataaca
aaagtaca 
71 
 
acgatgtaagctcaaataaactttacgaaacacgatgtaag
ctcatttacgatgtaagcttaaaaaataacaaaaaatatgta
agctgttttagaaacaaaaaagc 
106 acgatgtaagctcaaataaac
tttacgaaacacgatgtaagc
tcatttgtgcgaaaaataaca
aaagtaca 
71 
214 
 
acgatgtaagctcatttaggcggtacgatgtaagctgtaaa
aataaactttaggcggtacgatgtaagctcatttaggcggt
acgatgtaagcttaaaaaataacaaaaaatatgtaagctgt
tttagaaacaaaaaagc 
140 acgatgtaagctcatttaggc
ggtacgatgtaagctgtaaaa
ataaactttaggcggtacgat
gtaagctcatttgtggtaaaa
ataacaaaagtaca  
98 
 
acgatgtaagctcatttaggcggtacgatgtaagctgtaaa
aataaactttaggcggtacgatgtaagctcatttacgatgta
agcttaaaaaataacaaaaaatatgtaagctgttttagaaac
aaaaaagc 
133 acgatgtaagctcatttgtgg
aaaaaataaactttaggcggt
acgatgtaagctcatttgtgc
gaaaaataacaaaagtaca 
82 
 
acgatgtaagctcatttaggcggtacgatgtaagctgtaaa
aataaactttaggcggtacgatgtaagctcatttacgatgta
agcttaaaaaataacaaaaaatatgtaagctgttttagaaac
aaaaaagc 
133 acgatgtaagctcatttgtgg
aaaaaataaactttaggcggt
acgatgtaagctcatttgtgc
gaaaaataacaaaagtaca  
82 
215 
 
acgatgtaagctcatttacgatgtaagctgtaaaaataaact
ttaggcggtacgatgtaagctcatttaggcggtacgatgta
agcttaaaaaataacaaaaaatatgtaagctgttttagaaac
aaaaaagc 
133 acgatgtaagctcatttacgat
gtaagctgtaaaaataaacttt
aggcggtacgatgtaagctc
atttgtggtaaaaataacaaa
agtaca 
91 
 
acgatgtaagctcatttacgatgtaagctgtaaaaataaact
ttaagctcaaataacaaaaaatatgtaagctgttttagaaac
aaaaaagc 
92 acgatgtaagctcatttgtac
gaaaaataaactttaagctca
aataacaaaagtaca  
57 
 
acgatgtaagctcatttacgatgtaagctgtaaaaataaact
ttacgatgtaagctcaaataacaaaaaatatgtaagctgtttt
agaaacaaaaaagc 
99 acgatgtaagctcatttgtac
gaaaaataaactttacgatgt
aagctcaaataacaaaagta
ca 
64 
 
acgatgtaagctgtaataaactttaataacaaaaaatatgta
agctgttttagaaacaaaaaagc 
65 gtacgaataaactttaataac
aaaagtaca 
30 
 
acgatgtaagctctacgatgtaagctcaaataaactttacg
atgtaagctcaaataacaaaaaatatgtaagctgttttagaa
acaaaaaagc 
93 acgatgtaagctctacgatgt
aagctcaaataaactttacga
tgtaagctcaaataacaaaag
taca 
67 
216 
 
acgatgtaagctctacgatgtaagctcatttacgatgtaag
ctgtaaaaataaactttacgatgtaagctctacgatgtaagc
tcatttacgatgtaagctctacgatgtaagcttaaaaaataa
caaaaaatatgtaagctgttttagaaacaaaaaagc 
161 acgatgtaagctctacgatgt
aagctcatttacgatgtaagct
gtaaaaataaactttacgatgt
aagctctacgatgtaagctca
tttacgatgtaagctctgtgcg
aaaaataacaaaagtaca 
126 
 
acgctgttttagaaaacaaaaagctcaaataaactttaggc
ggtacgctgtaagctcaaataacaaaaaatatgtaagctgt
tttagaaacaaaaaagc 
99 acgctgttttagaaaacaaaa
agctcaaataaactttaggcg
gtgtttcaataacaaaagtac
a 
64 
 
acgctgttttagaaaacaaaaagctcaaataaactttaataa
caaaaaatatgtaagctgttttagaaacaaaaaagc 
78 acgctgttttagaaaacaaaa
agctcaaataaactttaataac
aaaagtaca 
52 
 
acgctgttttagaaaacaaaaagctcaaataaactttaataa
caaaaaatatgtaagctgttttagaaacaaaaaagc  
78 acgctgttttagaaaacaaaa
agctcaaataaactttaataac
aaaagtaca 
52 
 
acgctgttttagaaaacaaaaagctcaaataaactttacgct
gtaagctcaaataacaaaaaatatgtaagctgttttagaaa
caaaaaagc 
92 acgctgttttagaaaacaaaa
agctcaaataaactttgtttca
ataacaaaagtaca 
57 
217 
 
acgctgttttagaaaacaaaaagctcaaataaactttacga
aacacgatgtaagctcaaataacaaaaaatatgtaagctgt
tttagaaacaaaaaagc 
99 acgctgttttagaaaacaaaa
agctcaaataaactttgtacc
aataacaaaagtaca 
57 
 
acgccatttgtaagctcaaataaactttaataaacaataaca
aaaaatatgtaagctgttttagaaacaaaaaagc 
76 acgccatttgtaagctcaaat
aaactttaataaacaataaca
aaagtaca 
50 
 
acgccatttgtaagctcaaataaactttacgctgtaagctca
aataacaaaaaatatgtaagctgttttagaaacaaaaaagc 
83 acgccatttgtaagctcaaat
aaactttgtttcaataacaaaa
gtaca 
48 
 
acgccatttgtaagctcaaataaactttaggcggtacgatg
taagctcaaataacaaaaaatatgtaagctgttttagaaaca
aaaaagc 
90 acgccatttgtaagctcaaat
aaactttaggcggtacgatgt
aagctcaaataacaaaagta
ca 
64 
 
acgccatttgtaagctcaaataaactttaggcgttacgatgt
aagctcaaataacaaaaaatatgtaagctgttttagaaaca
aaaaagc 
90 acgccatttgtaag
ctcaaataaactttaggcgtta
cgatgtaagctcaaataacaa
aagtaca 
64 
218 
 
acgctgtaagctcaaataaactttaagctcatttacgctgta
agcttaaaaaataacaaaaaatatgtaagctgttttagaaac
aaaaaagc 
92 acgctgtaagctcaaataaac
tttaagctcatttgtgtcaaaa
ataacaaaagtaca 
57 
 
acgctgtaagctcaaataaactttaagctcatttaagcttaa
aaaataacaaaaaatatgtaagctgttttagaaacaaaaaa
gc  
85 gtttcaataaactttaagctcat
ttaagcttaaaaaataacaaa
agtaca  
50 
 
acgctgtaagctcaaataaactttaataacaaaaaatatgta
agctgttttagaaacaaaaaagc 
65 gtttcaataaactttaataaca
aaagtaca  
30 
 
acgctgtaagctcaaataaactttaggcgttacgatgtaag
ctcaaataacaaaaaatatgtaagctgttttagaaacaaaa
aagc 
86 gtttcaataaactttaggcgtt
acgatgtaagctcaaataaca
aaagtaca 
51 
 
acgctgtaagctcaaataaactttaataacaaaaaatatgta
agctgttttagaaacaaaaaagc 
65 gtttcaataaactttaataaca
aaagtaca 
30 
219 
 
acgctgtaagctcaaataaactttacgccatttgtaagctca
aataacaaaaaatatgtaagctgttttagaaacaaaaaagc 
83 gtttcaataaactttacgccatt
tgtaagctcaaataacaaaag
taca 
48 
 
acgctgtaagctcaaataaactttacgatgtaagctcattta
cgatgtaagcttaaaaaataacaaaaaatatgtaagctgttt
tagaaacaaaaaagc 
99 gtttcaataaactttacgatgt
aagctcatttgtgcgaaaaat
aacaaaagtaca 
55 
 
acgctgtaagctcaaataaactttacgatgtaagctcaaat
aacaaaaaatatgtaagctgttttagaaacaaaaaagc 
79 gtttcaataaactttacgatgt
aagctcaaataacaaaagta
ca 
44 
 
acgctgtaagctcatttacgatgtaagctgtaaaaataaact
ttacgctgtaagctcatttacgatgtaagcttaaaaaataac
aaaaaatatgtaagctgttttagaaacaaaaaagc 
119 gtttctttacgatgtaagctgta
aaaataaactttacgctgtaa
gctcatttgtgcgaaaaataa
caaaagtaca 
75 
 
acgctgtaagctcatttacgatgtaagctgtaaaaataaact
ttacgatgtaagctcaaataacaaaaaatatgtaagctgtttt
agaaacaaaaaagc 
99 gtttctttgtcctaaaaataaac
tttacgatgtaagctcaaataa
caaaagtaca 
55 
220 
 
acgctgtaagctcatttacgatgtaagctgtaaaaataaact
ttacgctgtaagctcatttacgctgtaagcttaaaaaataac
aaaaaatatgtaagctgttttagaaacaaaaaagc 
119 acgctgtaagctcatttacgat
gtaagctgtaaaaataaacttt
acgctgtaagctcatttgtgtc
aaaaataacaaaagtaca 
84 
 
acgctgtaagctcatttaagctgtaaaaataaactttaagct
catttaagcttaaaaaataacaaaaaatatgtaagctgtttta
gaaacaaaaaagc 
98 gttgaaataaactttaagctca
tttaagcttaaaaaataacaaa
agtaca 
50 
 
acgctgtaagctcatttaagctgtaaaaataaactttacgct
gtaagctcatttaagcttaaaaaataacaaaaaatatgtaag
ctgttttagaaacaaaaaagc 
105 gtttctttaagctgtaaaaata
aactttacgctgtaagctcatt
taagcttaaaaaataacaaaa
gtaca 
70 
 
acgctgtaagctcatttaagctgtaaaaataaactttaagct
caaataacaaaaaatatgtaagctgttttagaaacaaaaaa
gc 
85 gtttctttaagctgtaaaaata
aactttaagctcaaataacaa
aagtaca 
50 
221 
 
acgctgtaagctcaaataaactttacgatgtaagctcattta
cgatgtaagcttaaaaaataacaaaaaatatgtaagctgttt
tagaaacaaaaaagc 
99 gtttcaataaactttacgatgt
aagctcatttgtgcgaaaaat
aacaaaagtaca 
55 
 
acgctgtaagctcaaataaactttacgatgtaagctcaaat
aacaaaaaatatgtaagctgttttagaaacaaaaaagc 
79 gtttcaataaactttacgatgt
aagctcaaataacaaaagta
ca 
44 
 
acgctgtaagctcaaataaactttacgctgtaagctcaaat
aacaaaaaatatgtaagctgttttagaaacaaaaaagc 
79 gtttcaataaactttacgctgt
aagctcaaataacaaaagta
ca  
44 
 
acgctgtaagctcaaataaactttacgctgtaagctcaaat
aacaaaaaatatgtaagctgttttagaaacaaaaaagc  
79 gtttcaataaactttacgctgt
aagctcaaataacaaaagta
ca 
44 
 
agaaaacaagctcaaataaactttaataacaaaaaatatgt
aagctgttttagaaacaaaaaagc 
65 gttgtaataaactttaataaca
aaagtaca 
30 
222 
 
agaaaagacgatgttttagaaaacaaaaagctcaaataaa
ctttagaaaagacgatgtaagctcaaataacaaaaaatatg
taagctgttttagaaacaaaaaagc 
106 gttggaataaactttgttgcaa
taacaaaagtaca 
35 
 
agaaaagacgatgttttagaaaacaaaaagctcaaataaa
ctttagaaaagacgatgttttagaaaacaaaaagctcaaat
aacaaaaaatatgtaagctgttttagaaacaaaaaagc  
119 gttggaataaactttagaaaa
gacgatgttttagaaaacaaa
aagctcaaataacaaaagta
ca  
64 
 
agaaaagacgatgttttagaaaacaaaaagctcaaataaa
ctttaataaactttaataacaaaaaataacaaaaaatatgta
agctgttttagaaacaaaaaagc  
105 gttggaataaactttaataaac
tttaataacaaaaaataacaa
aagtaca  
50 
 
agaaaagacgatgttttagaaaacaaaaagctcaaataaa
ctttaatagccaataacaaaaaatatgtaagctgttttagaa
acaaaaaagc 
92 gttggaataaactttaatagcc
aataacaaaagtaca 
37 
223 
 
agaaaagacgatgttttagaaaacaaaaagctcaaataaa
ctttacgatgttttagaaaacaaaaagctcaaataacaaaa
aatatgtaagctgttttagaaacaaaaaagc 
112 gttggaataaactttacgatgt
tttagaaaacaaaaagctcaa
ataacaaaagtaca 
57 
 
agaaaagacgatgttttagaaaacaaaaagctcatttagaa
aagacgatgttttagaaaacaaaaagctgtaaaaataaact
ttagaaaagacgatgttttagaaaacaaaaagctcaaataa
caaaaaatatgtaagctgttttagaaacaaaaaagc  
159 gttggtttagaaaaggtgaga
aaaataaactttagaaaagac
gatgttttagaaaacaaaaag
ctcaaataacaaaagtaca 
82 
 
agaaaagacgatgtaagctcaaataaactttagaaaagac
gatgtaagctcaaataacaaaaaatatgtaagctgttttaga
aacaaaaaagc 
93 gttgcaataaactttagaaaa
gacgatgtaagctcaaataa
caaaagtaca  
51 
 
agaaaagacgatgtaagctcaaataaactttaatagccaat
aacaaaaaatatgtaagctgttttagaaacaaaaaagc 
79 gttgcaataaactttaatagcc
aataacaaaagtaca 
37 
224 
 
agaaaagacgatgttttagaaaacaaaaagctcaaataaa
ctttaataacaaaaaatatgtaagctgttttagaaacaaaaa
agc 
85 gttggaataaactttaataaca
aaagtaca  
30 
 
agaaaagacgatgtaagctcaaataaactttacgatgtaa
gctcaaataacaaaaaatatgtaagctgttttagaaacaaa
aaagc  
86 gttgcaataaactttacgatgt
aagctcaaataacaaaagta
ca 
44 
 
aagctgttttacgatgttttagaaaacaaaaagctcaaataa
acaaatttacgatgtaagctcaaataacaaaaaatatgtaa
gctgttttagaaacaaaaaagc 
105 aagctgttttacgatgttttaga
aaacaaaaagctcaaataaa
caaatttacgatgtaagctca
aataacaaaagtaca  
79 
 
aagctgttttacgatgttttagaaaacaaaaagctcaaataa
acaaatttacgatgtaagctcaaataacaaaaaatatgtaa
gctgttttagaaacaaaaaagc  
105 aagctgttttacgatgttttaga
aaacaaaaagctcaaataaa
caaatttacgatgtaagctca
aataacaaaagtaca  
79 
 
aagctgttttacgatgtaagctcaaataaacaaatttaataa
actttaataacaaaaaataacaaaaaatatgtaagctgtttta
gaaacaaaaaagc 
98 aagctgttttacgatgtaagct
caaataaacaaatttaataaa
ctttaataacaaaaaataaca
aaagtaca 
72 
225 
 
aagctgttttacgatgtaagctcaaataaacaaatttacgat
gttttagaaaacaaaaagctcaaataacaaaaaatatgtaa
gctgttttagaaacaaaaaagc 
105 aagctgttttacgatgtaagct
caaataaacaaatttacgatg
ttttagaaaacaaaaagctca
aataacaaaagtaca  
79 
 
aagctgttttaggtaacacgatgtaagctcaaataaacaaa
tttaggtaacacgatgtaagctcaaataacaaaaaatatgt
aagctgttttagaaacaaaaaagc 
106 aagctgttttaggtaacacga
tgtaagctcaaataaacaaat
ttaggtaacacgatgtaagct
caaataacaaaagtaca 
80 
 
aagctgttttaataaacaaatttaagctcaaataacaaaaaa
tatgtaagctgttttagaaacaaaaaagc 
71 aagctgttttaataaacaaattt
aagctcaaataacaaaagta
ca 
45 
 
aagctgttttaataaacaaatttaataacaaaaaatatgtaa
gctgttttagaaacaaaaaagc 
64 aagctgttttaataaacaaattt
aataacaaaagtaca 
38 
 
aagctgttttaagctcaaataaacaaatttacgatgttttaga
aaacaaaaagctcaaataacaaaaaatatgtaagctgtttt
agaaacaaaaaagc  
98 aagctgttttaagctcaaataa
acaaatttacgatgttttagaa
aacaaaaagctcaaataaca
aaagtaca 
72 
226 
 
aagctgttttacgctgtaagctcaaataaacaaatttacgcc
atttgtaagctcaaataacaaaaaatatgtaagctgttttaga
aacaaaaaagc 
96 aagctgttttgtttcaataaac
aaatttacgccatttgtaagct
caaataacaaaagtaca 
61 
 
aagctgttttaagctcaaataaacaaatttaataacaaaaaa
tatgtaagctgttttagaaacaaaaaagc 
71 aagctgttttaagctcaaataa
acaaatttaataacaaaagta
ca 
45 
 
aagctcaaataaactttaagctcaaataacaaaaaatatgt
aagctgttttagaaacaaaaaagc  
65 aagctcaaataaactttaagc
tcaaataacaaaagtaca 
39 
 
aagctcaaataaactttaataaacaataacaaaaaatatgta
agctgttttagaaacaaaaaagc 
65 aagctcaaataaactttaataa
acaataacaaaagtaca  
39 
 
aagcacaacgatgtaagctcaaataaactttaagcacaac
gatgtaagctcaaataacaaaaaatatgtaagctgttttaga
aacaaaaaagc 
93 aagcacaacgatgtaagctc
aaataaactttaagcacaacg
atgtaagctcaaataacaaaa
gtaca 
67 
 
aagctcatttaagctgtaaaaataaactttaagctcaaataa
caaaaaatatgtaagctgttttagaaacaaaaaagc 
78 aagctcatttaagctgtaaaa
ataaactttaagctcaaataac
aaaagtaca 
52 
227 
 
aagctcatttaagctgtaaaaataaactttaagctcatttaag
cttaaaaaataacaaaaaatatgtaagctgttttagaaacaa
aaaagc 
91 aagctcatttaagctgtaaaa
ataaactttaagctcatttaag
cttaaaaaataacaaaagtac
a 
65 
 
aagctcaaataaactttacgaaacacgatgtaagctcaaat
aacaaaaaatatgtaagctgttttagaaacaaaaaagc 
79 aagctcaaataaactttgtac
caataacaaaagtaca 
37 
 
aagctcaaataaactttaataacaaaaaatatgtaagctgtt
ttagaaacaaaaaagc 
58 aagctcaaataaactttaataa
caaaagtaca 
32 
 
aagctcaaataaactttaataacaaaaaatatgtaagctgtt
ttagaaacaaaaaagc 
58 aagctcaaataaactttaataa
caaaagtaca 
32 
 
aagctcaaataaactttacgccatttgtaagctcaaataaca
aaaaatatgtaagctgttttagaaacaaaaaagc 
76 aagctcaaataaactttacgc
catttgtaagctcaaataaca
aaagtaca 
50 
 
    
 
    
 
agaaaagacgatctaagctctacgatgtaaga 32 
  
228 
 
acgcaactttagaaaagaaaacgatctaagctctacgatgt
aaga 
45 
  
 
acgaaactttagaaaagaaaacgatctaagctctacgatgt
aaga 
45 
  
 
    
 
agaaaagacgatctacgctctacgaataacgatgtaaga  39 
  
 
acgatctacgctctacgaataacgatgtaaga  32 
  
 
acgctctacgaataacgatgtaaga  25 
  
 
acgaataacgatgtaagaccccagtcaggcctaacgta 38 
  
 
acgatgtaagaccccagtcaggcctaacgta  31 
  
 
agaaaagacgatctacgctctacga  25 
  
 
agaaaagacgatctacgcccccagtcaggcctaacgta 38 
  
 
agaaaagacgaccccagtcaggcctaacgta  31 
  
1 
 
 
